{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T03:44:10Z","timestamp":1794887050534,"version":"4.9.1"},"reference-count":746,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2021R1A6A1A03038890"],"award-info":[{"award-number":["NRF-2021R1A6A1A03038890"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2023-00268276"],"award-info":[{"award-number":["RS-2023-00268276"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002701","name":"Ministry of Education","doi-asserted-by":"publisher","award":["2021R1A6C101A564"],"award-info":[{"award-number":["2021R1A6C101A564"]}],"id":[{"id":"10.13039\/501100002701","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002701","name":"Ministry of Education","doi-asserted-by":"publisher","award":["RS-2024-00436674"],"award-info":[{"award-number":["RS-2024-00436674"]}],"id":[{"id":"10.13039\/501100002701","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003052","name":"Ministry of Trade, Industry and Energy","doi-asserted-by":"publisher","award":["RS-2024-00403190"],"award-info":[{"award-number":["RS-2024-00403190"]}],"id":[{"id":"10.13039\/501100003052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004080","name":"Korea Drug Development Fund","doi-asserted-by":"publisher","award":["RS-2024-00463605"],"award-info":[{"award-number":["RS-2024-00463605"]}],"id":[{"id":"10.13039\/501100004080","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Vascular endothelial growth factor (VEGF) signaling is a critical regulator of vasculogenesis, angiogenesis, and lymphangiogenesis, processes that are vital for the development of vascular and lymphatic systems, tissue repair, and the maintenance of homeostasis. VEGF ligands and their receptors orchestrate endothelial cell proliferation, migration, and survival, playing a pivotal role in dynamic vascular remodeling. Dysregulated VEGF signaling drives diverse pathological conditions, including tumor angiogenesis, cardiovascular diseases, and ocular disorders. Excessive VEGF activity promotes tumor growth, invasion, and metastasis, while insufficient signaling contributes to impaired wound healing and ischemic diseases. VEGF-targeted therapies, such as monoclonal antibodies and tyrosine kinase inhibitors, have revolutionized the treatment of diseases involving pathological angiogenesis, offering significant clinical benefits in oncology and ophthalmology. These therapies inhibit angiogenesis and slow disease progression, but they often face challenges such as therapeutic resistance, suboptimal efficacy, and adverse effects. To further explore these issues, this review provides a comprehensive overview of VEGF ligands and receptors, elucidating their molecular mechanisms and regulatory networks. It evaluates the latest progress in VEGF-targeted therapies and examines strategies to address current challenges, such as resistance mechanisms. Moreover, the discussion includes emerging therapeutic strategies such as innovative drug delivery systems and combination therapies, highlighting the continuous efforts to improve the effectiveness and safety of VEGF-targeted treatments. This review highlights the translational potential of recent discoveries in VEGF biology for improving patient outcomes.<\/jats:p>","DOI":"10.1038\/s41392-025-02249-0","type":"journal-article","created":{"date-parts":[[2025,5,18]],"date-time":"2025-05-18T19:02:48Z","timestamp":1747594968000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":452,"title":["Vascular endothelial growth factor signaling in health and disease: from molecular mechanisms to therapeutic perspectives"],"prefix":"10.1038","volume":"10","author":[{"given":"Chunsik","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myung-Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-Woong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1551-9828","authenticated-orcid":false,"given":"Yunlong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8574-4938","authenticated-orcid":false,"given":"Yonghwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,19]]},"reference":[{"key":"2249_CR1","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1038\/nature04478","volume":"438","author":"P Carmeliet","year":"2005","unstructured":"Carmeliet, P. Angiogenesis in life, disease and medicine. Nature 438, 932\u2013936 (2005).","journal-title":"Nature"},{"key":"2249_CR2","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/nature04483","volume":"438","author":"N Ferrara","year":"2005","unstructured":"Ferrara, N. & Kerbel, R. S. Angiogenesis as a therapeutic target. Nature 438, 967\u2013974 (2005).","journal-title":"Nature"},{"key":"2249_CR3","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.cell.2019.01.021","volume":"176","author":"RS Apte","year":"2019","unstructured":"Apte, R. S., Chen, D. S. & Ferrara, N. VEGF in signaling and disease: beyond discovery and development. Cell 176, 1248\u20131264 (2019).","journal-title":"Cell"},{"key":"2249_CR4","doi-asserted-by":"publisher","first-page":"895019","DOI":"10.1155\/2013\/895019","volume":"2013","author":"JA Stephenson","year":"2013","unstructured":"Stephenson, J. A., Goddard, J. C., Al-Taan, O., Dennison, A. R. & Morgan, B. Tumour angiogenesis: a growth area\u2014from John Hunter to Judah Folkman and beyond. J. Cancer Res. 2013, 895019 (2013).","journal-title":"J. Cancer Res."},{"key":"2249_CR5","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s10456-016-9496-7","volume":"19","author":"P Lenzi","year":"2016","unstructured":"Lenzi, P., Bocci, G. & Natale, G. John Hunter and the origin of the term \u201cangiogenesis\u201d. Angiogenesis 19, 255\u2013256 (2016).","journal-title":"Angiogenesis"},{"key":"2249_CR6","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s10456-017-9569-2","volume":"20","author":"A Bikfalvi","year":"2017","unstructured":"Bikfalvi, A. History and conceptual developments in vascular biology and angiogenesis research: a personal view. Angiogenesis 20, 463\u2013478 (2017).","journal-title":"Angiogenesis"},{"key":"2249_CR7","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","volume":"285","author":"J Folkman","year":"1971","unstructured":"Folkman, J. Tumor angiogenesis: therapeutic implications. New Engl. J. Med. 285, 1182\u20131186 (1971).","journal-title":"New Engl. J. Med."},{"key":"2249_CR8","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1126\/science.6823562","volume":"219","author":"DR Senger","year":"1983","unstructured":"Senger, D. R. et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219, 983\u2013985 (1983).","journal-title":"Science"},{"key":"2249_CR9","first-page":"1774","volume":"50","author":"DR Senger","year":"1990","unstructured":"Senger, D. R., Connolly, D. T., Van de Water, L., Feder, J. & Dvorak, H. F. Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res. 50, 1774\u20131778 (1990).","journal-title":"Cancer Res."},{"key":"2249_CR10","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/0006-291X(89)92678-8","volume":"161","author":"N Ferrara","year":"1989","unstructured":"Ferrara, N. & Henzel, W. J. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem. Biophys. Res. Commun. 161, 851\u2013858 (1989).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2249_CR11","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1126\/science.2479986","volume":"246","author":"DW Leung","year":"1989","unstructured":"Leung, D. W., Cachianes, G., Kuang, W. J., Goeddel, D. V. & Ferrara, N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246, 1306\u20131309 (1989).","journal-title":"Science"},{"key":"2249_CR12","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1126\/science.2479987","volume":"246","author":"PJ Keck","year":"1989","unstructured":"Keck, P. J. et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 246, 1309\u20131312 (1989).","journal-title":"Science"},{"key":"2249_CR13","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1101\/gr.6.2.124","volume":"6","author":"S Grimmond","year":"1996","unstructured":"Grimmond, S. et al. Cloning and characterization of a novel human gene related to vascular endothelial growth factor. Genome Res. 6, 124\u2013131 (1996).","journal-title":"Genome Res."},{"key":"2249_CR14","doi-asserted-by":"publisher","first-page":"2576","DOI":"10.1073\/pnas.93.6.2576","volume":"93","author":"B Olofsson","year":"1996","unstructured":"Olofsson, B. et al. Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc. Natl. Acad. Sci. USA 93, 2576\u20132581 (1996).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2249_CR15","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1002\/j.1460-2075.1996.tb00359.x","volume":"15","author":"V Joukov","year":"1996","unstructured":"Joukov, V. et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J. 15, 290\u2013298 (1996).","journal-title":"EMBO J."},{"key":"2249_CR16","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1006\/geno.1997.4774","volume":"42","author":"Y Yamada","year":"1997","unstructured":"Yamada, Y., Nezu, J., Shimane, M. & Hirata, Y. Molecular cloning of a novel vascular endothelial growth factor, VEGF-D. Genomics 42, 483\u2013488 (1997).","journal-title":"Genomics"},{"key":"2249_CR17","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s10456-006-9055-8","volume":"9","author":"M Shibuya","year":"2006","unstructured":"Shibuya, M. Vascular endothelial growth factor receptor-1 (VEGFR-1\/Flt-1): a dual regulator for angiogenesis. Angiogenesis 9, 225\u2013230 (2006).","journal-title":"Angiogenesis"},{"key":"2249_CR18","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1152\/physrev.00005.2002","volume":"82","author":"L Jussila","year":"2002","unstructured":"Jussila, L. & Alitalo, K. Vascular growth factors and lymphangiogenesis. Physiol. Rev. 82, 673\u2013700 (2002).","journal-title":"Physiol. Rev."},{"key":"2249_CR19","doi-asserted-by":"publisher","first-page":"11947","DOI":"10.1016\/S0021-9258(18)99049-6","volume":"266","author":"E Tischer","year":"1991","unstructured":"Tischer, E. et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J. Biol. Chem. 266, 11947\u201311954 (1991).","journal-title":"J. Biol. Chem."},{"key":"2249_CR20","doi-asserted-by":"publisher","first-page":"702","DOI":"10.3390\/biom13040702","volume":"13","author":"AL White","year":"2023","unstructured":"White, A. L. & Bix, G. J. VEGFA isoforms as pro-angiogenic therapeutics for cerebrovascular diseases. Biomolecules 13, 702 (2023).","journal-title":"Biomolecules"},{"key":"2249_CR21","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3390\/biology10020167","volume":"10","author":"J Kunnapuu","year":"2021","unstructured":"Kunnapuu, J., Bokharaie, H. & Jeltsch, M. Proteolytic cleavages in the VEGF family: generating diversity among angiogenic VEGFs, essential for the activation of lymphangiogenic VEGFs. Biology 10, 167 (2021).","journal-title":"Biology"},{"key":"2249_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2005-6-2-209","volume":"6","author":"DIR Holmes","year":"2005","unstructured":"Holmes, D. I. R. & Zachary, I. The vascular endothelial growth factor (VEGF) family: angiogenic factors in health and disease. Genome Biol. 6, 209 (2005).","journal-title":"Genome Biol."},{"key":"2249_CR23","doi-asserted-by":"publisher","first-page":"4304","DOI":"10.1111\/j.1742-4658.2011.08350.x","volume":"278","author":"S Iyer","year":"2011","unstructured":"Iyer, S. & Acharya, K. R. Tying the knot: the cystine signature and molecular-recognition processes of the vascular endothelial growth factor family of angiogenic cytokines. FEBS J. 278, 4304\u20134322 (2011).","journal-title":"FEBS J."},{"key":"2249_CR24","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1242\/jcs.114.5.853","volume":"114","author":"CJ Robinson","year":"2001","unstructured":"Robinson, C. J. & Stringer, S. E. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J. Cell. Sci. 114, 853\u2013865 (2001).","journal-title":"J. Cell. Sci."},{"key":"2249_CR25","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1210\/mend-5-12-1806","volume":"5","author":"KA Houck","year":"1991","unstructured":"Houck, K. A. et al. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol. Endocrinol. 5, 1806\u20131814 (1991).","journal-title":"Mol. Endocrinol."},{"key":"2249_CR26","doi-asserted-by":"publisher","first-page":"3287","DOI":"10.1111\/febs.16660","volume":"291","author":"L Perez-Gutierrez","year":"2022","unstructured":"Perez-Gutierrez, L., Li, P. & Ferrara, N. Endothelial cell diversity: the many facets of the crystal. FEBS J. 291, 3287\u20133302 (2022).","journal-title":"FEBS J."},{"key":"2249_CR27","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1083\/jcb.200703052","volume":"179","author":"P Mineur","year":"2007","unstructured":"Mineur, P. et al. Newly identified biologically active and proteolysis-resistant VEGF-A isoform VEGF111 is induced by genotoxic agents. J. Cell Biol. 179, 1261\u20131273 (2007).","journal-title":"J. Cell Biol."},{"key":"2249_CR28","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/S0003-9861(02)00239-4","volume":"404","author":"NJ Gaspar","year":"2002","unstructured":"Gaspar, N. J. et al. Cysteine 116 participates in intermolecular bonding of the human VEGF(121) homodimer. Arch. Biochem. Biophys. 404, 126\u2013135 (2002).","journal-title":"Arch. Biochem. Biophys."},{"key":"2249_CR29","doi-asserted-by":"publisher","first-page":"7151","DOI":"10.1074\/jbc.272.11.7151","volume":"272","author":"Z Poltorak","year":"1997","unstructured":"Poltorak, Z. et al. VEGF145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix. J. Biol. Chem. 272, 7151\u20137158 (1997).","journal-title":"J. Biol. Chem."},{"key":"2249_CR30","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.3390\/ijms19041264","volume":"19","author":"CJ Peach","year":"2018","unstructured":"Peach, C. J. et al. Molecular pharmacology of VEGF-A isoforms: binding and signalling at VEGFR2. Int. J. Mol. Sci. 19, 1264 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"2249_CR31","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3003149","volume":"3","author":"Y Cao","year":"2011","unstructured":"Cao, Y. et al. Forty-year journey of angiogenesis translational research. Sci. Transl. Med. 3, 114rv113 (2011).","journal-title":"Sci. Transl. Med."},{"key":"2249_CR32","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.cytogfr.2014.07.009","volume":"25","author":"S Moens","year":"2014","unstructured":"Moens, S., Goveia, J., Stapor, P. C., Cantelmo, A. R. & Carmeliet, P. The multifaceted activity of VEGF in angiogenesis - Implications for therapy responses. Cytokine Growth Factor Rev. 25, 473\u2013482 (2014).","journal-title":"Cytokine Growth Factor Rev."},{"key":"2249_CR33","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nrm.2016.87","volume":"17","author":"M Simons","year":"2016","unstructured":"Simons, M., Gordon, E. & Claesson-Welsh, L. Mechanisms and regulation of endothelial VEGF receptor signalling. Nat. Rev. Mol. Cell Biol. 17, 611\u2013625 (2016).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2249_CR34","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S0969-2126(98)00065-3","volume":"6","author":"WJ Fairbrother","year":"1998","unstructured":"Fairbrother, W. J., Champe, M. A., Christinger, H. W., Keyt, B. A. & Starovasnik, M. A. Solution structure of the heparin-binding domain of vascular endothelial growth factor. Structure 6, 637\u2013648 (1998).","journal-title":"Structure"},{"key":"2249_CR35","doi-asserted-by":"publisher","first-page":"8823","DOI":"10.1021\/bi4011682","volume":"52","author":"KW Jeong","year":"2013","unstructured":"Jeong, K. W., Jeong, M. C., Jin, B. & Kim, Y. Relationship between structural flexibility and function in the C-terminal region of the heparin-binding domain of VEGF165. Biochemistry 52, 8823\u20138832 (2013).","journal-title":"Biochemistry"},{"key":"2249_CR36","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1006\/bbrc.1998.9717","volume":"252","author":"X Huang","year":"1998","unstructured":"Huang, X., Gottstein, C., Brekken, R. A. & Thorpe, P. E. Expression of soluble VEGF receptor 2 and characterization of its binding by surface plasmon resonance. Biochem. Biophys. Res. Commun. 252, 643\u2013648 (1998).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2249_CR37","doi-asserted-by":"publisher","first-page":"7192","DOI":"10.1073\/pnas.94.14.7192","volume":"94","author":"YA Muller","year":"1997","unstructured":"Muller, Y. A. et al. Vascular endothelial growth factor: crystal structure and functional mapping of the kinase domain receptor binding site. Proc. Natl. Acad. Sci. USA 94, 7192\u20137197 (1997).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2249_CR38","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1042\/CS20040370","volume":"109","author":"H Takahashi","year":"2005","unstructured":"Takahashi, H. & Shibuya, M. The vascular endothelial growth factor (VEGF)\/VEGF receptor system and its role under physiological and pathological conditions. Clin. Sci. 109, 227\u2013241 (2005).","journal-title":"Clin. Sci."},{"key":"2249_CR39","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1073\/pnas.0914318107","volume":"107","author":"VM Lepp\u00e4nen","year":"2010","unstructured":"Lepp\u00e4nen, V. M. et al. Structural determinants of growth factor binding and specificity by VEGF receptor 2. Proc. Natl. Acad. Sci. USA 107, 2425\u20132430 (2010).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2249_CR40","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1091\/mbc.4.12.1317","volume":"4","author":"JE Park","year":"1993","unstructured":"Park, J. E., Keller, G. A. & Ferrara, N. The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol. Biol. Cell 4, 1317\u20131326 (1993).","journal-title":"Mol. Biol. Cell"},{"key":"2249_CR41","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1096\/fj.07-0504ufm","volume":"21","author":"MA von Wronski","year":"2007","unstructured":"von Wronski, M. A., Tweedle, M. F. & Nunn, A. D. Binding of the C-terminal amino acids of VEGF121 directly with neuropilin-1 should be considered. FASEB J. 21, 1292 (2007).","journal-title":"FASEB J."},{"key":"2249_CR42","doi-asserted-by":"publisher","first-page":"31273","DOI":"10.1074\/jbc.273.47.31273","volume":"273","author":"S Ogawa","year":"1998","unstructured":"Ogawa, S. et al. A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilizes KDR\/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain. J. Biol. Chem. 273, 31273\u201331282 (1998).","journal-title":"J. Biol. Chem."},{"key":"2249_CR43","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/S0167-4781(98)00240-1","volume":"1443","author":"J Lei","year":"1998","unstructured":"Lei, J., Jiang, A. & Pei, D. Identification and characterization of a new splicing variant of vascular endothelial growth factor: VEGF183. Biochim. Biophys. Acta 1443, 400\u2013406 (1998).","journal-title":"Biochim. Biophys. Acta"},{"key":"2249_CR44","first-page":"752","volume":"40","author":"L Jingjing","year":"1999","unstructured":"Jingjing, L., Xue, Y., Agarwal, N. & Roque, R. S. Human M\u00fcller cells express VEGF183, a novel spliced variant of vascular endothelial growth factor. Invest. Ophthalmol. Vis. Sci. 40, 752\u2013759 (1999).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"2249_CR45","doi-asserted-by":"publisher","first-page":"288","DOI":"10.3390\/cells8040288","volume":"8","author":"M Stevens","year":"2019","unstructured":"Stevens, M. & Oltean, S. Modulation of receptor tyrosine kinase activity through alternative splicing of ligands and receptors in the VEGF-A\/VEGFR axis. Cells 8, 288 (2019).","journal-title":"Cells"},{"key":"2249_CR46","doi-asserted-by":"publisher","first-page":"H2851","DOI":"10.1152\/ajpheart.01218.2004","volume":"288","author":"F Mac Gabhann","year":"2005","unstructured":"Mac Gabhann, F. & Popel, A. S. Differential binding of VEGF isoforms to VEGF receptor 2 in the presence of neuropilin-1: a computational model. Am. J. Physiol. Heart Circ. Physiol. 288, H2851\u2013H2860 (2005).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"2249_CR47","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/S0143-4004(05)80424-2","volume":"15","author":"FW Anthony","year":"1994","unstructured":"Anthony, F. W., Wheeler, T., Elcock, C. L., Pickett, M. & Thomas, E. J. Short report: identification of a specific pattern of vascular endothelial growth factor mRNA expression in human placenta and cultured placental fibroblasts. Placenta 15, 557\u2013561 (1994).","journal-title":"Placenta"},{"key":"2249_CR48","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.pupt.2005.02.007","volume":"19","author":"AD Nash","year":"2006","unstructured":"Nash, A. D., Baca, M., Wright, C. & Scotney, P. D. The biology of vascular endothelial growth factor-B (VEGF-B). Pulm. Pharmacol. Ther. 19, 61\u201369 (2006).","journal-title":"Pulm. Pharmacol. Ther."},{"key":"2249_CR49","doi-asserted-by":"publisher","first-page":"21217","DOI":"10.1074\/jbc.274.30.21217","volume":"274","author":"T Makinen","year":"1999","unstructured":"Makinen, T. et al. Differential binding of vascular endothelial growth factor B splice and proteolytic isoforms to neuropilin-1. J. Biol. Chem. 274, 21217\u201321222 (1999).","journal-title":"J. Biol. Chem."},{"key":"2249_CR50","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3109\/08977190109001075","volume":"19","author":"X Li","year":"2001","unstructured":"Li, X., Aase, K., Li, H., von Euler, G. & Eriksson, U. Isoform-specific expression of VEGF-B in normal tissues and tumors. Growth Factors 19, 49\u201359 (2001).","journal-title":"Growth Factors"},{"key":"2249_CR51","doi-asserted-by":"publisher","first-page":"19310","DOI":"10.1074\/jbc.271.32.19310","volume":"271","author":"B Olofsson","year":"1996","unstructured":"Olofsson, B. et al. Genomic organization of the mouse and human genes for vascular endothelial growth factor B (VEGF-B) and characterization of a second splice isoform. J. Biol. Chem. 271, 19310\u201319317 (1996).","journal-title":"J. Biol. Chem."},{"key":"2249_CR52","doi-asserted-by":"publisher","first-page":"11709","DOI":"10.1073\/pnas.95.20.11709","volume":"95","author":"B Olofsson","year":"1998","unstructured":"Olofsson, B. et al. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc. Natl. Acad. Sci. USA 95, 11709\u201311714 (1998).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2249_CR53","doi-asserted-by":"publisher","first-page":"re1","DOI":"10.1126\/scisignal.259re1","volume":"2","author":"Y Cao","year":"2009","unstructured":"Cao, Y. Positive and negative modulation of angiogenesis by VEGFR1 ligands. Sci. Signal. 2, re1 (2009).","journal-title":"Sci. Signal."},{"key":"2249_CR54","doi-asserted-by":"publisher","first-page":"23779","DOI":"10.1074\/jbc.M110.130658","volume":"285","author":"S Iyer","year":"2010","unstructured":"Iyer, S., Darley, P. I. & Acharya, K. R. Structural insights into the binding of VEGF-B by VEGFR-1D2: recognition and specificity. J. Biol. Chem. 285, 23779 (2010).","journal-title":"J. Biol. Chem."},{"key":"2249_CR55","doi-asserted-by":"publisher","first-page":"ra52","DOI":"10.1126\/scisignal.2003905","volume":"6","author":"A Anisimov","year":"2013","unstructured":"Anisimov, A. et al. The basis for the distinct biological activities of vascular endothelial growth factor receptor\u20131 ligands. Sci. Signal. 6, ra52 (2013).","journal-title":"Sci. Signal."},{"key":"2249_CR56","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1152\/physrev.00028.2013","volume":"94","author":"M Bry","year":"2014","unstructured":"Bry, M., Kivel\u00e4, R., Lepp\u00e4nen, V. M. & Alitalo, K. Vascular endothelial growth factor-B in physiology and disease. Physiol. Rev. 94, 779\u2013794 (2014).","journal-title":"Physiol. Rev."},{"key":"2249_CR57","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.phrs.2019.03.002","volume":"143","author":"R Chen","year":"2019","unstructured":"Chen, R., Lee, C., Lin, X., Zhao, C. & Li, X. Novel function of VEGF-B as an antioxidant and therapeutic implications. Pharmacol. Res. 143, 33\u201339 (2019).","journal-title":"Pharmacol. Res."},{"key":"2249_CR58","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.exer.2006.03.019","volume":"83","author":"N Rahimi","year":"2006","unstructured":"Rahimi, N. Vascular endothelial growth factor receptors: molecular mechanisms of activation and therapeutic potentials. Exp. Eye Res. 83, 1005\u20131016 (2006).","journal-title":"Exp. Eye Res."},{"key":"2249_CR59","doi-asserted-by":"publisher","first-page":"4064","DOI":"10.1093\/emboj\/19.15.4064","volume":"19","author":"H Gille","year":"2000","unstructured":"Gille, H. et al. A repressor sequence in the juxtamembrane domain of Flt-1 (VEGFR-1) constitutively inhibits VEGF-dependent PI 3 kinase activation and endothelial cell migration. EMBO J. 19, 4064\u20134073 (2000).","journal-title":"EMBO J."},{"key":"2249_CR60","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1073\/pnas.93.5.1988","volume":"93","author":"J Lee","year":"1996","unstructured":"Lee, J. et al. Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4. Proc. Natl. Acad. Sci. USA 93, 1988\u20131992 (1996).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2249_CR61","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.1093\/emboj\/16.13.3898","volume":"16","author":"V Joukov","year":"1997","unstructured":"Joukov, V. et al. Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J. 16, 3898\u20133911 (1997).","journal-title":"EMBO J."},{"key":"2249_CR62","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1172\/JCI200317220","volume":"111","author":"G Siegfried","year":"2003","unstructured":"Siegfried, G. et al. The secretory proprotein convertases furin, PC5, and PC7 activate VEGF-C to induce tumorigenesis. J. Clin. Invest. 111, 1723\u20131732 (2003).","journal-title":"J. Clin. Invest."},{"key":"2249_CR63","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3389\/fbioe.2018.00007","volume":"6","author":"K Rauniyar","year":"2018","unstructured":"Rauniyar, K., Jha, S. K. & Jeltsch, M. Biology of vascular endothelial growth factor C in the morphogenesis of lymphatic vessels. Front. Bioeng. Biotechnol. 6, 7 (2018).","journal-title":"Front. Bioeng. Biotechnol."},{"key":"2249_CR64","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.44478","volume":"8","author":"SK Jha","year":"2019","unstructured":"Jha, S. K. et al. KLK3\/PSA and cathepsin D activate VEGF-C and VEGF-D. eLife 8, e44478 (2019).","journal-title":"eLife"},{"key":"2249_CR65","doi-asserted-by":"publisher","first-page":"44307","DOI":"10.1074\/jbc.M106188200","volume":"276","author":"ME Baldwin","year":"2001","unstructured":"Baldwin, M. E. et al. Multiple forms of mouse vascular endothelial growth factor-D are generated by RNA splicing and proteolysis. J. Biol. Chem. 276, 44307\u201344314 (2001).","journal-title":"J. Biol. Chem."},{"key":"2249_CR66","doi-asserted-by":"publisher","first-page":"32127","DOI":"10.1074\/jbc.274.45.32127","volume":"274","author":"SA Stacker","year":"1999","unstructured":"Stacker, S. A. et al. Biosynthesis of vascular endothelial growth factor-D involves proteolytic processing which generates non-covalent homodimers. J. Biol. Chem. 274, 32127\u201332136 (1999).","journal-title":"J. Biol. Chem."},{"key":"2249_CR67","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1182\/blood-2010-08-301549","volume":"117","author":"V-M Lepp\u00e4nen","year":"2011","unstructured":"Lepp\u00e4nen, V.-M. et al. Structural determinants of vascular endothelial growth factor-D receptor binding and specificity. Blood 117, 1507\u20131515 (2011).","journal-title":"Blood"},{"key":"2249_CR68","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1073\/pnas.95.2.548","volume":"95","author":"MG Achen","year":"1998","unstructured":"Achen, M. G. et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc. Natl. Acad. Sci. USA 95, 548\u2013553 (1998).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2249_CR69","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1084\/jem.20030361","volume":"198","author":"BK McColl","year":"2003","unstructured":"McColl, B. K. et al. Plasmin activates the lymphangiogenic growth factors VEGF-C and VEGF-D. J. Exp. Med. 198, 863\u2013868 (2003).","journal-title":"J. Exp. Med."},{"key":"2249_CR70","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ceb.2008.12.012","volume":"21","author":"M Lohela","year":"2009","unstructured":"Lohela, M., Bry, M., Tammela, T. & Alitalo, K. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr. Opin. Cell Biol. 21, 154\u2013165 (2009).","journal-title":"Curr. Opin. Cell Biol."},{"key":"2249_CR71","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1093\/cvr\/cvaa291","volume":"117","author":"RM Monaghan","year":"2021","unstructured":"Monaghan, R. M., Page, D. J., Ostergaard, P. & Keavney, B. D. The physiological and pathological functions of VEGFR3 in cardiac and lymphatic development and related diseases. Cardiovasc. Res. 117, 1877\u20131890 (2021).","journal-title":"Cardiovasc. Res."},{"key":"2249_CR72","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1161\/CIRCULATIONAHA.113.002779","volume":"129","author":"M Jeltsch","year":"2014","unstructured":"Jeltsch, M. et al. CCBE1 enhances lymphangiogenesis via A disintegrin and metalloprotease with thrombospondin motifs-3-mediated vascular endothelial growth factor-C activation. Circulation 129, 1962\u20131971 (2014).","journal-title":"Circulation"},{"key":"2249_CR73","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1080\/08977190290031969","volume":"20","author":"MG Achen","year":"2002","unstructured":"Achen, M. G. et al. The angiogenic and lymphangiogenic factor vascular endothelial growth factor-D exhibits a paracrine mode of action in cancer. Growth Factors 20, 99\u2013107 (2002).","journal-title":"Growth Factors"},{"key":"2249_CR74","doi-asserted-by":"publisher","first-page":"283","DOI":"10.3109\/08977194.2012.704917","volume":"30","author":"MG Achen","year":"2012","unstructured":"Achen, M. G. & Stacker, S. A. Vascular endothelial growth factor-D: signaling mechanisms, biology, and clinical relevance. Growth Factors 30, 283\u2013296 (2012).","journal-title":"Growth Factors"},{"key":"2249_CR75","first-page":"4123","volume":"62","author":"DO Bates","year":"2002","unstructured":"Bates, D. O. et al. VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res. 62, 4123\u20134131 (2002).","journal-title":"Cancer Res."},{"key":"2249_CR76","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-9-320","volume":"9","author":"R Catena","year":"2010","unstructured":"Catena, R. et al. VEGF121b and VEGF165b are weakly angiogenic isoforms of VEGF-A. Mol. Cancer 9, 320 (2010).","journal-title":"Mol. Cancer"},{"key":"2249_CR77","doi-asserted-by":"publisher","first-page":"3487","DOI":"10.1242\/jcs.016410","volume":"121","author":"DG Nowak","year":"2008","unstructured":"Nowak, D. G. et al. Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors. J. Cell. Sci. 121, 3487\u20133495 (2008).","journal-title":"J. Cell. Sci."},{"key":"2249_CR78","doi-asserted-by":"publisher","first-page":"e35231","DOI":"10.1371\/journal.pone.0035231","volume":"7","author":"S Harris","year":"2012","unstructured":"Harris, S. et al. Do anti-angiogenic VEGF (VEGFxxxb) isoforms exist? A cautionary tale. PLoS ONE 7, e35231 (2012).","journal-title":"PLoS ONE"},{"key":"2249_CR79","doi-asserted-by":"publisher","first-page":"e0197123","DOI":"10.1371\/journal.pone.0197123","volume":"13","author":"D Lomet","year":"2018","unstructured":"Lomet, D., Pi\u00e9gu, B., Wood, S. H. & Dardente, H. Anti-angiogenic VEGFAxxxb transcripts are not expressed in the medio-basal hypothalamus of the seasonal sheep. PLoS ONE 13, e0197123 (2018).","journal-title":"PLoS ONE"},{"key":"2249_CR80","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-00100-3","volume":"7","author":"S Bridgett","year":"2017","unstructured":"Bridgett, S., Dellett, M. & Simpson, D. A. RNA-sequencing data supports the existence of novel VEGFA splicing events but not of VEGFA(xxx)b isoforms. Sci. Rep. 7, 58 (2017).","journal-title":"Sci. Rep."},{"key":"2249_CR81","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1042\/BST0371207","volume":"37","author":"Y Qiu","year":"2009","unstructured":"Qiu, Y., Hoareau-Aveilla, C., Oltean, S., Harper, S. J. & Bates, D. O. The anti-angiogenic isoforms of VEGF in health and disease. Biochem. Soc. Trans. 37, 1207\u20131213 (2009).","journal-title":"Biochem. Soc. Trans."},{"key":"2249_CR82","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1038\/nm.3703","volume":"20","author":"R Kikuchi","year":"2014","unstructured":"Kikuchi, R. et al. An antiangiogenic isoform of VEGF-A contributes to impaired vascularization in peripheral artery disease. Nat. Med. 20, 1464\u20131471 (2014).","journal-title":"Nat. Med."},{"key":"2249_CR83","doi-asserted-by":"publisher","first-page":"9267","DOI":"10.1073\/pnas.88.20.9267","volume":"88","author":"D Maglione","year":"1991","unstructured":"Maglione, D., Guerriero, V., Viglietto, G., Delli-Bovi, P. & Persico, M. G. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc. Natl. Acad. Sci. USA 88, 9267\u20139271 (1991).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2249_CR84","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nature10144","volume":"473","author":"P Carmeliet","year":"2011","unstructured":"Carmeliet, P. & Jain, R. K. Molecular mechanisms and clinical applications of angiogenesis. Nature 473, 298\u2013307 (2011).","journal-title":"Nature"},{"key":"2249_CR85","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3109\/08977199308991586","volume":"9","author":"S Hauser","year":"1993","unstructured":"Hauser, S. & Weich, H. A. A heparin-binding form of placenta growth factor (PlGF-2) is expressed in human umbilical vein endothelial cells and in placenta. Growth Factors 9, 259\u2013268 (1993).","journal-title":"Growth Factors"},{"key":"2249_CR86","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1006\/bbrc.1997.6813","volume":"235","author":"Y Cao","year":"1997","unstructured":"Cao, Y., Ji, W. R., Qi, P., Rosin, A. & Cao, Y. Placenta growth factor: identification and characterization of a novel isoform generated by RNA alternative splicing. Biochem. Biophys. Res. Commun. 235, 493\u2013498 (1997).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2249_CR87","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/87904","volume":"7","author":"P Carmeliet","year":"2001","unstructured":"Carmeliet, P. et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat. Med. 7, 575\u2013583 (2001).","journal-title":"Nat. Med."},{"key":"2249_CR88","doi-asserted-by":"publisher","first-page":"3154","DOI":"10.1074\/jbc.271.6.3154","volume":"271","author":"Y Cao","year":"1996","unstructured":"Cao, Y. et al. Heterodimers of placenta growth factor\/vascular endothelial growth factor. Endothelial activity, tumor cell expression, and high affinity binding to Flk-1\/KDR. J. Biol. Chem. 271, 3154\u20133162 (1996).","journal-title":"J. Biol. Chem."},{"key":"2249_CR89","doi-asserted-by":"publisher","first-page":"17976","DOI":"10.1074\/jbc.M113.451831","volume":"288","author":"DC Hoffmann","year":"2013","unstructured":"Hoffmann, D. C. et al. Proteolytic processing regulates placental growth factor activities. J. Biol. Chem. 288, 17976\u201317989 (2013).","journal-title":"J. Biol. Chem."},{"key":"2249_CR90","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0165-0378(03)00082-2","volume":"60","author":"W Yang","year":"2003","unstructured":"Yang, W., Ahn, H., Hinrichs, M., Torry, R. J. & Torry, D. S. Evidence of a novel isoform of placenta growth factor (PlGF-4) expressed in human trophoblast and endothelial cells. J. Reprod. Immunol. 60, 53\u201360 (2003).","journal-title":"J. Reprod. Immunol."},{"key":"2249_CR91","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1517\/14728222.2014.948420","volume":"18","author":"M Dewerchin","year":"2014","unstructured":"Dewerchin, M. & Carmeliet, P. Placental growth factor in cancer. Expert Opin. Ther. Targets 18, 1339\u20131354 (2014).","journal-title":"Expert Opin. Ther. Targets"},{"key":"2249_CR92","doi-asserted-by":"publisher","first-page":"H153","DOI":"10.1152\/ajpheart.00254.2003","volume":"286","author":"F Mac Gabhann","year":"2004","unstructured":"Mac Gabhann, F. & Popel, A. S. Model of competitive binding of vascular endothelial growth factor and placental growth factor to VEGF receptors on endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 286, H153\u2013H164 (2004).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"2249_CR93","first-page":"519","volume":"5","author":"M Shibuya","year":"1990","unstructured":"Shibuya, M. et al. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene 5, 519\u2013524 (1990).","journal-title":"Oncogene"},{"key":"2249_CR94","doi-asserted-by":"publisher","first-page":"10705","DOI":"10.1073\/pnas.90.22.10705","volume":"90","author":"RL Kendall","year":"1993","unstructured":"Kendall, R. L. & Thomas, K. A. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc. Natl. Acad. Sci. USA 90, 10705\u201310709 (1993).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2249_CR95","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s10456-011-9249-6","volume":"15","author":"N Papadopoulos","year":"2012","unstructured":"Papadopoulos, N. et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 15, 171\u2013185 (2012).","journal-title":"Angiogenesis"},{"key":"2249_CR96","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1111\/j.1349-7006.1997.tb00463.x","volume":"88","author":"K Tanaka","year":"1997","unstructured":"Tanaka, K., Yamaguchi, S., Sawano, A. & Shibuya, M. Characterization of the extracellular domain in vascular endothelial growth factor receptor-1 (Flt-1 tyrosine kinase). Jpn. J. Cancer Res. 88, 867\u2013876 (1997).","journal-title":"Jpn. J. Cancer Res."},{"key":"2249_CR97","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.3390\/biom10121673","volume":"10","author":"F Shaik","year":"2020","unstructured":"Shaik, F. et al. Structural basis for vascular endothelial growth factor receptor activation and implications for disease therapy. Biomolecules 10, 1673 (2020).","journal-title":"Biomolecules"},{"key":"2249_CR98","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1002\/iub.234","volume":"61","author":"E Stuttfeld","year":"2009","unstructured":"Stuttfeld, E. & Ballmer-Hofer, K. Structure and function of VEGF receptors. IUBMB Life 61, 915\u2013922 (2009).","journal-title":"IUBMB Life"},{"key":"2249_CR99","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.str.2016.12.012","volume":"25","author":"S Markovic-Mueller","year":"2017","unstructured":"Markovic-Mueller, S. Structure of the full-length VEGFR-1 extracellular domain in complex with VEGFA. Structure 25, 341\u2013352 (2017).","journal-title":"Structure"},{"key":"2249_CR100","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/nrm1911","volume":"7","author":"AK Olsson","year":"2006","unstructured":"Olsson, A. K., Dimberg, A., Kreuger, J. & Claesson-Welsh, L. VEGF receptor signalling - in control of vascular function. Nat. Rev. Mol. Cell Biol. 7, 359\u2013371 (2006).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2249_CR101","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/nm0603-669","volume":"9","author":"N Ferrara","year":"2003","unstructured":"Ferrara, N., Gerber, H. P. & LeCouter, J. The biology of VEGF and its receptors. Nat. Med. 9, 669\u2013676 (2003).","journal-title":"Nat. Med."},{"key":"2249_CR102","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45499-2","volume":"15","author":"MP Chakraborty","year":"2024","unstructured":"Chakraborty, M. P. et al. Molecular basis of VEGFR1 autoinhibition at the plasma membrane. Nat. Commun. 15, 1346 (2024).","journal-title":"Nat. Commun."},{"key":"2249_CR103","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1074\/jbc.M506454200","volume":"281","author":"RD Meyer","year":"2006","unstructured":"Meyer, R. D., Mohammadi, M. & Rahimi, N. A single amino acid substitution in the activation loop defines the decoy characteristic of VEGFR-1\/FLT-1. J. Biol. Chem. 281, 867\u2013875 (2006).","journal-title":"J. Biol. Chem."},{"key":"2249_CR104","doi-asserted-by":"publisher","first-page":"818","DOI":"10.2741\/1839","volume":"11","author":"N Rahimi","year":"2006","unstructured":"Rahimi, N. VEGFR-1 and VEGFR-2: two non-identical twins with a unique physiognomy. Front. Biosci. 11, 818\u2013829 (2006).","journal-title":"Front. Biosci."},{"key":"2249_CR105","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s10456-024-09942-8","volume":"27","author":"LE Wazan","year":"2024","unstructured":"Wazan, L. E., Widhibrata, A. & Liu, G. S. Soluble FLT-1 in angiogenesis: pathophysiological roles and therapeutic implications. Angiogenesis 27, 641\u2013661 (2024).","journal-title":"Angiogenesis"},{"key":"2249_CR106","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/labinvest.3780050","volume":"80","author":"C Hornig","year":"2000","unstructured":"Hornig, C. et al. Release and complex formation of soluble VEGFR-1 from endothelial cells and biological fluids. Lab. Invest. 80, 443\u2013454 (2000).","journal-title":"Lab. Invest."},{"key":"2249_CR107","doi-asserted-by":"publisher","first-page":"5130","DOI":"10.1093\/nar\/gkq198","volume":"38","author":"CP Thomas","year":"2010","unstructured":"Thomas, C. P., Raikwar, N. S., Kelley, E. A. & Liu, K. Z. Alternate processing of Flt1 transcripts is directed by conserved cis-elements within an intronic region of FLT1 that reciprocally regulates splicing and polyadenylation. Nucleic Acids Res. 38, 5130\u20135140 (2010).","journal-title":"Nucleic Acids Res."},{"key":"2249_CR108","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-36728-y","volume":"9","author":"C Abou Faycal","year":"2019","unstructured":"Abou Faycal, C., Gazzeri, S. & Eymin, B. A VEGF-A\/SOX2\/SRSF2 network controls VEGFR1 pre-mRNA alternative splicing in lung carcinoma cells. Sci. Rep. 9, 336 (2019).","journal-title":"Sci. Rep."},{"key":"2249_CR109","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.placenta.2008.12.010","volume":"30","author":"M Heydarian","year":"2009","unstructured":"Heydarian, M. et al. Novel splice variants of sFlt1 are upregulated in preeclampsia. Placenta 30, 250\u2013255 (2009).","journal-title":"Placenta"},{"key":"2249_CR110","first-page":"1677","volume":"6","author":"BI Terman","year":"1991","unstructured":"Terman, B. I. et al. Identification of a new endothelial cell growth factor receptor tyrosine kinase. Oncogene 6, 1677\u20131683 (1991).","journal-title":"Oncogene"},{"key":"2249_CR111","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/0092-8674(93)90573-9","volume":"72","author":"B Millauer","year":"1993","unstructured":"Millauer, B. et al. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 72, 835\u2013846 (1993).","journal-title":"Cell"},{"key":"2249_CR112","doi-asserted-by":"publisher","first-page":"9026","DOI":"10.1073\/pnas.88.20.9026","volume":"88","author":"W Matthews","year":"1991","unstructured":"Matthews, W. et al. A receptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit. Proc. Natl. Acad. Sci. USA 88, 9026\u20139030 (1991).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2249_CR113","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1182\/blood-2011-11-390922","volume":"119","author":"MS Brozzo","year":"2012","unstructured":"Brozzo, M. S. et al. Thermodynamic and structural description of allosterically regulated VEGFR-2 dimerization. Blood 119, 1781\u20131788 (2012).","journal-title":"Blood"},{"key":"2249_CR114","doi-asserted-by":"publisher","first-page":"599281","DOI":"10.3389\/fcell.2020.599281","volume":"8","author":"X Wang","year":"2020","unstructured":"Wang, X., Bove, A. M., Simone, G. & Ma, B. Molecular bases of VEGFR-2-mediated physiological function and pathological role. Front. Cell Dev. Biol. 8, 599281 (2020).","journal-title":"Front. Cell Dev. Biol."},{"key":"2249_CR115","doi-asserted-by":"publisher","first-page":"31283","DOI":"10.1074\/jbc.273.47.31283","volume":"273","author":"A Shinkai","year":"1998","unstructured":"Shinkai, A. et al. Mapping of the sites involved in ligand association and dissociation at the extracellular domain of the kinase insert domain-containing receptor for vascular endothelial growth factor. J. Biol. Chem. 273, 31283\u201331288 (1998).","journal-title":"J. Biol. Chem."},{"key":"2249_CR116","doi-asserted-by":"publisher","first-page":"3802","DOI":"10.1128\/MCB.06787-11","volume":"32","author":"CA Hyde","year":"2012","unstructured":"Hyde, C. A. et al. Targeting extracellular domains D4 and D7 of vascular endothelial growth factor receptor 2 reveals allosteric receptor regulatory sites. Mol. Cell. Biol. 32, 3802\u20133813 (2012).","journal-title":"Mol. Cell. Biol."},{"key":"2249_CR117","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1016\/j.bbagen.2017.08.021","volume":"1861","author":"C King","year":"2017","unstructured":"King, C., Wirth, D., Workman, S. & Hristova, K. Cooperative interactions between VEGFR2 extracellular Ig-like subdomains ensure VEGFR2 dimerization. Biochim. Biophys. Acta Gen. Subj. 1861, 2559\u20132567 (2017).","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"2249_CR118","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.bbamem.2013.08.021","volume":"1838","author":"KS Mineev","year":"2014","unstructured":"Mineev, K. S. et al. NMR-based approach to measure the free energy of transmembrane helix-helix interactions. Biochim. Biophys. Acta 1838, 164\u2013172 (2014).","journal-title":"Biochim. Biophys. Acta"},{"key":"2249_CR119","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1096\/fj.09-132670","volume":"24","author":"DD Dosch","year":"2010","unstructured":"Dosch, D. D. & Ballmer-Hofer, K. Transmembrane domain-mediated orientation of receptor monomers in active VEGFR-2 dimers. FASEB J. 24, 32\u201338 (2010).","journal-title":"FASEB J."},{"key":"2249_CR120","doi-asserted-by":"publisher","first-page":"16788","DOI":"10.1021\/bi981291f","volume":"37","author":"CV Parast","year":"1998","unstructured":"Parast, C. V. et al. Characterization and kinetic mechanism of catalytic domain of human vascular endothelial growth factor receptor-2 tyrosine kinase (VEGFR2 TK), a key enzyme in angiogenesis. Biochemistry 37, 16788\u201316801 (1998).","journal-title":"Biochemistry"},{"key":"2249_CR121","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1042\/BJ20110301","volume":"437","author":"S Koch","year":"2011","unstructured":"Koch, S., Tugues, S., Li, X., Gualandi, L. & Claesson-Welsh, L. Signal transduction by vascular endothelial growth factor receptors. Biochem. J. 437, 169\u2013183 (2011).","journal-title":"Biochem. J."},{"key":"2249_CR122","doi-asserted-by":"publisher","first-page":"27081","DOI":"10.1074\/jbc.M110544200","volume":"277","author":"RD Meyer","year":"2002","unstructured":"Meyer, R. D., Dayanir, V., Majnoun, F. & Rahimi, N. The presence of a single tyrosine residue at the carboxyl domain of vascular endothelial growth factor receptor-2\/FLK-1 regulates its autophosphorylation and activation of signaling molecules. J. Biol. Chem. 277, 27081\u201327087 (2002).","journal-title":"J. Biol. Chem."},{"key":"2249_CR123","doi-asserted-by":"publisher","first-page":"4914","DOI":"10.1096\/fj.14-256206","volume":"28","author":"S Manni","year":"2014","unstructured":"Manni, S., Kisko, K., Schleier, T., Missimer, J. & Ballmer-Hofer, K. Functional and structural characterization of the kinase insert and the carboxy terminal domain in VEGF receptor 2 activation. FASEB J. 28, 4914\u20134923 (2014).","journal-title":"FASEB J."},{"key":"2249_CR124","doi-asserted-by":"publisher","first-page":"12960","DOI":"10.1073\/pnas.1301415110","volume":"110","author":"VM Lepp\u00e4nen","year":"2013","unstructured":"Lepp\u00e4nen, V. M. et al. Structural and mechanistic insights into VEGF receptor 3 ligand binding and activation. Proc. Natl. Acad. Sci. USA 110, 12960\u201312965 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2249_CR125","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.cca.2016.08.008","volume":"461","author":"J Wang","year":"2016","unstructured":"Wang, J. et al. Pathway-related molecules of VEGFC\/D-VEGFR3\/NRP2 axis in tumor lymphangiogenesis and lymphatic metastasis. Clin. Chim. Acta 461, 165\u2013171 (2016).","journal-title":"Clin. Chim. Acta"},{"key":"2249_CR126","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1161\/ATVBAHA.114.303215","volume":"35","author":"CK Domigan","year":"2015","unstructured":"Domigan, C. K., Ziyad, S. & Iruela-Arispe, M. L. Canonical and noncanonical vascular endothelial growth factor pathways: new developments in biology and signal transduction. Arterioscler. Thromb. Vasc. Biol. 35, 30\u201339 (2015).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2249_CR127","doi-asserted-by":"publisher","first-page":"9064","DOI":"10.1074\/jbc.RA119.007737","volume":"294","author":"C King","year":"2019","unstructured":"King, C. & Hristova, K. Direct measurements of VEGF\u2013VEGFR2 binding affinities reveal the coupling between ligand binding and receptor dimerization. J. Biol. Chem. 294, 9064\u20139075 (2019).","journal-title":"J. Biol. Chem."},{"key":"2249_CR128","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.bpc.2007.03.010","volume":"128","author":"F Mac Gabhann","year":"2007","unstructured":"Mac Gabhann, F. & Popel, A. S. Dimerization of VEGF receptors and implications for signal transduction: a computational study. Biophys. Chem. 128, 125\u2013139 (2007).","journal-title":"Biophys. Chem."},{"key":"2249_CR129","doi-asserted-by":"publisher","first-page":"e13876","DOI":"10.7554\/eLife.13876","volume":"5","author":"S Sarabipour","year":"2016","unstructured":"Sarabipour, S., Ballmer-Hofer, K. & Hristova, K. VEGFR-2 conformational switch in response to ligand binding. eLife 5, e13876 (2016).","journal-title":"eLife"},{"key":"2249_CR130","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms1977","volume":"3","author":"MJ Cudmore","year":"2012","unstructured":"Cudmore, M. J. et al. The role of heterodimerization between VEGFR-1 and VEGFR-2 in the regulation of endothelial cell homeostasis. Nat. Commun. 3, 972 (2012).","journal-title":"Nat. Commun."},{"key":"2249_CR131","doi-asserted-by":"publisher","first-page":"40973","DOI":"10.1074\/jbc.M304499200","volume":"278","author":"J Dixelius","year":"2003","unstructured":"Dixelius, J. et al. Ligand-induced vascular endothelial growth factor receptor-3 (VEGFR-3) heterodimerization with VEGFR-2 in primary lymphatic endothelial cells regulates tyrosine phosphorylation sites. J. Biol. Chem. 278, 40973\u201340979 (2003).","journal-title":"J. Biol. Chem."},{"key":"2249_CR132","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1038\/emboj.2010.30","volume":"29","author":"I Nilsson","year":"2010","unstructured":"Nilsson, I. et al. VEGF receptor 2\/-3 heterodimers detected in situ by proximity ligation on angiogenic sprouts. EMBO J. 29, 1377\u20131388 (2010).","journal-title":"EMBO J."},{"key":"2249_CR133","doi-asserted-by":"publisher","first-page":"e0269818","DOI":"10.1371\/journal.pone.0269818","volume":"17","author":"J Sarkar","year":"2022","unstructured":"Sarkar, J. et al. VEGF receptor heterodimers and homodimers are differentially expressed in neuronal and endothelial cell types. PLoS ONE 17, e0269818 (2022).","journal-title":"PLoS ONE"},{"key":"2249_CR134","doi-asserted-by":"publisher","first-page":"26690","DOI":"10.1016\/S0021-9258(19)61431-6","volume":"275","author":"G Fuh","year":"2000","unstructured":"Fuh, G., Garcia, K. C. & de Vos, A. M. The interaction of neuropilin-1 with vascular endothelial growth factor and its receptor flt-1. J. Biol. Chem. 275, 26690\u201326695 (2000).","journal-title":"J. Biol. Chem."},{"key":"2249_CR135","doi-asserted-by":"publisher","first-page":"18688","DOI":"10.1074\/jbc.M006909200","volume":"276","author":"Z Gluzman-Poltorak","year":"2001","unstructured":"Gluzman-Poltorak, Z., Cohen, T., Shibuya, M. & Neufeld, G. Vascular endothelial growth factor receptor-1 and neuropilin-2 form complexes. J. Biol. Chem. 276, 18688\u201318694 (2001).","journal-title":"J. Biol. Chem."},{"key":"2249_CR136","doi-asserted-by":"publisher","first-page":"3479","DOI":"10.1242\/jcs.00673","volume":"116","author":"A Orecchia","year":"2003","unstructured":"Orecchia, A. et al. Vascular endothelial growth factor receptor-1 is deposited in the extracellular matrix by endothelial cells and is a ligand for the alpha 5 beta 1 integrin. J. Cell. Sci. 116, 3479\u20133489 (2003).","journal-title":"J. Cell. Sci."},{"key":"2249_CR137","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/s41392-023-01539-9","volume":"8","author":"C Lee","year":"2023","unstructured":"Lee, C. et al. VEGF-B prevents excessive angiogenesis by inhibiting FGF2\/FGFR1 pathway. Signal Transduct. Target. Ther. 8, 305 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2249_CR138","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1159\/000354169","volume":"99","author":"I Zachary","year":"2014","unstructured":"Zachary, I. Neuropilins: role in signalling, angiogenesis and disease. Chem. Immunol. Allergy 99, 37\u201370 (2014).","journal-title":"Chem. Immunol. Allergy"},{"key":"2249_CR139","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.devcel.2014.02.010","volume":"28","author":"S Koch","year":"2014","unstructured":"Koch, S. et al. NRP1 presented in trans to the endothelium arrests VEGFR2 endocytosis, preventing angiogenic signaling and tumor initiation. Dev. Cell 28, 633\u2013646 (2014).","journal-title":"Dev. Cell"},{"key":"2249_CR140","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1002\/jcb.10140","volume":"85","author":"S Soker","year":"2002","unstructured":"Soker, S., Miao, H. Q., Nomi, M., Takashima, S. & Klagsbrun, M. VEGF165 mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding. J. Cell. Biochem. 85, 357\u2013368 (2002).","journal-title":"J. Cell. Biochem."},{"key":"2249_CR141","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1182\/bloodadvances.2019000019","volume":"3","author":"A Guti\u00e9rrez-Gonz\u00e1lez","year":"2019","unstructured":"Guti\u00e9rrez-Gonz\u00e1lez, A. et al. \u03b14\u03b21 integrin associates with VEGFR2 in CLL cells and contributes to VEGF binding and intracellular signaling. Blood Adv. 3, 2144\u20132148 (2019).","journal-title":"Blood Adv."},{"key":"2249_CR142","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/nature07424","volume":"456","author":"JI Greenberg","year":"2008","unstructured":"Greenberg, J. I. et al. A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature 456, 809\u2013813 (2008).","journal-title":"Nature"},{"key":"2249_CR143","doi-asserted-by":"publisher","first-page":"167006","DOI":"10.1016\/j.jmb.2021.167006","volume":"433","author":"MD Paul","year":"2021","unstructured":"Paul, M. D. & Hristova, K. Interactions between Ligand-Bound EGFR and VEGFR2. J. Mol. Biol. 433, 167006 (2021).","journal-title":"J. Mol. Biol."},{"key":"2249_CR144","doi-asserted-by":"publisher","first-page":"5236","DOI":"10.1182\/blood-2009-04-219204","volume":"114","author":"M Tremmel","year":"2009","unstructured":"Tremmel, M. et al. A CD44v6 peptide reveals a role of CD44 in VEGFR-2 signaling and angiogenesis. Blood 114, 5236\u20135244 (2009).","journal-title":"Blood"},{"key":"2249_CR145","first-page":"1789","volume":"19","author":"Q Chen","year":"2020","unstructured":"Chen, Q. et al. Possible role of EphA4 and VEGFR2 interactions in neural stem and progenitor cell differentiation. Exp. Ther. Med. 19, 1789\u20131796 (2020).","journal-title":"Exp. Ther. Med."},{"key":"2249_CR146","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1083\/jcb.200602080","volume":"174","author":"MG Lampugnani","year":"2006","unstructured":"Lampugnani, M. G., Orsenigo, F., Gagliani, M. C., Tacchetti, C. & Dejana, E. Vascular endothelial cadherin controls VEGFR-2 internalization and signaling from intracellular compartments. J. Cell Biol. 174, 593\u2013604 (2006).","journal-title":"J. Cell Biol."},{"key":"2249_CR147","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ccr.2012.05.037","volume":"22","author":"KV Lu","year":"2012","unstructured":"Lu, K. V. et al. VEGF inhibits tumor cell invasion and mesenchymal transition through a MET\/VEGFR2 complex. Cancer Cell 22, 21\u201335 (2012).","journal-title":"Cancer Cell"},{"key":"2249_CR148","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1182\/blood-2005-11-4447","volume":"108","author":"B Favier","year":"2006","unstructured":"Favier, B. et al. Neuropilin-2 interacts with VEGFR-2 and VEGFR-3 and promotes human endothelial cell survival and migration. Blood 108, 1243\u20131250 (2006).","journal-title":"Blood"},{"key":"2249_CR149","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S0092-8674(00)81402-6","volume":"92","author":"S Soker","year":"1998","unstructured":"Soker, S., Takashima, S., Miao, H. Q., Neufeld, G. & Klagsbrun, M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92, 735\u2013745 (1998).","journal-title":"Cell"},{"key":"2249_CR150","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/978-1-4615-0119-0_5","volume":"515","author":"F Nakamura","year":"2002","unstructured":"Nakamura, F. & Goshima, Y. Structural and functional relation of neuropilins. Adv. Exp. Med. Biol. 515, 55\u201369 (2002).","journal-title":"Adv. Exp. Med. Biol."},{"key":"2249_CR151","doi-asserted-by":"publisher","first-page":"25110","DOI":"10.1074\/jbc.C800137200","volume":"283","author":"C Prahst","year":"2008","unstructured":"Prahst, C. et al. Neuropilin-1-VEGFR-2 complexing requires the PDZ-binding domain of neuropilin-1. J. Biol. Chem. 283, 25110\u201325114 (2008).","journal-title":"J. Biol. Chem."},{"key":"2249_CR152","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.str.2015.01.018","volume":"23","author":"MW Parker","year":"2015","unstructured":"Parker, M. W. et al. Structural basis for VEGF-C binding to neuropilin-2 and sequestration by a soluble splice form. Structure 23, 677\u2013687 (2015).","journal-title":"Structure"},{"key":"2249_CR153","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1006\/bbrc.1997.6156","volume":"231","author":"SA Cunningham","year":"1997","unstructured":"Cunningham, S. A., Stephan, C. C., Arrate, M. P., Ayer, K. G. & Brock, T. A. Identification of the extracellular domains of Flt-1 that mediate ligand interactions. Biochem. Biophys. Res. Commun. 231, 596\u2013599 (1997).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2249_CR154","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1161\/01.RES.0000243989.46006.b9","volume":"99","author":"S Ahmad","year":"2006","unstructured":"Ahmad, S. et al. Direct evidence for endothelial vascular endothelial growth factor receptor-1 function in nitric oxide-mediated angiogenesis. Circ. Res. 99, 715\u2013722 (2006).","journal-title":"Circ. Res."},{"key":"2249_CR155","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1006\/bbrc.1997.7327","volume":"238","author":"A Sawano","year":"1997","unstructured":"Sawano, A., Takahashi, T., Yamaguchi, S. & Shibuya, M. The phosphorylated 1169-tyrosine containing region of flt-1 kinase (VEGFR-1) is a major binding site for PLC\u03b3. Biochem. Biophys. Res. Commun. 238, 487\u2013491 (1997).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2249_CR156","doi-asserted-by":"publisher","first-page":"23410","DOI":"10.1074\/jbc.273.36.23410","volume":"273","author":"N Ito","year":"1998","unstructured":"Ito, N., Wernstedt, C., Engstr\u00f6m, U. & Claesson-Welsh, L. Identification of vascular endothelial growth factor receptor-1 tyrosine phosphorylation sites and binding of SH2 domain-containing molecules. J. Biol. Chem. 273, 23410\u201323418 (1998).","journal-title":"J. Biol. Chem."},{"key":"2249_CR157","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1042\/bj3580465","volume":"358","author":"Y Yu","year":"2001","unstructured":"Yu, Y. et al. Direct identification of a major autophosphorylation site on vascular endothelial growth factor receptor Flt-1 that mediates phosphatidylinositol 3\u2019-kinase binding. Biochem. J. 358, 465\u2013472 (2001).","journal-title":"Biochem. J."},{"key":"2249_CR158","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S0898-6568(01)00209-1","volume":"13","author":"N Ito","year":"2001","unstructured":"Ito, N., Huang, K. & Claesson-Welsh, L. Signal transduction by VEGF receptor-1 wild type and mutant proteins. Cell. Signal. 13, 849\u2013854 (2001).","journal-title":"Cell. Signal."},{"key":"2249_CR159","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1161\/CIRCRESAHA.116.309516","volume":"120","author":"VC Ganta","year":"2017","unstructured":"Ganta, V. C., Choi, M., Kutateladze, A. & Annex, B. H. VEGF165b modulates endothelial VEGFR1-STAT3 signaling pathway and angiogenesis in human and experimental peripheral arterial disease. Circ. Res. 120, 282\u2013295 (2017).","journal-title":"Circ. Res."},{"key":"2249_CR160","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1046\/j.1440-1681.2002.03769.x","volume":"29","author":"PD Scotney","year":"2002","unstructured":"Scotney, P. D. et al. Human vascular endothelial growth factor B: characterization of recombinant isoforms and generation of neutralizing monoclonal antibodies. Clin. Exp. Pharmacol. Physiol. 29, 1024\u20131029 (2002).","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"2249_CR161","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1182\/blood-2012-03-419234","volume":"121","author":"NK Singh","year":"2013","unstructured":"Singh, N. K., Hansen, D. E. 3rd, Kundumani-Sridharan, V. & Rao, G. N. Both Kdr and Flt1 play a vital role in hypoxia-induced Src-PLD1-PKC\u03b3-cPLA(2) activation and retinal neovascularization. Blood 121, 1911\u20131923 (2013).","journal-title":"Blood"},{"key":"2249_CR162","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1038\/nm884","volume":"9","author":"M Autiero","year":"2003","unstructured":"Autiero, M. et al. Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat. Med. 9, 936\u2013943 (2003).","journal-title":"Nat. Med."},{"key":"2249_CR163","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1080\/10623320590933888","volume":"12","author":"S Ahmad","year":"2005","unstructured":"Ahmad, S. & Ahmed, A. Antiangiogenic effect of soluble vascular endothelial growth factor receptor-1 in placental angiogenesis. Endothelium 12, 89\u201395 (2005).","journal-title":"Endothelium"},{"key":"2249_CR164","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1016\/j.febslet.2013.05.038","volume":"587","author":"T Saito","year":"2013","unstructured":"Saito, T. et al. VEGF-A induces its negative regulator, soluble form of VEGFR-1, by modulating its alternative splicing. FEBS Lett. 587, 2179\u20132185 (2013).","journal-title":"FEBS Lett."},{"key":"2249_CR165","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1038\/s41416-018-0128-4","volume":"118","author":"C Abou Faycal","year":"2018","unstructured":"Abou Faycal, C. et al. The sVEGFR1-i13 splice variant regulates a \u03b21 integrin\/VEGFR autocrine loop involved in the progression and the response to anti-angiogenic therapies of squamous cell lung carcinoma. Br. J. Cancer 118, 1596\u20131608 (2018).","journal-title":"Br. J. Cancer"},{"key":"2249_CR166","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.cell.2012.08.037","volume":"151","author":"J Jin","year":"2012","unstructured":"Jin, J. et al. Soluble FLT1 binds lipid microdomains in podocytes to control cell morphology and glomerular barrier function. Cell 151, 384\u2013399 (2012).","journal-title":"Cell"},{"key":"2249_CR167","doi-asserted-by":"publisher","first-page":"108187","DOI":"10.1016\/j.celrep.2020.108187","volume":"32","author":"B da Rocha-Azevedo","year":"2020","unstructured":"da Rocha-Azevedo, B. et al. Heterogeneity in VEGF receptor-2 mobility and organization on the endothelial cell surface leads to diverse models of activation by VEGF. Cell Rep. 32, 108187 (2020).","journal-title":"Cell Rep."},{"key":"2249_CR168","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.3390\/cells13161346","volume":"13","author":"M Corsini","year":"2024","unstructured":"Corsini, M., Ravelli, C., Grillo, E., Domenichini, M. & Mitola, S. Mutation in the kinase domain alters the VEGFR2 membrane dynamics. Cells 13, 1346 (2024).","journal-title":"Cells"},{"key":"2249_CR169","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1038\/sj.emboj.7600709","volume":"24","author":"T Matsumoto","year":"2005","unstructured":"Matsumoto, T. et al. VEGF receptor-2 Y951 signaling and a role for the adapter molecule TSAd in tumor angiogenesis. EMBO J. 24, 2342\u20132353 (2005).","journal-title":"EMBO J."},{"key":"2249_CR170","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.cellsig.2009.02.004","volume":"21","author":"C Caron","year":"2009","unstructured":"Caron, C. et al. Non-redundant roles of the Gab1 and Gab2 scaffolding adapters in VEGF-mediated signalling, migration, and survival of endothelial cells. Cell. Signal. 21, 943\u2013953 (2009).","journal-title":"Cell. Signal."},{"key":"2249_CR171","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11017","volume":"7","author":"X Li","year":"2016","unstructured":"Li, X. et al. VEGFR2 pY949 signalling regulates adherens junction integrity and metastatic spread. Nat. Commun. 7, 11017 (2016).","journal-title":"Nat. Commun."},{"key":"2249_CR172","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1038\/sj.onc.1202478","volume":"18","author":"M Dougher","year":"1999","unstructured":"Dougher, M. & Terman, B. I. Autophosphorylation of KDR in the kinase domain is required for maximal VEGF-stimulated kinase activity and receptor internalization. Oncogene 18, 1619\u20131627 (1999).","journal-title":"Oncogene"},{"key":"2249_CR173","doi-asserted-by":"publisher","first-page":"22267","DOI":"10.1074\/jbc.M312729200","volume":"279","author":"K Holmqvist","year":"2004","unstructured":"Holmqvist, K. et al. The adaptor protein shb binds to tyrosine 1175 in vascular endothelial growth factor (VEGF) receptor-2 and regulates VEGF-dependent cellular migration. J. Biol. Chem. 279, 22267\u201322275 (2004).","journal-title":"J. Biol. Chem."},{"key":"2249_CR174","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1042\/bj3470501","volume":"347","author":"AJ Warner","year":"2000","unstructured":"Warner, A. J., Lopez-Dee, J., Knight, E. L., Feramisco, J. R. & Prigent, S. A. The Shc-related adaptor protein, Sck, forms a complex with the vascular-endothelial-growth-factor receptor KDR in transfected cells. Biochem. J. 347, 501\u2013509 (2000).","journal-title":"Biochem. J."},{"key":"2249_CR175","doi-asserted-by":"publisher","DOI":"10.1172\/JCI161366","volume":"133","author":"E Sj\u00f6berg","year":"2023","unstructured":"Sj\u00f6berg, E. et al. Endothelial VEGFR2-PLC\u03b3 signaling regulates vascular permeability and antitumor immunity through eNOS\/Src. J. Clin. Invest. 133, e161366 (2023).","journal-title":"J. Clin. Invest."},{"key":"2249_CR176","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/sj.onc.1207034","volume":"23","author":"L Lamalice","year":"2004","unstructured":"Lamalice, L., Houle, F., Jourdan, G. & Huot, J. Phosphorylation of tyrosine 1214 on VEGFR2 is required for VEGF-induced activation of Cdc42 upstream of SAPK2\/p38. Oncogene 23, 434\u2013445 (2004).","journal-title":"Oncogene"},{"key":"2249_CR177","doi-asserted-by":"publisher","first-page":"34009","DOI":"10.1074\/jbc.M603928200","volume":"281","author":"L Lamalice","year":"2006","unstructured":"Lamalice, L., Houle, F. & Huot, J. Phosphorylation of Tyr1214 within VEGFR-2 triggers the recruitment of Nck and activation of Fyn leading to SAPK2\/p38 activation and endothelial cell migration in response to VEGF. J. Biol. Chem. 281, 34009\u201334020 (2006).","journal-title":"J. Biol. Chem."},{"key":"2249_CR178","doi-asserted-by":"publisher","DOI":"10.15252\/embr.201947845","volume":"20","author":"C Testini","year":"2019","unstructured":"Testini, C. et al. Myc-dependent endothelial proliferation is controlled by phosphotyrosine 1212 in VEGF receptor-2. EMBO Rep. 20, e47845 (2019).","journal-title":"EMBO Rep."},{"key":"2249_CR179","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1128\/MCB.01006-10","volume":"31","author":"RD Meyer","year":"2011","unstructured":"Meyer, R. D. et al. PEST motif serine and tyrosine phosphorylation controls vascular endothelial growth factor receptor 2 stability and downregulation. Mol. Cell. Biol. 31, 2010\u20132025 (2011).","journal-title":"Mol. Cell. Biol."},{"key":"2249_CR180","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1002\/pmic.201400183","volume":"15","author":"N Rahimi","year":"2015","unstructured":"Rahimi, N. & Costello, C. E. Emerging roles of post-translational modifications in signal transduction and angiogenesis. Proteomics 15, 300\u2013309 (2015).","journal-title":"Proteomics"},{"key":"2249_CR181","doi-asserted-by":"publisher","first-page":"3423","DOI":"10.1182\/blood-2005-04-1388","volume":"106","author":"A Salameh","year":"2005","unstructured":"Salameh, A., Galvagni, F., Bardelli, M., Bussolino, F. & Oliviero, S. Direct recruitment of CRK and GRB2 to VEGFR-3 induces proliferation, migration, and survival of endothelial cells through the activation of ERK, AKT, and JNK pathways. Blood 106, 3423\u20133431 (2005).","journal-title":"Blood"},{"key":"2249_CR182","first-page":"921","volume":"11","author":"E Fournier","year":"1995","unstructured":"Fournier, E., Dubreuil, P., Birnbaum, D. & Borg, J. P. Mutation at tyrosine residue 1337 abrogates ligand-dependent transforming capacity of the FLT4 receptor. Oncogene 11, 921\u2013931 (1995).","journal-title":"Oncogene"},{"key":"2249_CR183","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/75997","volume":"25","author":"MJ Karkkainen","year":"2000","unstructured":"Karkkainen, M. J. et al. Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema. Nat. Genet. 25, 153\u2013159 (2000).","journal-title":"Nat. Genet."},{"key":"2249_CR184","doi-asserted-by":"publisher","first-page":"16157","DOI":"10.1073\/pnas.0908201106","volume":"106","author":"T Teesalu","year":"2009","unstructured":"Teesalu, T., Sugahara, K. N., Kotamraju, V. R. & Ruoslahti, E. C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration. Proc. Natl. Acad. Sci. USA 106, 16157\u201316162 (2009).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2249_CR185","doi-asserted-by":"publisher","first-page":"11082","DOI":"10.1074\/jbc.M111.331140","volume":"287","author":"MW Parker","year":"2012","unstructured":"Parker, M. W., Xu, P., Li, X. & Vander Kooi, C. W. Structural basis for selective vascular endothelial growth factor-A (VEGF-A) binding to neuropilin-1. J. Biol. Chem. 287, 11082\u201311089 (2012).","journal-title":"J. Biol. Chem."},{"key":"2249_CR186","doi-asserted-by":"publisher","first-page":"e49177","DOI":"10.1371\/journal.pone.0049177","volume":"7","author":"MW Parker","year":"2012","unstructured":"Parker, M. W., Xu, P., Guo, H.-F. & Vander Kooi, C. W. Mechanism of selective VEGF-A binding by neuropilin-1 reveals a basis for specific ligand inhibition. PLoS ONE 7, e49177 (2012).","journal-title":"PLoS ONE"},{"key":"2249_CR187","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/978-1-4615-0119-0_3","volume":"515","author":"M Klagsbrun","year":"2002","unstructured":"Klagsbrun, M., Takashima, S. & Mamluk, R. The role of neuropilin in vascular and tumor biology. Adv. Exp. Med. Biol. 515, 33\u201348 (2002).","journal-title":"Adv. Exp. Med. Biol."},{"key":"2249_CR188","doi-asserted-by":"publisher","first-page":"48848","DOI":"10.1074\/jbc.M310047200","volume":"278","author":"L Wang","year":"2003","unstructured":"Wang, L., Zeng, H., Wang, P., Soker, S. & Mukhopadhyay, D. Neuropilin-1-mediated vascular permeability factor\/vascular endothelial growth factor-dependent endothelial cell migration. J. Biol. Chem. 278, 48848\u201348860 (2003).","journal-title":"J. Biol. Chem."},{"key":"2249_CR189","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1084\/jem.20160311","volume":"214","author":"A Fantin","year":"2017","unstructured":"Fantin, A. et al. VEGF165-induced vascular permeability requires NRP1 for ABL-mediated SRC family kinase activation. J. Exp. Med. 214, 1049\u20131064 (2017).","journal-title":"J. Exp. Med."},{"key":"2249_CR190","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1096\/fj.05-5646com","volume":"20","author":"T K\u00e4rp\u00e4nen","year":"2006","unstructured":"K\u00e4rp\u00e4nen, T. et al. Functional interaction of VEGF-C and VEGF-D with neuropilin receptors. FASEB J. 20, 1462\u20131472 (2006).","journal-title":"FASEB J."},{"key":"2249_CR191","doi-asserted-by":"publisher","first-page":"9566","DOI":"10.1158\/0008-5472.CAN-06-1488","volume":"66","author":"Y Zeng","year":"2006","unstructured":"Zeng, Y., Opeskin, K., Goad, J. & Williams, E. D. Tumor-induced activation of lymphatic endothelial cells via vascular endothelial growth factor receptor-2 is critical for prostate cancer lymphatic metastasis. Cancer Res. 66, 9566\u20139575 (2006).","journal-title":"Cancer Res."},{"key":"2249_CR192","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/sj.bjc.6603487","volume":"96","author":"JL Su","year":"2007","unstructured":"Su, J. L. et al. The role of the VEGF-C\/VEGFR-3 axis in cancer progression. Br. J. Cancer 96, 541\u2013545 (2007).","journal-title":"Br. J. Cancer"},{"key":"2249_CR193","first-page":"213","volume":"79","author":"A Papapetropoulos","year":"1999","unstructured":"Papapetropoulos, A. et al. Direct actions of angiopoietin-1 on human endothelium: evidence for network stabilization, cell survival, and interaction with other angiogenic growth factors. Lab. Investig. 79, 213\u2013223 (1999).","journal-title":"Lab. Investig."},{"key":"2249_CR194","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s10456-009-9130-z","volume":"12","author":"NR London","year":"2009","unstructured":"London, N. R., Whitehead, K. J. & Li, D. Y. Endogenous endothelial cell signaling systems maintain vascular stability. Angiogenesis 12, 149\u2013158 (2009).","journal-title":"Angiogenesis"},{"key":"2249_CR195","doi-asserted-by":"publisher","first-page":"117080","DOI":"10.1016\/j.lfs.2019.117080","volume":"239","author":"G Nicolini","year":"2019","unstructured":"Nicolini, G., Forini, F., Kusmic, C., Iervasi, G. & Balzan, S. Angiopoietin 2 signal complexity in cardiovascular disease and cancer. Life Sci. 239, 117080 (2019).","journal-title":"Life Sci."},{"key":"2249_CR196","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-020-00250-z","volume":"6","author":"QD Nguyen","year":"2020","unstructured":"Nguyen, Q. D. et al. The Tie2 signaling pathway in retinal vascular diseases: a novel therapeutic target in the eye. Int. J. Retin. Vitreous 6, 48 (2020).","journal-title":"Int. J. Retin. Vitreous"},{"key":"2249_CR197","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1006\/mvre.2001.2377","volume":"63","author":"AC Tsiamis","year":"2002","unstructured":"Tsiamis, A. C., Morris, P. N., Marron, M. B. & Brindle, N. P. Vascular endothelial growth factor modulates the Tie-2:Tie-1 receptor complex. Microvasc. Res. 63, 149\u2013158 (2002).","journal-title":"Microvasc. Res."},{"key":"2249_CR198","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1083\/jcb.200811159","volume":"185","author":"M Winderlich","year":"2009","unstructured":"Winderlich, M. et al. VE-PTP controls blood vessel development by balancing Tie-2 activity. J. Cell Biol. 185, 657\u2013671 (2009).","journal-title":"J. Cell Biol."},{"key":"2249_CR199","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1084\/jem.20150718","volume":"212","author":"M Frye","year":"2015","unstructured":"Frye, M. et al. Interfering with VE-PTP stabilizes endothelial junctions in vivo via Tie-2 in the absence of VE-cadherin. J. Exp. Med. 212, 2267\u20132287 (2015).","journal-title":"J. Exp. Med."},{"key":"2249_CR200","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1158\/0008-5472.CAN-09-1977","volume":"70","author":"H Hashizume","year":"2010","unstructured":"Hashizume, H. et al. Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth. Cancer Res. 70, 2213\u20132223 (2010).","journal-title":"Cancer Res."},{"key":"2249_CR201","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1158\/0008-5472.CAN-12-4697","volume":"73","author":"D Gerald","year":"2013","unstructured":"Gerald, D., Chintharlapalli, S., Augustin, H. G. & Benjamin, L. E. Angiopoietin-2: an attractive target for improved antiangiogenic tumor therapy. Cancer Res. 73, 1649\u20131657 (2013).","journal-title":"Cancer Res."},{"key":"2249_CR202","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/s41573-023-00671-z","volume":"22","author":"Y Cao","year":"2023","unstructured":"Cao, Y., Langer, R. & Ferrara, N. Targeting angiogenesis in oncology, ophthalmology and beyond. Nat. Rev. Drug Discov. 22, 476\u2013495 (2023).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2249_CR203","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1023\/A:1026544214667","volume":"19","author":"GL Semenza","year":"2000","unstructured":"Semenza, G. L. HIF-1: using two hands to flip the angiogenic switch. Cancer Metastasis Rev. 19, 59\u201365 (2000).","journal-title":"Cancer Metastasis Rev."},{"key":"2249_CR204","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1006\/scdb.2001.0287","volume":"13","author":"PH Maxwell","year":"2002","unstructured":"Maxwell, P. H. & Ratcliffe, P. J. Oxygen sensors and angiogenesis. Semin. Cell Dev. Biol. 13, 29\u201337 (2002).","journal-title":"Semin. Cell Dev. Biol."},{"key":"2249_CR205","doi-asserted-by":"publisher","first-page":"4604","DOI":"10.1128\/MCB.16.9.4604","volume":"16","author":"JA Forsythe","year":"1996","unstructured":"Forsythe, J. A. et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol. 16, 4604\u20134613 (1996).","journal-title":"Mol. Cell. Biol."},{"key":"2249_CR206","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1042\/bj3270419","volume":"327","author":"A Damert","year":"1997","unstructured":"Damert, A., Ikeda, E. & Risau, W. Activator-protein-1 binding potentiates the hypoxia-induciblefactor-1-mediated hypoxia-induced transcriptional activation of vascular-endothelial growth factor expression in C6 glioma cells. Biochem. J. 327, 419\u2013423 (1997).","journal-title":"Biochem. J."},{"key":"2249_CR207","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1038\/nature06613","volume":"451","author":"Z Arany","year":"2008","unstructured":"Arany, Z. et al. HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1alpha. Nature 451, 1008\u20131012 (2008).","journal-title":"Nature"},{"key":"2249_CR208","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1002\/oby.20206","volume":"21","author":"K Takahashi","year":"2013","unstructured":"Takahashi, K. et al. Endogenous oxidative stress, but not ER stress, induces hypoxia-independent VEGF120 release through PI3K-dependent pathways in 3T3-L1 adipocytes. Obesity 21, 1625\u20131634 (2013).","journal-title":"Obesity"},{"key":"2249_CR209","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.cmet.2008.11.009","volume":"9","author":"Y Xue","year":"2009","unstructured":"Xue, Y. et al. Hypoxia-independent angiogenesis in adipose tissues during cold acclimation. Cell Metab. 9, 99\u2013109 (2009).","journal-title":"Cell Metab."},{"key":"2249_CR210","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.3390\/cells11081289","volume":"11","author":"M Katsman","year":"2022","unstructured":"Katsman, M., Azriel, A., Horev, G., Reizel, Y. & Levi, B. Z. N.-V. E. G. F. The autoregulatory arm of VEGF-A. Cells 11, 1289 (2022).","journal-title":"Cells"},{"key":"2249_CR211","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1006\/bbrc.1996.5979","volume":"230","author":"G Silins","year":"1997","unstructured":"Silins, G., Grimmond, S., Egerton, M. & Hayward, N. Analysis of the promoter region of the human VEGF-related factor gene. Biochem. Biophys. Res. Commun. 230, 413\u2013418 (1997).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2249_CR212","doi-asserted-by":"publisher","first-page":"25176","DOI":"10.1074\/jbc.272.40.25176","volume":"272","author":"D Chilov","year":"1997","unstructured":"Chilov, D. et al. Genomic organization of human and mouse genes for vascular endothelial growth factor C. J. Biol. Chem. 272, 25176\u201325183 (1997).","journal-title":"J. Biol. Chem."},{"key":"2249_CR213","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.ejca.2008.12.006","volume":"45","author":"J Ming","year":"2009","unstructured":"Ming, J., Zhang, Q., Qiu, X. & Wang, E. Interleukin 7\/interleukin 7 receptor induce c-Fos\/c-Jun-dependent vascular endothelial growth factor-D up-regulation: a mechanism of lymphangiogenesis in lung cancer. Eur. J. Cancer 45, 866\u2013873 (2009).","journal-title":"Eur. J. Cancer"},{"key":"2249_CR214","doi-asserted-by":"publisher","first-page":"110082","DOI":"10.1016\/j.isci.2024.110082","volume":"27","author":"K Chen","year":"2024","unstructured":"Chen, K., Li, W. D. & Li, X. Q. The role of m6A in angiogenesis and vascular diseases. iScience 27, 110082 (2024).","journal-title":"iScience"},{"key":"2249_CR215","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1158\/0008-5472.CAN-22-2449","volume":"83","author":"H Zhang","year":"2023","unstructured":"Zhang, H. et al. N6-methyladenosine promotes translation of VEGFA to accelerate angiogenesis in lung cancer. Cancer Res. 83, 2208\u20132225 (2023).","journal-title":"Cancer Res."},{"key":"2249_CR216","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202300344RRR","volume":"37","author":"M Ye","year":"2023","unstructured":"Ye, M. et al. WTAP activates MAPK signaling through m6A methylation in VEGFA mRNA-mediated by YTHDC1 to promote colorectal cancer development. FASEB J. 37, e23090 (2023).","journal-title":"FASEB J."},{"key":"2249_CR217","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202307242","volume":"11","author":"J Wen","year":"2024","unstructured":"Wen, J. et al. YTHDF2 is a therapeutic target for HCC by suppressing immune evasion and angiogenesis through ETV5\/PD-L1\/VEGFA axis. Adv. Sci. 11, e2307242 (2024).","journal-title":"Adv. Sci."},{"key":"2249_CR218","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1042\/BC20070078","volume":"100","author":"M Kato","year":"2008","unstructured":"Kato, M. & Slack, F. J. microRNAs: small molecules with big roles\u2014C. elegans to human cancer. Biol. Cell 100, 71\u201381 (2008).","journal-title":"Biol. Cell"},{"key":"2249_CR219","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1146\/annurev-biochem-060308-103103","volume":"79","author":"MR Fabian","year":"2010","unstructured":"Fabian, M. R., Sonenberg, N. & Filipowicz, W. Regulation of mRNA translation and stability by microRNAs. Annu. Rev. Biochem. 79, 351\u2013379 (2010).","journal-title":"Annu. Rev. Biochem."},{"key":"2249_CR220","doi-asserted-by":"publisher","first-page":"154631","DOI":"10.1016\/j.prp.2023.154631","volume":"248","author":"AT Jalil","year":"2023","unstructured":"Jalil, A. T. et al. The emerging role of microRNA-126 as a potential therapeutic target in cancer: a comprehensive review. Pathol. Res. Pract. 248, 154631 (2023).","journal-title":"Pathol. Res. Pract."},{"key":"2249_CR221","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.devcel.2008.07.002","volume":"15","author":"S Wang","year":"2008","unstructured":"Wang, S. et al. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev. Cell 15, 261\u2013271 (2008).","journal-title":"Dev. Cell"},{"key":"2249_CR222","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.3892\/or.2013.2633","volume":"30","author":"Y Zhang","year":"2013","unstructured":"Zhang, Y. et al. Epigenetic silencing of miR-126 contributes to tumor invasion and angiogenesis in colorectal cancer. Oncol. Rep. 30, 1976\u20131984 (2013).","journal-title":"Oncol. Rep."},{"key":"2249_CR223","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1093\/carcin\/bgs333","volume":"34","author":"CY Sun","year":"2013","unstructured":"Sun, C. Y. et al. miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF. Carcinogenesis 34, 426\u2013435 (2013).","journal-title":"Carcinogenesis"},{"key":"2249_CR224","doi-asserted-by":"publisher","first-page":"10222","DOI":"10.18632\/oncotarget.3390","volume":"6","author":"YT Tung","year":"2015","unstructured":"Tung, Y. T. et al. Lung tumorigenesis induced by human vascular endothelial growth factor (hVEGF)-A165 overexpression in transgenic mice and amelioration of tumor formation by miR-16. Oncotarget 6, 10222\u201310238 (2015).","journal-title":"Oncotarget"},{"key":"2249_CR225","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2016.194","volume":"7","author":"Y Hu","year":"2016","unstructured":"Hu, Y. et al. miRNA-205 targets VEGFA and FGF2 and regulates resistance to chemotherapeutics in breast cancer. Cell Death Dis. 7, e2291 (2016).","journal-title":"Cell Death Dis."},{"key":"2249_CR226","first-page":"2207","volume":"16","author":"X Zhao","year":"2018","unstructured":"Zhao, X. et al. MicroRNA-205 is downregulated in hepatocellular carcinoma and inhibits cell growth and metastasis via directly targeting vascular endothelial growth factor A. Oncol. Lett. 16, 2207\u20132214 (2018).","journal-title":"Oncol. Lett."},{"key":"2249_CR227","doi-asserted-by":"publisher","first-page":"3972","DOI":"10.7150\/thno.18990","volume":"7","author":"YE Du","year":"2017","unstructured":"Du, Y. E. et al. MiR-205\/YAP1 in activated fibroblasts of breast tumor promotes VEGF-independent angiogenesis through STAT3 signaling. Theranostics 7, 3972\u20133988 (2017).","journal-title":"Theranostics"},{"key":"2249_CR228","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/iub.2620","volume":"75","author":"G Fontemaggi","year":"2023","unstructured":"Fontemaggi, G. Non-coding RNA regulatory networks in post-transcriptional regulation of VEGFA in cancer. IUBMB Life 75, 30\u201339 (2023).","journal-title":"IUBMB Life"},{"key":"2249_CR229","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13578-024-01217-5","volume":"14","author":"P Gandhi","year":"2024","unstructured":"Gandhi, P., Wang, Y., Li, G. & Wang, S. The role of long noncoding RNAs in ocular angiogenesis and vascular oculopathy. Cell Biosci. 14, 39 (2024).","journal-title":"Cell Biosci."},{"key":"2249_CR230","doi-asserted-by":"publisher","first-page":"24731","DOI":"10.1074\/jbc.M702029200","volume":"282","author":"Y Zhou","year":"2007","unstructured":"Zhou, Y. et al. Activation of p53 by MEG3 non-coding RNA. J. Biol. Chem. 282, 24731\u201324742 (2007).","journal-title":"J. Biol. Chem."},{"key":"2249_CR231","doi-asserted-by":"publisher","first-page":"R45","DOI":"10.1530\/JME-12-0008","volume":"48","author":"Y Zhou","year":"2012","unstructured":"Zhou, Y., Zhang, X. & Klibanski, A. MEG3 noncoding RNA: a tumor suppressor. J. Mol. Endocrinol. 48, R45\u2013R53 (2012).","journal-title":"J. Mol. Endocrinol."},{"key":"2249_CR232","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.bbrc.2016.01.164","volume":"471","author":"GZ Qiu","year":"2016","unstructured":"Qiu, G. Z., Tian, W., Fu, H. T., Li, C. P. & Liu, B. Long noncoding RNA-MEG3 is involved in diabetes mellitus-related microvascular dysfunction. Biochem. Biophys. Res. Commun. 471, 135\u2013141 (2016).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2249_CR233","first-page":"2337","volume":"16","author":"D Zhang","year":"2018","unstructured":"Zhang, D. et al. LncRNA MEG3 overexpression inhibits the development of diabetic retinopathy by regulating TGF-\u03b21 and VEGF. Exp. Ther. Med. 16, 2337\u20132342 (2018).","journal-title":"Exp. Ther. Med."},{"key":"2249_CR234","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.gene.2018.01.072","volume":"649","author":"W Ruan","year":"2018","unstructured":"Ruan, W. et al. Knockdown of long noncoding RNA MEG3 impairs VEGF-stimulated endothelial sprouting angiogenesis via modulating VEGFR2 expression in human umbilical vein endothelial cells. Gene 649, 32\u201339 (2018).","journal-title":"Gene"},{"key":"2249_CR235","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1002\/jcp.29047","volume":"235","author":"N Han","year":"2020","unstructured":"Han, N., Tian, W., Yu, N. & Yu, L. YAP1 is required for the angiogenesis in retinal microvascular endothelial cells via the inhibition of MALAT1-mediated miR-200b-3p in high glucose-induced diabetic retinopathy. J. Cell. Physiol. 235, 1309\u20131320 (2020).","journal-title":"J. Cell. Physiol."},{"key":"2249_CR236","doi-asserted-by":"publisher","first-page":"118299","DOI":"10.1016\/j.lfs.2020.118299","volume":"260","author":"Y Wang","year":"2020","unstructured":"Wang, Y., Wang, X., Wang, Y. X., Ma, Y. & Di, Y. Effect and mechanism of the long noncoding RNA MALAT1 on retinal neovascularization in retinopathy of prematurity. Life Sci. 260, 118299 (2020).","journal-title":"Life Sci."},{"key":"2249_CR237","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0167-4838(94)00144-6","volume":"1246","author":"KP Claffey","year":"1995","unstructured":"Claffey, K. P., Senger, D. R. & Spiegelman, B. M. Structural requirements for dimerization, glycosylation, secretion, and biological function of VPF\/VEGF. Biochim. Biophys. Acta 1246, 1\u20139 (1995).","journal-title":"Biochim. Biophys. Acta"},{"key":"2249_CR238","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.pep.2012.01.001","volume":"82","author":"N Davydova","year":"2012","unstructured":"Davydova, N. et al. Preparation of human vascular endothelial growth factor-D for structural and preclinical therapeutic studies. Protein Expr. Purif. 82, 232\u2013239 (2012).","journal-title":"Protein Expr. Purif."},{"key":"2249_CR239","doi-asserted-by":"publisher","first-page":"13117","DOI":"10.1074\/jbc.RA119.008643","volume":"294","author":"KB Chandler","year":"2019","unstructured":"Chandler, K. B. et al. N-Glycosylation regulates ligand-dependent activation and signaling of vascular endothelial growth factor receptor 2 (VEGFR2). J. Biol. Chem. 294, 13117\u201313130 (2019).","journal-title":"J. Biol. Chem."},{"key":"2249_CR240","doi-asserted-by":"publisher","first-page":"8223","DOI":"10.1074\/jbc.R800050200","volume":"284","author":"ET Yeh","year":"2009","unstructured":"Yeh, E. T. SUMOylation and De-SUMOylation: wrestling with life\u2019s processes. J. Biol. Chem. 284, 8223\u20138227 (2009).","journal-title":"J. Biol. Chem."},{"key":"2249_CR241","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1146\/annurev-biochem-061909-093311","volume":"82","author":"A Flotho","year":"2013","unstructured":"Flotho, A. & Melchior, F. Sumoylation: a regulatory protein modification in health and disease. Annu. Rev. Biochem. 82, 357\u2013385 (2013).","journal-title":"Annu. Rev. Biochem."},{"key":"2249_CR242","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05812-2","volume":"9","author":"HJ Zhou","year":"2018","unstructured":"Zhou, H. J. et al. SUMOylation of VEGFR2 regulates its intracellular trafficking and pathological angiogenesis. Nat. Commun. 9, 3303 (2018).","journal-title":"Nat. Commun."},{"key":"2249_CR243","doi-asserted-by":"publisher","first-page":"36682","DOI":"10.1074\/jbc.M110.164236","volume":"285","author":"Y Xu","year":"2010","unstructured":"Xu, Y. et al. Induction of SENP1 in endothelial cells contributes to hypoxia-driven VEGF expression and angiogenesis. J. Biol. Chem. 285, 36682\u201336688 (2010).","journal-title":"J. Biol. Chem."},{"key":"2249_CR244","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.3390\/ijms24032544","volume":"24","author":"Q He","year":"2023","unstructured":"He, Q. et al. SENP6-mediated deSUMOylation of VEGFR2 enhances its cell membrane transport in angiogenesis. Int. J. Mol. Sci. 24, 2544 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"2249_CR245","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1097\/CAD.0000000000000896","volume":"31","author":"M Wang","year":"2020","unstructured":"Wang, M. & Jiang, X. SUMOylation of vascular endothelial growth factor receptor 2 inhibits the proliferation, migration, and angiogenesis signaling pathway in non-small cell lung cancer. Anticancer Drugs 31, 492\u2013499 (2020).","journal-title":"Anticancer Drugs"},{"key":"2249_CR246","first-page":"1404","volume":"6","author":"GA Smith","year":"2017","unstructured":"Smith, G. A. et al. Ubiquitination of basal VEGFR2 regulates signal transduction and endothelial function. Biol. Open 6, 1404\u20131415 (2017).","journal-title":"Biol. Open"},{"key":"2249_CR247","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1084\/jem.20112446","volume":"209","author":"S Shaik","year":"2012","unstructured":"Shaik, S. et al. SCF(\u03b2-TRCP) suppresses angiogenesis and thyroid cancer cell migration by promoting ubiquitination and destruction of VEGF receptor 2. J. Exp. Med. 209, 1289\u20131307 (2012).","journal-title":"J. Exp. Med."},{"key":"2249_CR248","first-page":"237","volume":"162","author":"T Sakaue","year":"2017","unstructured":"Sakaue, T., Maekawa, M., Nakayama, H. & Higashiyama, S. Prospect of divergent roles for the CUL3 system in vascular endothelial cell function and angiogenesis. J. Biochem. 162, 237\u2013245 (2017).","journal-title":"J. Biochem."},{"key":"2249_CR249","doi-asserted-by":"publisher","DOI":"10.1038\/srep42845","volume":"7","author":"T Sakaue","year":"2017","unstructured":"Sakaue, T. et al. The CUL3-SPOP-DAXX axis is a novel regulator of VEGFR2 expression in vascular endothelial cells. Sci. Rep. 7, 42845 (2017).","journal-title":"Sci. Rep."},{"key":"2249_CR250","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.260657","volume":"136","author":"WR Critchley","year":"2023","unstructured":"Critchley, W. R., Smith, G. A., Zachary, I. C., Harrison, M. A. & Ponnambalam, S. The E2 ubiquitin-conjugating enzymes UBE2D1 and UBE2D2 regulate VEGFR2 dynamics and endothelial function. J. Cell. Sci. 136, jcs260657 (2023).","journal-title":"J. Cell. Sci."},{"key":"2249_CR251","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/tra.12341","volume":"17","author":"GA Smith","year":"2016","unstructured":"Smith, G. A. et al. VEGFR2 trafficking, signaling and proteolysis is regulated by the ubiquitin isopeptidase USP8. Traffic 17, 53\u201365 (2016).","journal-title":"Traffic"},{"key":"2249_CR252","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.phrs.2016.11.022","volume":"115","author":"F Corti","year":"2017","unstructured":"Corti, F. & Simons, M. Modulation of VEGF receptor 2 signaling by protein phosphatases. Pharmacol. Res. 115, 107\u2013123 (2017).","journal-title":"Pharmacol. Res."},{"key":"2249_CR253","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1074\/mcp.RA119.001716","volume":"18","author":"HCA Drexler","year":"2019","unstructured":"Drexler, H. C. A. et al. Vascular endothelial receptor tyrosine phosphatase: identification of novel substrates related to junctions and a ternary complex with EPHB4 and TIE2. Mol. Cell. Proteom. 18, 2058\u20132077 (2019).","journal-title":"Mol. Cell. Proteom."},{"key":"2249_CR254","doi-asserted-by":"publisher","first-page":"5948","DOI":"10.1038\/sj.onc.1202992","volume":"18","author":"G Fachinger","year":"1999","unstructured":"Fachinger, G., Deutsch, U. & Risau, W. Functional interaction of vascular endothelial-protein-tyrosine phosphatase with the angiopoietin receptor Tie-2. Oncogene 18, 5948\u20135953 (1999).","journal-title":"Oncogene"},{"key":"2249_CR255","doi-asserted-by":"publisher","first-page":"4885","DOI":"10.1093\/emboj\/cdf497","volume":"21","author":"R Nawroth","year":"2002","unstructured":"Nawroth, R. et al. VE-PTP and VE-cadherin ectodomains interact to facilitate regulation of phosphorylation and cell contacts. EMBO J. 21, 4885\u20134895 (2002).","journal-title":"EMBO J."},{"key":"2249_CR256","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms2683","volume":"4","author":"M Hayashi","year":"2013","unstructured":"Hayashi, M. et al. VE-PTP regulates VEGFR2 activity in stalk cells to establish endothelial cell polarity and lumen formation. Nat. Commun. 4, 1672 (2013).","journal-title":"Nat. Commun."},{"key":"2249_CR257","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1096\/fj.08-123810","volume":"23","author":"S Mellberg","year":"2009","unstructured":"Mellberg, S. et al. Transcriptional profiling reveals a critical role for tyrosine phosphatase VE-PTP in regulation of VEGFR2 activity and endothelial cell morphogenesis. FASEB J. 23, 1490\u20131502 (2009).","journal-title":"FASEB J."},{"key":"2249_CR258","doi-asserted-by":"publisher","first-page":"8698","DOI":"10.3390\/ijms24108698","volume":"24","author":"B Baccouche","year":"2023","unstructured":"Baccouche, B., Lietuvninkas, L. & Kazlauskas, A. Activin A limits VEGF-induced permeability via VE-PTP. Int. J. Mol. Sci. 24, 8698 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"2249_CR259","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1161\/CIRCRESAHA.107.167080","volume":"102","author":"Y Nakamura","year":"2008","unstructured":"Nakamura, Y. et al. Role of protein tyrosine phosphatase 1B in vascular endothelial growth factor signaling and cell-cell adhesions in endothelial cells. Circ. Res. 102, 1182\u20131191 (2008).","journal-title":"Circ. Res."},{"key":"2249_CR260","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.devcel.2010.02.016","volume":"18","author":"AA Lanahan","year":"2010","unstructured":"Lanahan, A. A. et al. VEGF receptor 2 endocytic trafficking regulates arterial morphogenesis. Dev. Cell 18, 713\u2013724 (2010).","journal-title":"Dev. Cell"},{"key":"2249_CR261","doi-asserted-by":"publisher","DOI":"10.1186\/1750-2187-3-8","volume":"3","author":"R Bhattacharya","year":"2008","unstructured":"Bhattacharya, R., Kwon, J., Wang, E., Mukherjee, P. & Mukhopadhyay, D. Src homology 2 (SH2) domain containing protein tyrosine phosphatase-1 (SHP-1) dephosphorylates VEGF Receptor-2 and attenuates endothelial DNA synthesis, but not migration. J. Mol. Signal. 3, 8 (2008).","journal-title":"J. Mol. Signal."},{"key":"2249_CR262","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1182\/blood-2013-01-482315","volume":"122","author":"L-Y Chu","year":"2013","unstructured":"Chu, L.-Y., Ramakrishnan, D. P. & Silverstein, R. L. Thrombospondin-1 modulates VEGF signaling via CD36 by recruiting SHP-1 to VEGFR2 complex in microvascular endothelial cells. Blood 122, 1822\u20131832 (2013).","journal-title":"Blood"},{"key":"2249_CR263","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1158\/2159-8290.CD-12-0018","volume":"2","author":"S Chandarlapaty","year":"2012","unstructured":"Chandarlapaty, S. Negative feedback and adaptive resistance to the targeted therapy of cancer. Cancer Discov. 2, 311\u2013319 (2012).","journal-title":"Cancer Discov."},{"key":"2249_CR264","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.tcb.2005.11.004","volume":"16","author":"JM Mason","year":"2006","unstructured":"Mason, J. M., Morrison, D. J., Basson, M. A. & Licht, J. D. Sprouty proteins: multifaceted negative-feedback regulators of receptor tyrosine kinase signaling. Trends Cell. Biol. 16, 45\u201354 (2006).","journal-title":"Trends Cell. Biol."},{"key":"2249_CR265","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.semcdb.2015.10.001","volume":"50","author":"S Anastasi","year":"2016","unstructured":"Anastasi, S., Lamberti, D., Alem\u00e0, S. & Segatto, O. Regulation of the ErbB network by the MIG6 feedback loop in physiology, tumor suppression and responses to oncogene-targeted therapeutics. Semin. Cell Dev. Biol. 50, 115\u2013124 (2016).","journal-title":"Semin. Cell Dev. Biol."},{"key":"2249_CR266","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1172\/JCI200421152","volume":"114","author":"K Watanabe","year":"2004","unstructured":"Watanabe, K. et al. Vasohibin as an endothelium-derived negative feedback regulator of angiogenesis. J. Clin. Invest. 114, 898\u2013907 (2004).","journal-title":"J. Clin. Invest."},{"key":"2249_CR267","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1172\/JCI23153","volume":"114","author":"RS Kerbel","year":"2004","unstructured":"Kerbel, R. S. Vasohibin: the feedback on a new inhibitor of angiogenesis. J. Clin. Invest. 114, 884\u2013886 (2004).","journal-title":"J. Clin. Invest."},{"key":"2249_CR268","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1096\/fj.05-5046fje","volume":"20","author":"J Shen","year":"2006","unstructured":"Shen, J. et al. Vasohibin is up-regulated by VEGF in the retina and suppresses VEGF receptor 2 and retinal neovascularization. FASEB J. 20, 723\u2013725 (2006).","journal-title":"FASEB J."},{"key":"2249_CR269","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1002\/dvdy.21134","volume":"236","author":"S Nimmagadda","year":"2007","unstructured":"Nimmagadda, S. et al. Expression pattern of Vasohibin during chick development. Dev. Dyn. 236, 1358\u20131362 (2007).","journal-title":"Dev. Dyn."},{"key":"2249_CR270","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/cgt.2016.13","volume":"23","author":"S Horie","year":"2016","unstructured":"Horie, S. et al. Distinctive role of vasohibin-1A and its splicing variant vasohibin-1B in tumor angiogenesis. Cancer Gene Ther. 23, 133\u2013141 (2016).","journal-title":"Cancer Gene Ther."},{"key":"2249_CR271","doi-asserted-by":"publisher","first-page":"4810","DOI":"10.1182\/blood-2008-07-170316","volume":"113","author":"H Kimura","year":"2009","unstructured":"Kimura, H. et al. Distinctive localization and opposed roles of vasohibin-1 and vasohibin-2 in the regulation of angiogenesis. Blood 113, 4810\u20134818 (2009).","journal-title":"Blood"},{"key":"2249_CR272","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1158\/1541-7786.MCR-12-0098-T","volume":"10","author":"Y Takahashi","year":"2012","unstructured":"Takahashi, Y. et al. Vasohibin-2 expressed in human serous ovarian adenocarcinoma accelerates tumor growth by promoting angiogenesis. Mol. Cancer Res. 10, 1135\u20131146 (2012).","journal-title":"Mol. Cancer Res."},{"key":"2249_CR273","doi-asserted-by":"publisher","first-page":"461","DOI":"10.5551\/jat.43398","volume":"25","author":"Y Sato","year":"2018","unstructured":"Sato, Y. Double-face of vasohibin-1 for the maintenance of vascular homeostasis and healthy longevity. J. Atheroscler. Thromb. 25, 461\u2013466 (2018).","journal-title":"J. Atheroscler. Thromb."},{"key":"2249_CR274","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1073\/pnas.0611206104","volume":"104","author":"IB Lobov","year":"2007","unstructured":"Lobov, I. B. et al. Delta-like ligand 4 (Dll4) is induced by VEGF as a negative regulator of angiogenic sprouting. Proc. Natl. Acad. Sci. USA 104, 3219\u20133224 (2007).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2249_CR275","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1042\/BST0371233","volume":"37","author":"L Jakobsson","year":"2009","unstructured":"Jakobsson, L., Bentley, K. & Gerhardt, H. VEGFRs and Notch: a dynamic collaboration in vascular patterning. Biochem. Soc. Trans. 37, 1233\u20131236 (2009).","journal-title":"Biochem. Soc. Trans."},{"key":"2249_CR276","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/nature05571","volume":"445","author":"M Hellstr\u00f6m","year":"2007","unstructured":"Hellstr\u00f6m, M. et al. Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature 445, 776\u2013780 (2007).","journal-title":"Nature"},{"key":"2249_CR277","doi-asserted-by":"publisher","first-page":"104","DOI":"10.4161\/cam.1.2.4488","volume":"1","author":"AF Siekmann","year":"2007","unstructured":"Siekmann, A. F. & Lawson, N. D. Notch signalling and the regulation of angiogenesis. Cell Adh. Migr. 1, 104\u2013105 (2007).","journal-title":"Cell Adh. Migr."},{"key":"2249_CR278","doi-asserted-by":"publisher","first-page":"133","DOI":"10.4161\/cam.1.3.4978","volume":"1","author":"M Hellstr\u00f6m","year":"2007","unstructured":"Hellstr\u00f6m, M., Phng, L.-K. & Gerhardt, H. VEGF and notch signaling. Cell Adh. Migr. 1, 133\u2013136 (2007).","journal-title":"Cell Adh. Migr."},{"key":"2249_CR279","doi-asserted-by":"publisher","first-page":"241","DOI":"10.4161\/org.4.4.7414","volume":"4","author":"H Gerhardt","year":"2008","unstructured":"Gerhardt, H. VEGF and endothelial guidance in angiogenic sprouting. Organogenesis 4, 241\u2013246 (2008).","journal-title":"Organogenesis"},{"key":"2249_CR280","doi-asserted-by":"publisher","first-page":"3796","DOI":"10.1242\/dev.137919","volume":"143","author":"M Shin","year":"2016","unstructured":"Shin, M. et al. Vegfa signals through ERK to promote angiogenesis, but not artery differentiation. Development 143, 3796\u20133805 (2016).","journal-title":"Development"},{"key":"2249_CR281","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.ceb.2010.08.010","volume":"22","author":"HM Eilken","year":"2010","unstructured":"Eilken, H. M. & Adams, R. H. Dynamics of endothelial cell behavior in sprouting angiogenesis. Curr. Opin. Cell Biol. 22, 617\u2013625 (2010).","journal-title":"Curr. Opin. Cell Biol."},{"key":"2249_CR282","doi-asserted-by":"publisher","first-page":"a006569","DOI":"10.1101\/cshperspect.a006569","volume":"3","author":"R Blanco","year":"2013","unstructured":"Blanco, R. & Gerhardt, H. VEGF and Notch in tip and stalk cell selection. Cold Spring Harb. Perspect. Med. 3, a006569 (2013).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"2249_CR283","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/j.cell.2009.03.025","volume":"137","author":"R Benedito","year":"2009","unstructured":"Benedito, R. et al. The notch ligands Dll4 and Jagged1 have opposing effects on angiogenesis. Cell 137, 1124\u20131135 (2009).","journal-title":"Cell"},{"key":"2249_CR284","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nature10908","volume":"484","author":"R Benedito","year":"2012","unstructured":"Benedito, R. et al. Notch-dependent VEGFR3 upregulation allows angiogenesis without VEGF-VEGFR2 signalling. Nature 484, 110\u2013114 (2012).","journal-title":"Nature"},{"issue":"Suppl 1","key":"2249_CR285","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/jth.12253","volume":"11","author":"R Monahan-Earley","year":"2013","unstructured":"Monahan-Earley, R., Dvorak, A. M. & Aird, W. C. Evolutionary origins of the blood vascular system and endothelium. J. Thromb. Haemost. 11(Suppl 1), 46\u201366 (2013).","journal-title":"J. Thromb. Haemost."},{"key":"2249_CR286","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1002\/bies.20497","volume":"28","author":"V Hartenstein","year":"2006","unstructured":"Hartenstein, V. & Mandal, L. The blood\/vascular system in a phylogenetic perspective. Bioessays 28, 1203\u20131210 (2006).","journal-title":"Bioessays"},{"key":"2249_CR287","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1146\/annurev.physiol.61.1.573","volume":"61","author":"CG Farmer","year":"1999","unstructured":"Farmer, C. G. Evolution of the vertebrate cardio-pulmonary system. Annu. Rev. Physiol. 61, 573\u2013592 (1999).","journal-title":"Annu. Rev. Physiol."},{"key":"2249_CR288","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-1-4419-8871-3_1","volume":"117","author":"S Patan","year":"2004","unstructured":"Patan, S. Vasculogenesis and angiogenesis. Cancer Treat. Res. 117, 3\u201332 (2004).","journal-title":"Cancer Treat. Res."},{"key":"2249_CR289","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2307\/4348383","volume":"69","author":"RJ Littman","year":"1975","unstructured":"Littman, R. J. The heart and the vascular system in ancient-Greek medicine\u2014 from Alcmaeon to Galen - Harris,Crs. Classical World 69, 143\u2013144 (1975).","journal-title":"Classical World"},{"key":"2249_CR290","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/BF00963592","volume":"337","author":"GI Schoefl","year":"1963","unstructured":"Schoefl, G. I. Studies on inflammation. Iii. Growing capillaries: their structure and permeability. Virchows Arch. Pathol. Anat. Physiol. Klin. Med 337, 97\u2013141 (1963).","journal-title":"Virchows Arch. Pathol. Anat. Physiol. Klin. Med"},{"key":"2249_CR291","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1098\/rstb.1963.0008","volume":"246","author":"WJ Cliff","year":"1963","unstructured":"Cliff, W. J. Observations on healing tissue\u2014a combined light and electron microscopic investigation. Philos. Trans. R. Soc. Lond. B Biol. Sci. 246, 305 (1963).","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"2249_CR292","first-page":"467","volume":"46","author":"J Folkman","year":"1986","unstructured":"Folkman, J. How is blood vessel growth regulated in normal and neoplastic tissue? G.H.A. Clowes memorial Award lecture. Cancer Res. 46, 467\u2013473 (1986).","journal-title":"Cancer Res."},{"key":"2249_CR293","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/nrm3176","volume":"12","author":"SP Herbert","year":"2011","unstructured":"Herbert, S. P. & Stainier, D. Y. Molecular control of endothelial cell behaviour during blood vessel morphogenesis. Nat. Rev. Mol. Cell Biol. 12, 551\u2013564 (2011).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2249_CR294","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.cell.2011.08.039","volume":"146","author":"M Potente","year":"2011","unstructured":"Potente, M., Gerhardt, H. & Carmeliet, P. Basic and therapeutic aspects of angiogenesis. Cell 146, 873\u2013887 (2011).","journal-title":"Cell"},{"key":"2249_CR295","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1001\/archopht.1996.01100140172010","volume":"114","author":"MJ Tolentino","year":"1996","unstructured":"Tolentino, M. J. et al. Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. Arch. Ophthalmol. 114, 964\u2013970 (1996).","journal-title":"Arch. Ophthalmol."},{"key":"2249_CR296","doi-asserted-by":"publisher","first-page":"6740","DOI":"10.1158\/0008-5472.CAN-04-0713","volume":"64","author":"M Abdelrahim","year":"2004","unstructured":"Abdelrahim, M., Smith, R. III, Burghardt, R. & Safe, S. Role of Sp proteins in regulation of vascular endothelial growth factor expression and proliferation of pancreatic cancer cells. Cancer Res. 64, 6740\u20136749 (2004).","journal-title":"Cancer Res."},{"key":"2249_CR297","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1152\/physrev.00014.2004","volume":"85","author":"R Hallmann","year":"2005","unstructured":"Hallmann, R. et al. Expression and function of laminins in the embryonic and mature vasculature. Physiol. Rev. 85, 979\u20131000 (2005).","journal-title":"Physiol. Rev."},{"key":"2249_CR298","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/bs.ctdb.2018.02.001","volume":"130","author":"RP Mecham","year":"2018","unstructured":"Mecham, R. P. & Ramirez, F. Extracellular determinants of arterial morphogenesis, growth, and homeostasis. Curr. Top. Dev. Biol. 130, 193\u2013216 (2018).","journal-title":"Curr. Top. Dev. Biol."},{"key":"2249_CR299","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.devcel.2013.08.020","volume":"26","author":"M Giannotta","year":"2013","unstructured":"Giannotta, M., Trani, M. & Dejana, E. VE-cadherin and endothelial adherens junctions: active guardians of vascular integrity. Dev. Cell 26, 441\u2013454 (2013).","journal-title":"Dev. Cell"},{"key":"2249_CR300","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2009-10-8-235","volume":"10","author":"M Lal-Nag","year":"2009","unstructured":"Lal-Nag, M. & Morin, P. J. The claudins. Genome Biol. 10, 235 (2009).","journal-title":"Genome Biol."},{"key":"2249_CR301","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.addr.2005.01.005","volume":"57","author":"KJ Mandell","year":"2005","unstructured":"Mandell, K. J. & Parkos, C. A. The JAM family of proteins. Adv. Drug Deliv. Rev. 57, 857\u2013867 (2005).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2249_CR302","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1161\/01.ATV.0000209518.58252.17","volume":"26","author":"VW van Hinsbergh","year":"2006","unstructured":"van Hinsbergh, V. W., Engelse, M. A. & Quax, P. H. Pericellular proteases in angiogenesis and vasculogenesis. Arterioscler. Thromb. Vasc. Biol. 26, 716\u2013728 (2006).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2249_CR303","doi-asserted-by":"publisher","first-page":"26031","DOI":"10.1016\/S0021-9258(18)35712-0","volume":"267","author":"KA Houck","year":"1992","unstructured":"Houck, K. A., Leung, D. W., Rowland, A. M., Winer, J. & Ferrara, N. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J. Biol. Chem. 267, 26031\u201326037 (1992).","journal-title":"J. Biol. Chem."},{"key":"2249_CR304","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1083\/jcb.200409115","volume":"169","author":"S Lee","year":"2005","unstructured":"Lee, S., Jilani, S. M., Nikolova, G. V., Carpizo, D. & Iruela-Arispe, M. L. Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J. Cell Biol. 169, 681\u2013691 (2005).","journal-title":"J. Cell Biol."},{"key":"2249_CR305","doi-asserted-by":"publisher","first-page":"13564","DOI":"10.1074\/jbc.M307688200","volume":"279","author":"NE Sounni","year":"2004","unstructured":"Sounni, N. E. et al. Up-regulation of vascular endothelial growth factor-A by active membrane-type 1 matrix metalloproteinase through activation of Src-tyrosine kinases. J. Biol. Chem. 279, 13564\u201313574 (2004).","journal-title":"J. Biol. Chem."},{"key":"2249_CR306","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1096\/fj.01-0790com","volume":"16","author":"NE Sounni","year":"2002","unstructured":"Sounni, N. E. et al. MT1-MMP expression promotes tumor growth and angiogenesis through an up-regulation of vascular endothelial growth factor expression. FASEB J. 16, 555\u2013564 (2002).","journal-title":"FASEB J."},{"key":"2249_CR307","doi-asserted-by":"publisher","first-page":"4238","DOI":"10.1074\/jbc.M210445200","volume":"278","author":"M Mongiat","year":"2003","unstructured":"Mongiat, M., Sweeney, S. M., San Antonio, J. D., Fu, J. & Iozzo, R. V. Endorepellin, a novel inhibitor of angiogenesis derived from the C terminus of perlecan. J. Biol. Chem. 278, 4238\u20134249 (2003).","journal-title":"J. Biol. Chem."},{"key":"2249_CR308","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S0092-8674(00)81848-6","volume":"88","author":"MS O\u2019Reilly","year":"1997","unstructured":"O\u2019Reilly, M. S. et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88, 277\u2013285 (1997).","journal-title":"Cell"},{"key":"2249_CR309","doi-asserted-by":"publisher","first-page":"6624","DOI":"10.1073\/pnas.87.17.6624","volume":"87","author":"DJ Good","year":"1990","unstructured":"Good, D. J. et al. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc. Natl. Acad. Sci. USA 87, 6624\u20136628 (1990).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2249_CR310","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1126\/science.1065298","volume":"295","author":"Y Maeshima","year":"2002","unstructured":"Maeshima, Y. et al. Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science 295, 140\u2013143 (2002).","journal-title":"Science"},{"key":"2249_CR311","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.1084\/jem.20080406","volume":"205","author":"AF Nottebaum","year":"2008","unstructured":"Nottebaum, A. F. et al. VE-PTP maintains the endothelial barrier via plakoglobin and becomes dissociated from VE-cadherin by leukocytes and by VEGF. J. Exp. Med. 205, 2929\u20132945 (2008).","journal-title":"J. Exp. Med."},{"key":"2249_CR312","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1038\/ncb1486","volume":"8","author":"J Gavard","year":"2006","unstructured":"Gavard, J. & Gutkind, J. S. VEGF controls endothelial-cell permeability by promoting the beta-arrestin-dependent endocytosis of VE-cadherin. Nat. Cell Biol. 8, 1223\u20131234 (2006).","journal-title":"Nat. Cell Biol."},{"key":"2249_CR313","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1038\/ncb1752","volume":"10","author":"A Taddei","year":"2008","unstructured":"Taddei, A. et al. Endothelial adherens junctions control tight junctions by VE-cadherin-mediated upregulation of claudin-5. Nat. Cell Biol. 10, 923\u2013934 (2008).","journal-title":"Nat. Cell Biol."},{"key":"2249_CR314","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1083\/jcb.201408103","volume":"208","author":"BG Coon","year":"2015","unstructured":"Coon, B. G. et al. Intramembrane binding of VE-cadherin to VEGFR2 and VEGFR3 assembles the endothelial mechanosensory complex. J. Cell Biol. 208, 975\u2013986 (2015).","journal-title":"J. Cell Biol."},{"key":"2249_CR315","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1073\/pnas.1613855114","volume":"114","author":"F Bordeleau","year":"2017","unstructured":"Bordeleau, F. et al. Matrix stiffening promotes a tumor vasculature phenotype. Proc. Natl. Acad. Sci. USA 114, 492\u2013497 (2017).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2249_CR316","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/978-3-319-95294-9_6","volume":"1092","author":"MR Zanotelli","year":"2018","unstructured":"Zanotelli, M. R. & Reinhart-King, C. A. Mechanical forces in tumor angiogenesis. Adv. Exp. Med. Biol. 1092, 91\u2013112 (2018).","journal-title":"Adv. Exp. Med. Biol."},{"key":"2249_CR317","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/(SICI)1521-1878(200003)22:3<219::AID-BIES3>3.0.CO;2-A","volume":"22","author":"E Zelzer","year":"2000","unstructured":"Zelzer, E. & Shilo, B. Z. Cell fate choices in Drosophila tracheal morphogenesis. Bioessays 22, 219\u2013226 (2000).","journal-title":"Bioessays"},{"key":"2249_CR318","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/BF00307145","volume":"133","author":"T Bar","year":"1972","unstructured":"Bar, T. & Wolff, J. R. The formation of capillary basement membranes during internal vascularization of the rat\u2019s cerebral cortex. Z. Zellforsch. Mikros Anat. 133, 231\u2013248 (1972).","journal-title":"Z. Zellforsch. Mikros Anat."},{"key":"2249_CR319","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1083\/jcb.200302047","volume":"161","author":"H Gerhardt","year":"2003","unstructured":"Gerhardt, H. et al. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J. Cell Biol. 161, 1163\u20131177 (2003).","journal-title":"J. Cell Biol."},{"key":"2249_CR320","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/nature07083","volume":"454","author":"T Tammela","year":"2008","unstructured":"Tammela, T. et al. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature 454, 656\u2013660 (2008).","journal-title":"Nature"},{"key":"2249_CR321","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.cell.2013.06.037","volume":"154","author":"K De Bock","year":"2013","unstructured":"De Bock, K. et al. Role of PFKFB3-driven glycolysis in vessel sprouting. Cell 154, 651\u2013663 (2013).","journal-title":"Cell"},{"key":"2249_CR322","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.cmet.2019.08.011","volume":"30","author":"X Li","year":"2019","unstructured":"Li, X., Sun, X. & Carmeliet, P. Hallmarks of endothelial cell metabolism in health and disease. Cell Metab. 30, 414\u2013433 (2019).","journal-title":"Cell Metab."},{"key":"2249_CR323","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1242\/dev.063933","volume":"138","author":"J Krueger","year":"2011","unstructured":"Krueger, J. et al. Flt1 acts as a negative regulator of tip cell formation and branching morphogenesis in the zebrafish embryo. Development 138, 2111\u20132120 (2011).","journal-title":"Development"},{"key":"2249_CR324","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1038\/ncb2331","volume":"13","author":"T Tammela","year":"2011","unstructured":"Tammela, T. et al. VEGFR-3 controls tip to stalk conversion at vessel fusion sites by reinforcing Notch signalling. Nat. Cell Biol. 13, 1202\u20131213 (2011).","journal-title":"Nat. Cell Biol."},{"key":"2249_CR325","doi-asserted-by":"publisher","first-page":"5102","DOI":"10.1182\/blood-2009-07-230284","volume":"115","author":"GA Strasser","year":"2010","unstructured":"Strasser, G. A., Kaminker, J. S. & Tessier-Lavigne, M. Microarray analysis of retinal endothelial tip cells identifies CXCR4 as a mediator of tip cell morphology and branching. Blood 115, 5102\u20135110 (2010).","journal-title":"Blood"},{"key":"2249_CR326","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1038\/ncb2103","volume":"12","author":"L Jakobsson","year":"2010","unstructured":"Jakobsson, L. et al. Endothelial cells dynamically compete for the tip cell position during angiogenic sprouting. Nat. Cell Biol. 12, 943\u2013953 (2010).","journal-title":"Nat. Cell Biol."},{"key":"2249_CR327","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood-2006-07-037952","volume":"109","author":"G Zeng","year":"2007","unstructured":"Zeng, G. et al. Orientation of endothelial cell division is regulated by VEGF signaling during blood vessel formation. Blood 109, 1345\u20131352 (2007).","journal-title":"Blood"},{"key":"2249_CR328","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.devcel.2009.08.011","volume":"17","author":"B Strilic","year":"2009","unstructured":"Strilic, B. et al. The molecular basis of vascular lumen formation in the developing mouse aorta. Dev. Cell 17, 505\u2013515 (2009).","journal-title":"Dev. Cell"},{"key":"2249_CR329","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.devcel.2013.05.010","volume":"25","author":"A Lenard","year":"2013","unstructured":"Lenard, A. et al. In vivo analysis reveals a highly stereotypic morphogenetic pathway of vascular anastomosis. Dev. Cell 25, 492\u2013506 (2013).","journal-title":"Dev. Cell"},{"key":"2249_CR330","doi-asserted-by":"publisher","first-page":"4031","DOI":"10.1242\/dev.097352","volume":"140","author":"LK Phng","year":"2013","unstructured":"Phng, L. K., Stanchi, F. & Gerhardt, H. Filopodia are dispensable for endothelial tip cell guidance. Development 140, 4031\u20134040 (2013).","journal-title":"Development"},{"key":"2249_CR331","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1242\/dev.145672","volume":"144","author":"JE Nesmith","year":"2017","unstructured":"Nesmith, J. E., Chappell, J. C., Cluceru, J. G. & Bautch, V. L. Blood vessel anastomosis is spatially regulated by Flt1 during angiogenesis. Development 144, 889\u2013896 (2017).","journal-title":"Development"},{"key":"2249_CR332","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1182\/blood-2009-12-257832","volume":"116","author":"A Fantin","year":"2010","unstructured":"Fantin, A. et al. Tissue macrophages act as cellular chaperones for vascular anastomosis downstream of VEGF-mediated endothelial tip cell induction. Blood 116, 829\u2013840 (2010).","journal-title":"Blood"},{"key":"2249_CR333","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/nature10085","volume":"474","author":"JA Stefater","year":"2011","unstructured":"Stefater, J. A. et al. Regulation of angiogenesis by a non-canonical Wnt-Flt1 pathway in myeloid cells. Nature 474, 511\u2013515 (2011).","journal-title":"Nature"},{"key":"2249_CR334","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/bs.ctdb.2024.02.001","volume":"159","author":"J Furtado","year":"2024","unstructured":"Furtado, J. & Eichmann, A. Vascular development, remodeling and maturation. Curr. Top. Dev. Biol. 159, 344\u2013370 (2024).","journal-title":"Curr. Top. Dev. Biol."},{"key":"2249_CR335","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1002\/dvdy.20407","volume":"233","author":"S Claxton","year":"2005","unstructured":"Claxton, S. & Fruttiger, M. Oxygen modifies artery differentiation and network morphogenesis in the retinal vasculature. Dev. Dyn. 233, 822\u2013828 (2005).","journal-title":"Dev. Dyn."},{"key":"2249_CR336","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/nature13701","volume":"515","author":"J Li","year":"2014","unstructured":"Li, J. et al. Piezo1 integration of vascular architecture with physiological force. Nature 515, 279\u2013282 (2014).","journal-title":"Nature"},{"key":"2249_CR337","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a041156","volume":"13","author":"GE Davis","year":"2023","unstructured":"Davis, G. E. & Kemp, S. S. Extracellular matrix regulation of vascular morphogenesis, maturation, and stabilization. Cold Spring Harb. Perspect. Med. 13, a041156 (2023).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"2249_CR338","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/nm0603-685","volume":"9","author":"RK Jain","year":"2003","unstructured":"Jain, R. K. Molecular regulation of vessel maturation. Nat. Med. 9, 685\u2013693 (2003).","journal-title":"Nat. Med."},{"key":"2249_CR339","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.jare.2024.01.016","volume":"67","author":"G Li","year":"2024","unstructured":"Li, G., Gao, J., Ding, P. & Gao, Y. The role of endothelial cell-pericyte interactions in vascularization and diseases. J. Adv. Res. 67, 269\u2013288 (2024).","journal-title":"J. Adv. Res."},{"key":"2249_CR340","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nrd2792","volume":"8","author":"A Beenken","year":"2009","unstructured":"Beenken, A. & Mohammadi, M. The FGF family: biology, pathophysiology and therapy. Nat. Rev. Drug Discov. 8, 235\u2013253 (2009).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2249_CR341","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/nrd.2016.278","volume":"16","author":"P Saharinen","year":"2017","unstructured":"Saharinen, P., Eklund, L. & Alitalo, K. Therapeutic targeting of the angiopoietin-TIE pathway. Nat. Rev. Drug Discov. 16, 635\u2013661 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2249_CR342","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1161\/01.RES.0000118600.91698.BB","volume":"94","author":"R Cao","year":"2004","unstructured":"Cao, R. et al. Comparative evaluation of FGF-2-, VEGF-A-, and VEGF-C-induced angiogenesis, lymphangiogenesis, vascular fenestrations, and permeability. Circ. Res. 94, 664\u2013670 (2004).","journal-title":"Circ. Res."},{"key":"2249_CR343","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1128\/MCB.20.6.2260-2268.2000","volume":"20","author":"DL Miller","year":"2000","unstructured":"Miller, D. L., Ortega, S., Bashayan, O., Basch, R. & Basilico, C. Compensation by fibroblast growth factor 1 (FGF1) does not account for the mild phenotypic defects observed in FGF2 null mice. Mol. Cell. Biol. 20, 2260\u20132268 (2000).","journal-title":"Mol. Cell. Biol."},{"key":"2249_CR344","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1126\/science.286.5449.2511","volume":"286","author":"G Thurston","year":"1999","unstructured":"Thurston, G. et al. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science 286, 2511\u20132514 (1999).","journal-title":"Science"},{"key":"2249_CR345","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/S0092-8674(00)81813-9","volume":"87","author":"C Suri","year":"1996","unstructured":"Suri, C. et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87, 1171\u20131180 (1996).","journal-title":"Cell"},{"key":"2249_CR346","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/S1534-5807(02)00217-4","volume":"3","author":"NW Gale","year":"2002","unstructured":"Gale, N. W. et al. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. Dev. Cell 3, 411\u2013423 (2002).","journal-title":"Dev. Cell"},{"key":"2249_CR347","doi-asserted-by":"publisher","first-page":"11205","DOI":"10.1073\/pnas.172161899","volume":"99","author":"IB Lobov","year":"2002","unstructured":"Lobov, I. B., Brooks, P. C. & Lang, R. A. Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc. Natl. Acad. Sci. USA 99, 11205\u201311210 (2002).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2249_CR348","doi-asserted-by":"publisher","first-page":"3759","DOI":"10.1242\/jcs.02483","volume":"118","author":"MR Kano","year":"2005","unstructured":"Kano, M. R. et al. VEGF-A and FGF-2 synergistically promote neoangiogenesis through enhancement of endogenous PDGF-B-PDGFRbeta signaling. J. Cell. Sci. 118, 3759\u20133768 (2005).","journal-title":"J. Cell. Sci."},{"key":"2249_CR349","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/s41586-024-07698-1","volume":"632","author":"X Pan","year":"2024","unstructured":"Pan, X. et al. Tumour vasculature at single-cell resolution. Nature 632, 429\u2013436 (2024).","journal-title":"Nature"},{"key":"2249_CR350","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1146\/annurev.cb.11.110195.000445","volume":"11","author":"W Risau","year":"1995","unstructured":"Risau, W. & Flamme, I. Vasculogenesis. Annu. Rev. Cell Dev. Biol. 11, 73\u201391 (1995).","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"2249_CR351","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1126\/science.1104819","volume":"307","author":"RK Jain","year":"2005","unstructured":"Jain, R. K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58\u201362 (2005).","journal-title":"Science"},{"key":"2249_CR352","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1006\/dbio.2001.0362","volume":"238","author":"A Caprioli","year":"2001","unstructured":"Caprioli, A. et al. Hemangioblast commitment in the avian allantois: cellular and molecular aspects. Dev. Biol. 238, 64\u201378 (2001).","journal-title":"Dev. Biol."},{"key":"2249_CR353","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.devcel.2009.01.014","volume":"16","author":"S De Val","year":"2009","unstructured":"De Val, S. & Black, B. L. Transcriptional control of endothelial cell development. Dev. Cell 16, 180\u2013195 (2009).","journal-title":"Dev. Cell"},{"key":"2249_CR354","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.semcdb.2011.05.001","volume":"22","author":"K Xu","year":"2011","unstructured":"Xu, K. & Cleaver, O. Tubulogenesis during blood vessel formation. Semin. Cell Dev. Biol. 22, 993\u20131004 (2011).","journal-title":"Semin. Cell Dev. Biol."},{"key":"2249_CR355","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1006\/dbio.2002.0711","volume":"248","author":"ND Lawson","year":"2002","unstructured":"Lawson, N. D. & Weinstein, B. M. In vivo imaging of embryonic vascular development using transgenic zebrafish. Dev. Biol. 248, 307\u2013318 (2002).","journal-title":"Dev. Biol."},{"key":"2249_CR356","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1387\/ijdb.103213sp","volume":"55","author":"S Patel-Hett","year":"2011","unstructured":"Patel-Hett, S. & D\u2019Amore, P. A. Signal transduction in vasculogenesis and developmental angiogenesis. Int. J. Dev. Biol. 55, 353\u2013363 (2011).","journal-title":"Int. J. Dev. Biol."},{"key":"2249_CR357","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1023\/A:1006493130855","volume":"50","author":"S Patan","year":"2000","unstructured":"Patan, S. Vasculogenesis and angiogenesis as mechanisms of vascular network formation, growth and remodeling. J. Neurooncol. 50, 1\u201315 (2000).","journal-title":"J. Neurooncol."},{"key":"2249_CR358","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/380435a0","volume":"380","author":"P Carmeliet","year":"1996","unstructured":"Carmeliet, P. et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380, 435\u2013439 (1996).","journal-title":"Nature"},{"key":"2249_CR359","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/380439a0","volume":"380","author":"N Ferrara","year":"1996","unstructured":"Ferrara, N. et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380, 439\u2013442 (1996).","journal-title":"Nature"},{"key":"2249_CR360","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/376062a0","volume":"376","author":"F Shalaby","year":"1995","unstructured":"Shalaby, F. et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376, 62\u201366 (1995).","journal-title":"Nature"},{"key":"2249_CR361","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1126\/science.282.5390.946","volume":"282","author":"DJ Dumont","year":"1998","unstructured":"Dumont, D. J. et al. Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Science 282, 946\u2013949 (1998).","journal-title":"Science"},{"key":"2249_CR362","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/376066a0","volume":"376","author":"GH Fong","year":"1995","unstructured":"Fong, G. H., Rossant, J., Gertsenstein, M. & Breitman, M. L. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376, 66\u201370 (1995).","journal-title":"Nature"},{"key":"2249_CR363","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/dvdy.10119","volume":"224","author":"VG Djonov","year":"2002","unstructured":"Djonov, V. G., Kurz, H. & Burri, P. H. Optimality in the developing vascular system: branching remodeling by means of intussusception as an efficient adaptation mechanism. Dev. Dyn. 224, 391\u2013402 (2002).","journal-title":"Dev. Dyn."},{"key":"2249_CR364","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s10456-011-9223-3","volume":"14","author":"BB Peebo","year":"2011","unstructured":"Peebo, B. B., Fagerholm, P., Traneus-Rockert, C. & Lagali, N. Cellular level characterization of capillary regression in inflammatory angiogenesis using an in vivo corneal model. Angiogenesis 14, 393\u2013405 (2011).","journal-title":"Angiogenesis"},{"key":"2249_CR365","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1002\/jemt.20169","volume":"66","author":"AN Makanya","year":"2005","unstructured":"Makanya, A. N., Stauffer, D., Ribatti, D., Burri, P. H. & Djonov, V. Microvascular growth, development, and remodeling in the embryonic avian kidney: the interplay between sprouting and intussusceptive angiogenic mechanisms. Microsc. Res. Tech. 66, 275\u2013288 (2005).","journal-title":"Microsc. Res. Tech."},{"key":"2249_CR366","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1053\/j.gastro.2011.12.052","volume":"142","author":"MT Dill","year":"2012","unstructured":"Dill, M. T. et al. Disruption of Notch1 induces vascular remodeling, intussusceptive angiogenesis, and angiosarcomas in livers of mice. Gastroenterology 142, 967\u2013977 e962 (2012).","journal-title":"Gastroenterology"},{"key":"2249_CR367","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1126\/science.1178577","volume":"326","author":"SP Herbert","year":"2009","unstructured":"Herbert, S. P. et al. Arterial-venous segregation by selective cell sprouting: an alternative mode of blood vessel formation. Science 326, 294\u2013298 (2009).","journal-title":"Science"},{"key":"2249_CR368","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.coi.2018.04.027","volume":"53","author":"D Ribatti","year":"2018","unstructured":"Ribatti, D. Historical overview of lymphangiogenesis. Curr. Opin. Immunol. 53, 161\u2013166 (2018).","journal-title":"Curr. Opin. Immunol."},{"key":"2249_CR369","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1002\/aja.1000010310","volume":"1","author":"FR Sabin","year":"1902","unstructured":"Sabin, F. R. On the origin of the lymphatic system from the veins and the development of the lymph hearts and thoracic duct in the pig. Am. J. Anat. 1, 367\u2013389 (1902).","journal-title":"Am. J. Anat."},{"key":"2249_CR370","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1101\/gad.1588407","volume":"21","author":"RS Srinivasan","year":"2007","unstructured":"Srinivasan, R. S. et al. Lineage tracing demonstrates the venous origin of the mammalian lymphatic vasculature. Genes Dev. 21, 2422\u20132432 (2007).","journal-title":"Genes Dev."},{"key":"2249_CR371","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1172\/JCI71603","volume":"124","author":"W Zheng","year":"2014","unstructured":"Zheng, W., Aspelund, A. & Alitalo, K. Lymphangiogenic factors, mechanisms, and applications. J. Clin. Invest. 124, 878\u2013887 (2014).","journal-title":"J. Clin. Invest."},{"key":"2249_CR372","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1101\/gad.303776.117","volume":"31","author":"K Vaahtomeri","year":"2017","unstructured":"Vaahtomeri, K., Karaman, S., Makinen, T. & Alitalo, K. Lymphangiogenesis guidance by paracrine and pericellular factors. Genes Dev. 31, 1615\u20131634 (2017).","journal-title":"Genes Dev."},{"key":"2249_CR373","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1126\/science.276.5317.1423","volume":"276","author":"M Jeltsch","year":"1997","unstructured":"Jeltsch, M. et al. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science 276, 1423\u20131425 (1997).","journal-title":"Science"},{"key":"2249_CR374","doi-asserted-by":"publisher","first-page":"11675","DOI":"10.1073\/pnas.93.21.11675","volume":"93","author":"M Orlandini","year":"1996","unstructured":"Orlandini, M., Marconcini, L., Ferruzzi, R. & Oliviero, S. Identification of a c-fos-induced gene that is related to the platelet-derived growth factor\/vascular endothelial growth factor family. Proc. Natl. Acad. Sci. USA 93, 11675\u201311680 (1996).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2249_CR375","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/ni1013","volume":"5","author":"MJ Karkkainen","year":"2004","unstructured":"Karkkainen, M. J. et al. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat. Immunol. 5, 74\u201380 (2004).","journal-title":"Nat. Immunol."},{"key":"2249_CR376","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1128\/MCB.25.6.2441-2449.2005","volume":"25","author":"ME Baldwin","year":"2005","unstructured":"Baldwin, M. E. et al. Vascular endothelial growth factor D is dispensable for development of the lymphatic system. Mol. Cell. Biol. 25, 2441\u20132449 (2005).","journal-title":"Mol. Cell. Biol."},{"key":"2249_CR377","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1038\/cr.2010.116","volume":"20","author":"L Zhang","year":"2010","unstructured":"Zhang, L. et al. VEGFR-3 ligand-binding and kinase activity are required for lymphangiogenesis but not for angiogenesis. Cell Res. 20, 1319\u20131331 (2010).","journal-title":"Cell Res."},{"key":"2249_CR378","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1084\/jem.20041896","volume":"201","author":"S Hirakawa","year":"2005","unstructured":"Hirakawa, S. et al. VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. J. Exp. Med. 201, 1089\u20131099 (2005).","journal-title":"J. Exp. Med."},{"key":"2249_CR379","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1096\/fj.03-1179fje","volume":"18","author":"YK Hong","year":"2004","unstructured":"Hong, Y. K. et al. VEGF-A promotes tissue repair-associated lymphatic vessel formation via VEGFR-2 and the alpha1beta1 and alpha2beta1 integrins. FASEB J. 18, 1111\u20131113 (2004).","journal-title":"FASEB J."},{"key":"2249_CR380","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1172\/JCI20465","volume":"113","author":"C Cursiefen","year":"2004","unstructured":"Cursiefen, C. et al. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J. Clin. Invest. 113, 1040\u20131050 (2004).","journal-title":"J. Clin. Invest."},{"key":"2249_CR381","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1161\/ATVBAHA.107.150433","volume":"28","author":"M Murakami","year":"2008","unstructured":"Murakami, M. et al. VEGFR1 tyrosine kinase signaling promotes lymphangiogenesis as well as angiogenesis indirectly via macrophage recruitment. Arterioscler. Thromb. Vasc. Biol. 28, 658\u2013664 (2008).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2249_CR382","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1182\/blood-2004-08-3327","volume":"105","author":"T Tammela","year":"2005","unstructured":"Tammela, T. et al. Angiopoietin-1 promotes lymphatic sprouting and hyperplasia. Blood 105, 4642\u20134648 (2005).","journal-title":"Blood"},{"key":"2249_CR383","doi-asserted-by":"publisher","first-page":"8868","DOI":"10.1073\/pnas.062040199","volume":"99","author":"H Kubo","year":"2002","unstructured":"Kubo, H. et al. Blockade of vascular endothelial growth factor receptor-3 signaling inhibits fibroblast growth factor-2-induced lymphangiogenesis in mouse cornea. Proc. Natl. Acad. Sci. USA 99, 8868\u20138873 (2002).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2249_CR384","doi-asserted-by":"publisher","first-page":"3531","DOI":"10.1182\/blood-2005-06-2538","volume":"107","author":"R Cao","year":"2006","unstructured":"Cao, R. et al. Hepatocyte growth factor is a lymphangiogenic factor with an indirect mechanism of action. Blood 107, 3531\u20133536 (2006).","journal-title":"Blood"},{"key":"2249_CR385","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.ccr.2004.08.034","volume":"6","author":"R Cao","year":"2004","unstructured":"Cao, R. et al. PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis. Cancer Cell 6, 333\u2013345 (2004).","journal-title":"Cancer Cell"},{"key":"2249_CR386","doi-asserted-by":"publisher","first-page":"15593","DOI":"10.1073\/pnas.0507865102","volume":"102","author":"M Bjorndahl","year":"2005","unstructured":"Bjorndahl, M. et al. Insulin-like growth factors 1 and 2 induce lymphangiogenesis in vivo. Proc. Natl. Acad. Sci. USA 102, 15593\u201315598 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2249_CR387","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.coi.2018.04.003","volume":"53","author":"M Sainz-Jaspeado","year":"2018","unstructured":"Sainz-Jaspeado, M. & Claesson-Welsh, L. Cytokines regulating lymphangiogenesis. Curr. Opin. Immunol. 53, 58\u201363 (2018).","journal-title":"Curr. Opin. Immunol."},{"key":"2249_CR388","doi-asserted-by":"publisher","first-page":"5048","DOI":"10.1182\/blood-2011-12-400267","volume":"119","author":"B Detry","year":"2012","unstructured":"Detry, B. et al. Matrix metalloproteinase-2 governs lymphatic vessel formation as an interstitial collagenase. Blood 119, 5048\u20135056 (2012).","journal-title":"Blood"},{"key":"2249_CR389","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1182\/blood-2010-11-317800","volume":"118","author":"W Zheng","year":"2011","unstructured":"Zheng, W. et al. Notch restricts lymphatic vessel sprouting induced by vascular endothelial growth factor. Blood 118, 1154\u20131162 (2011).","journal-title":"Blood"},{"key":"2249_CR390","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/S0002-9440(10)64255-1","volume":"161","author":"SF Schoppmann","year":"2002","unstructured":"Schoppmann, S. F. et al. Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am. J. Pathol. 161, 947\u2013956 (2002).","journal-title":"Am. J. Pathol."},{"key":"2249_CR391","doi-asserted-by":"publisher","first-page":"E29","DOI":"10.1161\/01.RES.86.2.e29","volume":"86","author":"D Bellomo","year":"2000","unstructured":"Bellomo, D. et al. Mice lacking the vascular endothelial growth factor-B gene (Vegfb) have smaller hearts, dysfunctional coronary vasculature, and impaired recovery from cardiac ischemia. Circ. Res. 86, E29\u2013E35 (2000).","journal-title":"Circ. Res."},{"key":"2249_CR392","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1172\/JCI17423","volume":"111","author":"V Eremina","year":"2003","unstructured":"Eremina, V. et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J. Clin. Invest. 111, 707\u2013716 (2003).","journal-title":"J. Clin. Invest."},{"key":"2249_CR393","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1242\/dev.126.6.1149","volume":"126","author":"HP Gerber","year":"1999","unstructured":"Gerber, H. P. et al. VEGF is required for growth and survival in neonatal mice. Development 126, 1149\u20131159 (1999).","journal-title":"Development"},{"key":"2249_CR394","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc8479","volume":"373","author":"M Grunewald","year":"2021","unstructured":"Grunewald, M. et al. Counteracting age-related VEGF signaling insufficiency promotes healthy aging and extends life span. Science 373, eabc8479 (2021).","journal-title":"Science"},{"key":"2249_CR395","first-page":"1","volume":"211","author":"G Grotte","year":"1956","unstructured":"Grotte, G. Passage of dextran molecules across the blood-lymph barrier. Acta Chir. Scand. Suppl. 211, 1\u201384 (1956).","journal-title":"Acta Chir. Scand. Suppl."},{"key":"2249_CR396","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1093\/cvr\/cvq062","volume":"87","author":"JR Levick","year":"2010","unstructured":"Levick, J. R. & Michel, C. C. Microvascular fluid exchange and the revised Starling principle. Cardiovasc. Res. 87, 198\u2013210 (2010).","journal-title":"Cardiovasc. Res."},{"key":"2249_CR397","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.molmed.2020.11.006","volume":"27","author":"L Claesson-Welsh","year":"2021","unstructured":"Claesson-Welsh, L., Dejana, E. & McDonald, D. M. Permeability of the endothelial barrier: identifying and reconciling controversies. Trends Mol. Med. 27, 314\u2013331 (2021).","journal-title":"Trends Mol. Med."},{"key":"2249_CR398","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s10456-008-9099-z","volume":"11","author":"JA Nagy","year":"2008","unstructured":"Nagy, J. A., Benjamin, L., Zeng, H., Dvorak, A. M. & Dvorak, H. F. Vascular permeability, vascular hyperpermeability and angiogenesis. Angiogenesis 11, 109\u2013119 (2008).","journal-title":"Angiogenesis"},{"key":"2249_CR399","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1084\/jem.20111343","volume":"209","author":"Z Sun","year":"2012","unstructured":"Sun, Z. et al. VEGFR2 induces c-Src signaling and vascular permeability in vivo via the adaptor protein TSAd. J. Exp. Med. 209, 1363\u20131377 (2012).","journal-title":"J. Exp. Med."},{"key":"2249_CR400","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/emboj\/20.11.2768","volume":"20","author":"T Takahashi","year":"2001","unstructured":"Takahashi, T., Yamaguchi, S., Chida, K. & Shibuya, M. A single autophosphorylation site on KDR\/Flk-1 is essential for VEGF-A-dependent activation of PLC-gamma and DNA synthesis in vascular endothelial cells. EMBO J. 20, 2768\u20132778 (2001).","journal-title":"EMBO J."},{"key":"2249_CR401","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1073\/pnas.0404984102","volume":"102","author":"Y Sakurai","year":"2005","unstructured":"Sakurai, Y., Ohgimoto, K., Kataoka, Y., Yoshida, N. & Shibuya, M. Essential role of Flk-1 (VEGF receptor 2) tyrosine residue 1173 in vasculogenesis in mice. Proc. Natl. Acad. Sci. USA 102, 1076\u20131081 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2249_CR402","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1172\/JCI24726","volume":"115","author":"E Ackah","year":"2005","unstructured":"Ackah, E. et al. Akt1\/protein kinase Balpha is critical for ischemic and VEGF-mediated angiogenesis. J. Clin. Invest. 115, 2119\u20132127 (2005).","journal-title":"J. Clin. Invest."},{"key":"2249_CR403","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1073\/pnas.0406092102","volume":"102","author":"PM Bauer","year":"2005","unstructured":"Bauer, P. M. et al. Endothelial-specific expression of caveolin-1 impairs microvascular permeability and angiogenesis. Proc. Natl. Acad. Sci. USA 102, 204\u2013209 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2249_CR404","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1091\/mbc.e02-07-0379","volume":"14","author":"L Labrecque","year":"2003","unstructured":"Labrecque, L. et al. Regulation of vascular endothelial growth factor receptor-2 activity by caveolin-1 and plasma membrane cholesterol. Mol. Biol. Cell 14, 334\u2013347 (2003).","journal-title":"Mol. Biol. Cell"},{"key":"2249_CR405","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.bbrc.2008.12.129","volume":"379","author":"Y Matsunaga","year":"2009","unstructured":"Matsunaga, Y., Yamazaki, Y., Suzuki, H. & Morita, T. VEGF-A and VEGF-F evoke distinct changes in vascular ultrastructure. Biochem. Biophys. Res. Commun. 379, 872\u2013875 (2009).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2249_CR406","first-page":"596","volume":"67","author":"S Kohn","year":"1992","unstructured":"Kohn, S., Nagy, J. A., Dvorak, H. F. & Dvorak, A. M. Pathways of macromolecular tracer transport across venules and small veins. Structural basis for the hyperpermeability of tumor blood vessels. Lab. Investig. 67, 596\u2013607 (1992).","journal-title":"Lab. Investig."},{"key":"2249_CR407","doi-asserted-by":"publisher","first-page":"6641","DOI":"10.1074\/jbc.RA119.011192","volume":"295","author":"J Yang","year":"2020","unstructured":"Yang, J. et al. ADAM10 and ADAM17 proteases mediate proinflammatory cytokine-induced and constitutive cleavage of endomucin from the endothelial surface. J. Biol. Chem. 295, 6641\u20136651 (2020).","journal-title":"J. Biol. Chem."},{"key":"2249_CR408","doi-asserted-by":"publisher","first-page":"9362","DOI":"10.1096\/fj.201900011R","volume":"33","author":"ME LeBlanc","year":"2019","unstructured":"LeBlanc, M. E. et al. Glycocalyx regulation of vascular endothelial growth factor receptor 2 activity. FASEB J. 33, 9362\u20139373 (2019).","journal-title":"FASEB J."},{"key":"2249_CR409","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/35091000","volume":"412","author":"J LeCouter","year":"2001","unstructured":"LeCouter, J. et al. Identification of an angiogenic mitogen selective for endocrine gland endothelium. Nature 412, 877\u2013884 (2001).","journal-title":"Nature"},{"key":"2249_CR410","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1210\/er.2012-1015","volume":"34","author":"IM Colin","year":"2013","unstructured":"Colin, I. M., Denef, J. F., Lengele, B., Many, M. C. & Gerard, A. C. Recent insights into the cell biology of thyroid angiofollicular units. Endocr. Rev. 34, 209\u2013238 (2013).","journal-title":"Endocr. Rev."},{"key":"2249_CR411","doi-asserted-by":"publisher","first-page":"H560","DOI":"10.1152\/ajpheart.00133.2005","volume":"290","author":"T Kamba","year":"2006","unstructured":"Kamba, T. et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am. J. Physiol. Heart Circ. Physiol. 290, H560\u2013H576 (2006).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"2249_CR412","doi-asserted-by":"publisher","first-page":"750","DOI":"10.15252\/emmm.201607341","volume":"9","author":"JY Jang","year":"2017","unstructured":"Jang, J. Y. et al. VEGFR2 but not VEGFR3 governs integrity and remodeling of thyroid angiofollicular unit in normal state and during goitrogenesis. EMBO Mol. Med. 9, 750\u2013769 (2017).","journal-title":"EMBO Mol. Med."},{"key":"2249_CR413","doi-asserted-by":"publisher","first-page":"12018","DOI":"10.1073\/pnas.1301331110","volume":"110","author":"Y Yang","year":"2013","unstructured":"Yang, Y. et al. Anti-VEGF- and anti-VEGF receptor-induced vascular alteration in mouse healthy tissues. Proc. Natl. Acad. Sci. USA 110, 12018\u201312023 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2249_CR414","doi-asserted-by":"publisher","first-page":"4158","DOI":"10.1073\/pnas.1601649113","volume":"113","author":"Y Zhang","year":"2016","unstructured":"Zhang, Y. et al. Endocrine vasculatures are preferable targets of an antitumor ineffective low dose of anti-VEGF therapy. Proc. Natl. Acad. Sci. USA 113, 4158\u20134163 (2016).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2249_CR415","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1089\/thy.2013.0147","volume":"23","author":"AA van der Veldt","year":"2013","unstructured":"van der Veldt, A. A., Lammertsma, A. A. & Smit, E. F. Reduction in thyroid perfusion after bevacizumab treatment. Thyroid 23, 1329\u20131330 (2013).","journal-title":"Thyroid"},{"key":"2249_CR416","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.cell.2007.06.054","volume":"130","author":"S Lee","year":"2007","unstructured":"Lee, S. et al. Autocrine VEGF signaling is required for vascular homeostasis. Cell 130, 691\u2013703 (2007).","journal-title":"Cell"},{"key":"2249_CR417","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel, R. L., Kratzer, T. B., Giaquinto, A. N., Sung, H. & Jemal, A. Cancer statistics, 2025. CA Cancer J. Clin. 75, 10\u201345 (2025).","journal-title":"CA Cancer J. Clin."},{"issue":"Suppl 3","key":"2249_CR418","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1159\/000088478","volume":"69","author":"P Carmeliet","year":"2005","unstructured":"Carmeliet, P. VEGF as a key mediator of angiogenesis in cancer. Oncology 69(Suppl 3), 4\u201310 (2005).","journal-title":"Oncology"},{"key":"2249_CR419","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1177\/1947601911423654","volume":"2","author":"BL Krock","year":"2011","unstructured":"Krock, B. L., Skuli, N. & Simon, M. C. Hypoxia-induced angiogenesis: good and evil. Genes Cancer 2, 1117\u20131133 (2011).","journal-title":"Genes Cancer"},{"key":"2249_CR420","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/BF00690598","volume":"14","author":"J Rak","year":"1995","unstructured":"Rak, J. et al. Oncogenes as inducers of tumor angiogenesis. Cancer Metastasis Rev. 14, 263\u2013277 (1995).","journal-title":"Cancer Metastasis Rev."},{"key":"2249_CR421","first-page":"4575","volume":"55","author":"J Rak","year":"1995","unstructured":"Rak, J. et al. Mutant ras oncogenes upregulate VEGF\/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res. 55, 4575\u20134580 (1995).","journal-title":"Cancer Res."},{"key":"2249_CR422","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.canlet.2008.10.049","volume":"276","author":"NV Khromova","year":"2009","unstructured":"Khromova, N. V., Kopnin, P. B., Stepanova, E. V., Agapova, L. S. & Kopnin, B. P. p53 hot-spot mutants increase tumor vascularization via ROS-mediated activation of the HIF1\/VEGF-A pathway. Cancer Lett. 276, 143\u2013151 (2009).","journal-title":"Cancer Lett."},{"key":"2249_CR423","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1146\/annurev.pathol.2.010506.134925","volume":"2","author":"JA Nagy","year":"2007","unstructured":"Nagy, J. A., Dvorak, A. M. & Dvorak, H. F. VEGF-A and the induction of pathological angiogenesis. Annu. Rev. Pathol. 2, 251\u2013275 (2007).","journal-title":"Annu. Rev. Pathol."},{"key":"2249_CR424","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-63762-w","volume":"14","author":"A Nayarisseri","year":"2024","unstructured":"Nayarisseri, A. et al. Potential inhibitors of VEGFR1, VEGFR2, and VEGFR3 developed through deep learning for the treatment of cervical cancer. Sci. Rep. 14, 13251 (2024).","journal-title":"Sci. Rep."},{"key":"2249_CR425","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.cell.2007.08.038","volume":"131","author":"C Fischer","year":"2007","unstructured":"Fischer, C. et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 131, 463\u2013475 (2007).","journal-title":"Cell"},{"key":"2249_CR426","doi-asserted-by":"publisher","first-page":"643","DOI":"10.2353\/ajpath.2006.051041","volume":"169","author":"M Marcellini","year":"2006","unstructured":"Marcellini, M. et al. Increased melanoma growth and metastasis spreading in mice overexpressing placenta growth factor. Am. J. Pathol. 169, 643\u2013654 (2006).","journal-title":"Am. J. Pathol."},{"key":"2249_CR427","doi-asserted-by":"publisher","first-page":"10840","DOI":"10.1158\/0008-5472.CAN-07-1034","volume":"67","author":"T Schomber","year":"2007","unstructured":"Schomber, T. et al. Placental growth factor-1 attenuates vascular endothelial growth factor-A-dependent tumor angiogenesis during beta cell carcinogenesis. Cancer Res. 67, 10840\u201310848 (2007).","journal-title":"Cancer Res."},{"key":"2249_CR428","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.cell.2010.01.033","volume":"141","author":"C Bais","year":"2010","unstructured":"Bais, C. et al. PlGF blockade does not inhibit angiogenesis during primary tumor growth. Cell 141, 166\u2013177 (2010).","journal-title":"Cell"},{"key":"2249_CR429","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1016\/S0002-9440(10)65392-8","volume":"154","author":"R Valtola","year":"1999","unstructured":"Valtola, R. et al. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am. J. Pathol. 154, 1381\u20131390 (1999).","journal-title":"Am. J. Pathol."},{"key":"2249_CR430","first-page":"1786","volume":"61","author":"T Karpanen","year":"2001","unstructured":"Karpanen, T. et al. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res. 61, 1786\u20131790 (2001).","journal-title":"Cancer Res."},{"key":"2249_CR431","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/84643","volume":"7","author":"M Skobe","year":"2001","unstructured":"Skobe, M. et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat. Med. 7, 192\u2013198 (2001).","journal-title":"Nat. Med."},{"key":"2249_CR432","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.cell.2010.01.045","volume":"140","author":"T Tammela","year":"2010","unstructured":"Tammela, T. & Alitalo, K. Lymphangiogenesis: molecular mechanisms and future promise. Cell 140, 460\u2013476 (2010).","journal-title":"Cell"},{"key":"2249_CR433","doi-asserted-by":"publisher","first-page":"4739","DOI":"10.1158\/0008-5472.CAN-04-4576","volume":"65","author":"Y He","year":"2005","unstructured":"He, Y. et al. Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res. 65, 4739\u20134746 (2005).","journal-title":"Cancer Res."},{"key":"2249_CR434","doi-asserted-by":"publisher","first-page":"13317","DOI":"10.3390\/ijms241713317","volume":"24","author":"SMZ Bokhari","year":"2023","unstructured":"Bokhari, S. M. Z. & Hamar, P. Vascular endothelial growth factor-D (VEGF-D): an angiogenesis bypass in malignant tumors. Int. J. Mol. Sci. 24, 13317 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"2249_CR435","doi-asserted-by":"publisher","first-page":"593","DOI":"10.3390\/cancers15030593","volume":"15","author":"Z Yang","year":"2023","unstructured":"Yang, Z. et al. Changes in serum growth factors during resistance to atezolizumab plus bevacizumab treatment in patients with unresectable hepatocellular carcinoma. Cancers 15, 593 (2023).","journal-title":"Cancers"},{"key":"2249_CR436","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1080\/07853890802516507","volume":"41","author":"PW Holm","year":"2009","unstructured":"Holm, P. W., Slart, R. H., Zeebregts, C. J., Hillebrands, J. L. & Tio, R. A. Atherosclerotic plaque development and instability: a dual role for VEGF. Ann. Med. 41, 257\u2013264 (2009).","journal-title":"Ann. Med."},{"key":"2249_CR437","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/j.1365-2362.2005.01555.x","volume":"35","author":"S Bhardwaj","year":"2005","unstructured":"Bhardwaj, S., Roy, H., Heikura, T. & Yla-Herttuala, S. VEGF-A, VEGF-D and VEGF-D(DeltaNDeltaC) induced intimal hyperplasia in carotid arteries. Eur. J. Clin. Invest. 35, 669\u2013676 (2005).","journal-title":"Eur. J. Clin. Invest."},{"key":"2249_CR438","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/86490","volume":"7","author":"FL Celletti","year":"2001","unstructured":"Celletti, F. L. et al. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat. Med. 7, 425\u2013429 (2001).","journal-title":"Nat. Med."},{"key":"2249_CR439","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1172\/JCI93025","volume":"128","author":"L Guo","year":"2018","unstructured":"Guo, L. et al. CD163+ macrophages promote angiogenesis and vascular permeability accompanied by inflammation in atherosclerosis. J. Clin. Invest. 128, 1106\u20131124 (2018).","journal-title":"J. Clin. Invest."},{"key":"2249_CR440","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1089\/hum.2005.16.1422","volume":"16","author":"H Roy","year":"2005","unstructured":"Roy, H. et al. Adenovirus-mediated gene transfer of placental growth factor to perivascular tissue induces angiogenesis via upregulation of the expression of endogenous vascular endothelial growth factor-A. Hum. Gene Ther. 16, 1422\u20131428 (2005).","journal-title":"Hum. Gene Ther."},{"key":"2249_CR441","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a011056","volume":"2","author":"M Dewerchin","year":"2012","unstructured":"Dewerchin, M. & Carmeliet, P. PlGF: a multitasking cytokine with disease-restricted activity. Cold Spring Harb. Perspect. Med. 2, a011056 (2012).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"2249_CR442","doi-asserted-by":"publisher","first-page":"2828","DOI":"10.1161\/CIRCULATIONAHA.104.495887","volume":"111","author":"R Khurana","year":"2005","unstructured":"Khurana, R. et al. Placental growth factor promotes atherosclerotic intimal thickening and macrophage accumulation. Circulation 111, 2828\u20132836 (2005).","journal-title":"Circulation"},{"key":"2249_CR443","doi-asserted-by":"publisher","first-page":"3336","DOI":"10.1182\/blood.V87.8.3336.bloodjournal8783336","volume":"87","author":"B Barleon","year":"1996","unstructured":"Barleon, B. et al. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 87, 3336\u20133343 (1996).","journal-title":"Blood"},{"key":"2249_CR444","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/35040568","volume":"408","author":"J Yamashita","year":"2000","unstructured":"Yamashita, J. et al. Flk1-positive cells derived from embryonic stem cells serve as vascular progenitors. Nature 408, 92\u201396 (2000).","journal-title":"Nature"},{"key":"2249_CR445","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1161\/CIRCRESAHA.109.210963","volume":"107","author":"J Zhang","year":"2010","unstructured":"Zhang, J. et al. VEGF blockade inhibits lymphocyte recruitment and ameliorates immune-mediated vascular remodeling. Circ. Res. 107, 408\u2013417 (2010).","journal-title":"Circ. Res."},{"key":"2249_CR446","doi-asserted-by":"publisher","first-page":"e010355","DOI":"10.1161\/JAHA.118.010355","volume":"7","author":"H Wada","year":"2018","unstructured":"Wada, H. et al. VEGF-C and mortality in patients with suspected or known coronary artery disease. J. Am. Heart Assoc. 7, e010355 (2018).","journal-title":"J. Am. Heart Assoc."},{"key":"2249_CR447","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1161\/CIRCRESAHA.120.317186","volume":"128","author":"C Silvestre-Roig","year":"2021","unstructured":"Silvestre-Roig, C. et al. Arterial delivery of VEGF-C stabilizes atherosclerotic lesions. Circ. Res. 128, 284\u2013286 (2021).","journal-title":"Circ. Res."},{"key":"2249_CR448","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0008-6363(03)00518-2","volume":"59","author":"J Rutanen","year":"2003","unstructured":"Rutanen, J. et al. Vascular endothelial growth factor-D expression in human atherosclerotic lesions. Cardiovasc. Res. 59, 971\u2013979 (2003).","journal-title":"Cardiovasc. Res."},{"key":"2249_CR449","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1038\/sj.gt.3302489","volume":"12","author":"J Rutanen","year":"2005","unstructured":"Rutanen, J. et al. Gene transfer using the mature form of VEGF-D reduces neointimal thickening through nitric oxide-dependent mechanism. Gene Ther. 12, 980\u2013987 (2005).","journal-title":"Gene Ther."},{"key":"2249_CR450","doi-asserted-by":"publisher","first-page":"e015761","DOI":"10.1161\/JAHA.119.015761","volume":"9","author":"H Wada","year":"2020","unstructured":"Wada, H. et al. Distinct characteristics of VEGF-D and VEGF-C to predict mortality in patients with suspected or known coronary artery disease. J. Am. Heart Assoc. 9, e015761 (2020).","journal-title":"J. Am. Heart Assoc."},{"key":"2249_CR451","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2170\/physiolsci.RP002305","volume":"56","author":"M Kuwabara","year":"2006","unstructured":"Kuwabara, M. et al. Nitric oxide stimulates vascular endothelial growth factor production in cardiomyocytes involved in angiogenesis. J. Physiol. Sci. 56, 95\u2013101 (2006).","journal-title":"J. Physiol. Sci."},{"key":"2249_CR452","doi-asserted-by":"publisher","first-page":"5294","DOI":"10.3390\/ijms21155294","volume":"21","author":"M Braile","year":"2020","unstructured":"Braile, M. et al. VEGF-A in cardiomyocytes and heart diseases. Int. J. Mol. Sci. 21, 5294 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"2249_CR453","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1002\/dvdy.149","volume":"249","author":"LX Cai","year":"2020","unstructured":"Cai, L. X., Alkassis, F. F. & Kasahara, H. Defective coronary vessel organization and reduction of VEGF-A in mouse embryonic hearts with gestational mild hypoxia. Dev. Dyn. 249, 636\u2013645 (2020).","journal-title":"Dev. Dyn."},{"key":"2249_CR454","doi-asserted-by":"publisher","first-page":"5780","DOI":"10.1073\/pnas.091415198","volume":"98","author":"FJ Giordano","year":"2001","unstructured":"Giordano, F. J. et al. A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function. Proc. Natl. Acad. Sci. USA 98, 5780\u20135785 (2001).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2249_CR455","doi-asserted-by":"publisher","first-page":"2990","DOI":"10.1016\/j.jacc.2019.03.503","volume":"73","author":"B Ferraro","year":"2019","unstructured":"Ferraro, B. et al. Pro-angiogenic macrophage phenotype to promote myocardial repair. J. Am. Coll. Cardiol. 73, 2990\u20133002 (2019).","journal-title":"J. Am. Coll. Cardiol."},{"key":"2249_CR456","doi-asserted-by":"publisher","first-page":"8555","DOI":"10.1096\/fj.201900060R","volume":"33","author":"Y Li","year":"2019","unstructured":"Li, Y. et al. Losartan protects against myocardial ischemia and reperfusion injury via vascular integrity preservation. FASEB J. 33, 8555\u20138564 (2019).","journal-title":"FASEB J."},{"key":"2249_CR457","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1161\/01.CIR.0000070540.80780.92","volume":"107","author":"M Hedman","year":"2003","unstructured":"Hedman, M. et al. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation 107, 2677\u20132683 (2003).","journal-title":"Circulation"},{"key":"2249_CR458","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1172\/JCI65112","volume":"123","author":"IM Jaba","year":"2013","unstructured":"Jaba, I. M. et al. NO triggers RGS4 degradation to coordinate angiogenesis and cardiomyocyte growth. J. Clin. Invest. 123, 1718\u20131731 (2013).","journal-title":"J. Clin. Invest."},{"key":"2249_CR459","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1161\/CIRCULATIONAHA.110.957332","volume":"122","author":"M Bry","year":"2010","unstructured":"Bry, M. et al. Vascular endothelial growth factor-B acts as a coronary growth factor in transgenic rats without inducing angiogenesis, vascular leak, or inflammation. Circulation 122, 1725\u20131733 (2010).","journal-title":"Circulation"},{"key":"2249_CR460","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/emmm.201303147","volume":"6","author":"R Kivel\u00e4","year":"2014","unstructured":"Kivel\u00e4, R. et al. VEGF-B-induced vascular growth leads to metabolic reprogramming and ischemia resistance in the heart. EMBO Mol. Med. 6, 307\u2013321 (2014).","journal-title":"EMBO Mol. Med."},{"key":"2249_CR461","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/nature14483","volume":"522","author":"L Klotz","year":"2015","unstructured":"Klotz, L. et al. Cardiac lymphatics are heterogeneous in origin and respond to injury. Nature 522, 62\u201367 (2015).","journal-title":"Nature"},{"key":"2249_CR462","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1161\/CIRCULATIONAHA.115.020143","volume":"133","author":"O Henri","year":"2016","unstructured":"Henri, O. et al. Selective stimulation of cardiac lymphangiogenesis reduces myocardial edema and fibrosis leading to improved cardiac function following myocardial infarction. Circulation 133, 1484\u20131497 (2016).","journal-title":"Circulation"},{"key":"2249_CR463","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s11010-015-2622-9","volume":"413","author":"XG Chen","year":"2016","unstructured":"Chen, X. G. et al. Vascular endothelial growth factor-C protects heart from ischemia\/reperfusion injury by inhibiting cardiomyocyte apoptosis. Mol. Cell. Biochem. 413, 9\u201323 (2016).","journal-title":"Mol. Cell. Biochem."},{"key":"2249_CR464","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1161\/01.CIR.0000115519.03688.A2","volume":"109","author":"J Rutanen","year":"2004","unstructured":"Rutanen, J. et al. Adenoviral catheter-mediated intramyocardial gene transfer using the mature form of vascular endothelial growth factor-D induces transmural angiogenesis in porcine heart. Circulation 109, 1029\u20131035 (2004).","journal-title":"Circulation"},{"key":"2249_CR465","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s11010-015-2646-1","volume":"413","author":"T Zhao","year":"2016","unstructured":"Zhao, T. et al. Vascular endothelial growth factor-D mediates fibrogenic response in myofibroblasts. Mol. Cell. Biochem. 413, 127\u2013135 (2016).","journal-title":"Mol. Cell. Biochem."},{"key":"2249_CR466","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1001\/jama.291.20.2441","volume":"291","author":"JF Piccirillo","year":"2004","unstructured":"Piccirillo, J. F., Tierney, R. M., Costas, I., Grove, L. & Spitznagel, E. L. Jr Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 291, 2441\u20132447 (2004).","journal-title":"JAMA"},{"key":"2249_CR467","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a006577","volume":"2","author":"KL Meadows","year":"2012","unstructured":"Meadows, K. L. & Hurwitz, H. I. Anti-VEGF therapies in the clinic. Cold Spring Harb. Perspect. Med. 2, a006577 (2012).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"2249_CR468","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1161\/HYPERTENSIONAHA.109.129973","volume":"54","author":"CS Facemire","year":"2009","unstructured":"Facemire, C. S., Nixon, A. B., Griffiths, R., Hurwitz, H. & Coffman, T. M. Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression. Hypertension 54, 652\u2013658 (2009).","journal-title":"Hypertension"},{"key":"2249_CR469","first-page":"H1054","volume":"274","author":"JD Hood","year":"1998","unstructured":"Hood, J. D., Meininger, C. J., Ziche, M. & Granger, H. J. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am. J. Physiol. 274, H1054\u2013H1058 (1998).","journal-title":"Am. J. Physiol."},{"key":"2249_CR470","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1161\/HYPERTENSIONAHA.110.160481","volume":"56","author":"ES Robinson","year":"2010","unstructured":"Robinson, E. S. et al. Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors. Hypertension 56, 1131\u20131136 (2010).","journal-title":"Hypertension"},{"key":"2249_CR471","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1161\/HYPERTENSIONAHA.110.168120","volume":"58","author":"EL Mayer","year":"2011","unstructured":"Mayer, E. L. et al. Contrary effects of the receptor tyrosine kinase inhibitor vandetanib on constitutive and flow-stimulated nitric oxide elaboration in humans. Hypertension 58, 85\u201392 (2011).","journal-title":"Hypertension"},{"key":"2249_CR472","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1161\/HYPERTENSIONAHA.111.173559","volume":"58","author":"MH Kappers","year":"2011","unstructured":"Kappers, M. H. et al. The vascular endothelial growth factor receptor inhibitor sunitinib causes a preeclampsia-like syndrome with activation of the endothelin system. Hypertension 58, 295\u2013302 (2011).","journal-title":"Hypertension"},{"key":"2249_CR473","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1161\/HYPERTENSIONAHA.109.149690","volume":"56","author":"MH Kappers","year":"2010","unstructured":"Kappers, M. H. et al. Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels. Hypertension 56, 675\u2013681 (2010).","journal-title":"Hypertension"},{"key":"2249_CR474","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1038\/ajh.2012.97","volume":"25","author":"N de Jesus-Gonzalez","year":"2012","unstructured":"de Jesus-Gonzalez, N. et al. Regorafenib induces rapid and reversible changes in plasma nitric oxide and endothelin-1. Am. J. Hypertens. 25, 1118\u20131123 (2012).","journal-title":"Am. J. Hypertens."},{"key":"2249_CR475","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1200\/JCO.2005.02.0503","volume":"24","author":"ML Veronese","year":"2006","unstructured":"Veronese, M. L. et al. Mechanisms of hypertension associated with BAY 43-9006. J. Clin. Oncol. 24, 1363\u20131369 (2006).","journal-title":"J. Clin. Oncol."},{"key":"2249_CR476","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1161\/hc3101.091158","volume":"104","author":"BI Levy","year":"2001","unstructured":"Levy, B. I., Ambrosio, G., Pries, A. R. & Struijker-Boudier, H. A. Microcirculation in hypertension: a new target for treatment?. Circulation 104, 735\u2013740 (2001).","journal-title":"Circulation"},{"key":"2249_CR477","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/nm.1960","volume":"15","author":"A Machnik","year":"2009","unstructured":"Machnik, A. et al. Macrophages regulate salt-dependent volume and blood pressure by a vascular endothelial growth factor-C-dependent buffering mechanism. Nat. Med. 15, 545\u2013552 (2009).","journal-title":"Nat. Med."},{"key":"2249_CR478","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1172\/JCI60113","volume":"123","author":"H Wiig","year":"2013","unstructured":"Wiig, H. et al. Immune cells control skin lymphatic electrolyte homeostasis and blood pressure. J. Clin. Invest. 123, 2803\u20132815 (2013).","journal-title":"J. Clin. Invest."},{"key":"2249_CR479","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1161\/HYPERTENSIONAHA.116.08565","volume":"69","author":"S Lankhorst","year":"2017","unstructured":"Lankhorst, S. et al. Salt sensitivity of angiogenesis inhibition-induced blood pressure rise: role of interstitial sodium accumulation?. Hypertension 69, 919\u2013926 (2017).","journal-title":"Hypertension"},{"key":"2249_CR480","doi-asserted-by":"publisher","first-page":"16012","DOI":"10.1038\/nrdp.2016.12","volume":"2","author":"TY Wong","year":"2016","unstructured":"Wong, T. Y., Cheung, C. M., Larsen, M., Sharma, S. & Simo, R. Diabetic retinopathy. Nat. Rev. Dis. Prim. 2, 16012 (2016).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"2249_CR481","doi-asserted-by":"publisher","first-page":"e240124225997","DOI":"10.2174\/0115733998274599231109034741","volume":"20","author":"A Kaur","year":"2024","unstructured":"Kaur, A., Kumar, R. & Sharma, A. Diabetic retinopathy leading to blindness\u2014a review. Curr. Diab. Rev. 20, e240124225997 (2024).","journal-title":"Curr. Diab. Rev."},{"key":"2249_CR482","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1056\/NEJMoa2204225","volume":"387","author":"CD Jhaveri","year":"2022","unstructured":"Jhaveri, C. D. et al. Aflibercept monotherapy or bevacizumab first for diabetic macular edema. New Engl. J. Med. 387, 692\u2013703 (2022).","journal-title":"New Engl. J. Med."},{"key":"2249_CR483","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-68488-z","volume":"10","author":"N Froger","year":"2020","unstructured":"Froger, N. et al. VEGF is an autocrine\/paracrine neuroprotective factor for injured retinal ganglion neurons. Sci. Rep. 10, 12409 (2020).","journal-title":"Sci. Rep."},{"key":"2249_CR484","doi-asserted-by":"publisher","first-page":"4738","DOI":"10.1523\/JNEUROSCI.15-07-04738.1995","volume":"15","author":"J Stone","year":"1995","unstructured":"Stone, J. et al. Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J. Neurosci. 15, 4738\u20134747 (1995).","journal-title":"J. Neurosci."},{"key":"2249_CR485","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.ydbio.2003.08.015","volume":"264","author":"DC Darland","year":"2003","unstructured":"Darland, D. C. et al. Pericyte production of cell-associated VEGF is differentiation-dependent and is associated with endothelial survival. Dev. Biol. 264, 275\u2013288 (2003).","journal-title":"Dev. Biol."},{"key":"2249_CR486","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-018-0886-z","volume":"18","author":"X Ding","year":"2018","unstructured":"Ding, X. et al. Microglia enhanced the angiogenesis, migration and proliferation of co-cultured RMECs. BMC Ophthalmol. 18, 249 (2018).","journal-title":"BMC Ophthalmol."},{"key":"2249_CR487","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1002\/path.2611","volume":"219","author":"Y Bai","year":"2009","unstructured":"Bai, Y. et al. Muller cell-derived VEGF is a significant contributor to retinal neovascularization. J. Pathol. 219, 446\u2013454 (2009).","journal-title":"J. Pathol."},{"key":"2249_CR488","doi-asserted-by":"publisher","first-page":"3135","DOI":"10.1167\/iovs.05-1229","volume":"47","author":"M Saint-Geniez","year":"2006","unstructured":"Saint-Geniez, M., Maldonado, A. E. & D\u2019Amore, P. A. VEGF expression and receptor activation in the choroid during development and in the adult. Invest. Ophthalmol. Vis. Sci. 47, 3135\u20133142 (2006).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"2249_CR489","first-page":"2115","volume":"40","author":"I Kim","year":"1999","unstructured":"Kim, I. et al. Constitutive expression of VEGF, VEGFR-1, and VEGFR-2 in normal eyes. Invest. Ophthalmol. Vis. Sci. 40, 2115\u20132121 (1999).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"2249_CR490","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s00018-019-03422-9","volume":"77","author":"P Mammadzada","year":"2020","unstructured":"Mammadzada, P., Corredoira, P. M. & Andre, H. The role of hypoxia-inducible factors in neovascular age-related macular degeneration: a gene therapy perspective. Cell Mol. Life Sci. 77, 819\u2013833 (2020).","journal-title":"Cell Mol. Life Sci."},{"key":"2249_CR491","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10347","volume":"7","author":"Y Kim","year":"2016","unstructured":"Kim, Y. et al. Methylation-dependent regulation of HIF-1alpha stability restricts retinal and tumour angiogenesis. Nat. Commun. 7, 10347 (2016).","journal-title":"Nat. Commun."},{"key":"2249_CR492","first-page":"2408","volume":"42","author":"T Qaum","year":"2001","unstructured":"Qaum, T. et al. VEGF-initiated blood-retinal barrier breakdown in early diabetes. Invest. Ophthalmol. Vis. Sci. 42, 2408\u20132413 (2001).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"2249_CR493","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1056\/NEJM199412013312203","volume":"331","author":"LP Aiello","year":"1994","unstructured":"Aiello, L. P. et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. New Engl. J. Med. 331, 1480\u20131487 (1994).","journal-title":"New Engl. J. Med."},{"key":"2249_CR494","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-019-0179-6","volume":"5","author":"S Ahuja","year":"2019","unstructured":"Ahuja, S. et al. Serum vascular endothelial growth factor is a biomolecular biomarker of severity of diabetic retinopathy. Int. J. Retin. Vitreous 5, 29 (2019).","journal-title":"Int. J. Retin. Vitreous"},{"key":"2249_CR495","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S0002-9394(14)75794-0","volume":"118","author":"AP Adamis","year":"1994","unstructured":"Adamis, A. P. et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am. J. Ophthalmol. 118, 445\u2013450 (1994).","journal-title":"Am. J. Ophthalmol."},{"key":"2249_CR496","doi-asserted-by":"publisher","first-page":"10242","DOI":"10.1073\/pnas.97.18.10242","volume":"97","author":"KL Jin","year":"2000","unstructured":"Jin, K. L., Mao, X. O. & Greenberg, D. A. Vascular endothelial growth factor: direct neuroprotective effect in in vitro ischemia. Proc. Natl. Acad. Sci. USA 97, 10242\u201310247 (2000).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2249_CR497","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-81482-3","volume":"11","author":"T Kida","year":"2021","unstructured":"Kida, T., Oku, H., Osuka, S., Horie, T. & Ikeda, T. Hyperglycemia-induced VEGF and ROS production in retinal cells is inhibited by the mTOR inhibitor, rapamycin. Sci. Rep. 11, 1885 (2021).","journal-title":"Sci. Rep."},{"key":"2249_CR498","doi-asserted-by":"publisher","first-page":"ra1","DOI":"10.1126\/scisignal.2004235","volume":"7","author":"CM Warren","year":"2014","unstructured":"Warren, C. M., Ziyad, S., Briot, A., Der, A. & Iruela-Arispe, M. L. A ligand-independent VEGFR2 signaling pathway limits angiogenic responses in diabetes. Sci. Signal. 7, ra1 (2014).","journal-title":"Sci. Signal."},{"key":"2249_CR499","doi-asserted-by":"publisher","first-page":"3942","DOI":"10.1096\/fj.14-251934","volume":"28","author":"D Sun","year":"2014","unstructured":"Sun, D. et al. Molecular imaging reveals elevated VEGFR-2 expression in retinal capillaries in diabetes: a novel biomarker for early diagnosis. FASEB J. 28, 3942\u20133951 (2014).","journal-title":"FASEB J."},{"key":"2249_CR500","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1136\/bjo.2006.101543","volume":"91","author":"B Zhao","year":"2007","unstructured":"Zhao, B., Smith, G., Cai, J., Ma, A. & Boulton, M. Vascular endothelial growth factor C promotes survival of retinal vascular endothelial cells via vascular endothelial growth factor receptor-2. Br. J. Ophthalmol. 91, 538\u2013545 (2007).","journal-title":"Br. J. Ophthalmol."},{"key":"2249_CR501","doi-asserted-by":"publisher","first-page":"5106","DOI":"10.1167\/iovs.06-0322","volume":"47","author":"NS Harhaj","year":"2006","unstructured":"Harhaj, N. S. et al. VEGF activation of protein kinase C stimulates occludin phosphorylation and contributes to endothelial permeability. Invest. Ophthalmol. Vis. Sci. 47, 5106\u20135115 (2006).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"2249_CR502","doi-asserted-by":"publisher","first-page":"21036","DOI":"10.1074\/jbc.M109.016766","volume":"284","author":"T Murakami","year":"2009","unstructured":"Murakami, T., Felinski, E. A. & Antonetti, D. A. Occludin phosphorylation and ubiquitination regulate tight junction trafficking and vascular endothelial growth factor-induced permeability. J. Biol. Chem. 284, 21036\u201321046 (2009).","journal-title":"J. Biol. Chem."},{"key":"2249_CR503","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1016\/j.bcp.2013.09.008","volume":"86","author":"G Lupo","year":"2013","unstructured":"Lupo, G. et al. Role of phospholipases A2 in diabetic retinopathy: in vitro and in vivo studies. Biochem. Pharmacol. 86, 1603\u20131613 (2013).","journal-title":"Biochem. Pharmacol."},{"key":"2249_CR504","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.2337\/db11-1367","volume":"61","author":"T Murakami","year":"2012","unstructured":"Murakami, T., Frey, T., Lin, C. & Antonetti, D. A. Protein kinase cbeta phosphorylates occludin regulating tight junction trafficking in vascular endothelial growth factor-induced permeability in vivo. Diabetes 61, 1573\u20131583 (2012).","journal-title":"Diabetes"},{"key":"2249_CR505","doi-asserted-by":"publisher","first-page":"107886","DOI":"10.1016\/j.exer.2019.107886","volume":"190","author":"JM Lu","year":"2020","unstructured":"Lu, J. M., Zhang, Z. Z., Ma, X., Fang, S. F. & Qin, X. H. Repression of microRNA-21 inhibits retinal vascular endothelial cell growth and angiogenesis via PTEN dependent-PI3K\/Akt\/VEGF signaling pathway in diabetic retinopathy. Exp. Eye Res. 190, 107886 (2020).","journal-title":"Exp. Eye Res."},{"key":"2249_CR506","doi-asserted-by":"publisher","first-page":"5552","DOI":"10.1167\/iovs.09-3694","volume":"50","author":"S Abhary","year":"2009","unstructured":"Abhary, S. et al. Common sequence variation in the VEGFA gene predicts risk of diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 50, 5552\u20135558 (2009).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"2249_CR507","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1007\/s10792-017-0738-5","volume":"38","author":"M Tetikoglu","year":"2018","unstructured":"Tetikoglu, M., Yuksel, Z., Aktas, S., Sagdik, H. M. & Ozcura, F. VEGF-A gene polymorphisms and responses to intravitreal ranibizumab treatment in patients with diabetic macular edema. Int. Ophthalmol. 38, 2381\u20132388 (2018).","journal-title":"Int. Ophthalmol."},{"key":"2249_CR508","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1167\/iovs.61.2.26","volume":"61","author":"F Wu","year":"2020","unstructured":"Wu, F. et al. Correlation of aqueous, vitreous, and plasma cytokine levels in patients with proliferative diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 61, 26 (2020).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"2249_CR509","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1080\/08977194.2018.1477140","volume":"36","author":"J Mesquita","year":"2018","unstructured":"Mesquita, J. et al. Evaluation of the growth factors VEGF-a and VEGF-B in the vitreous and serum of patients with macular and retinal vascular diseases. Growth Factors 36, 48\u201357 (2018).","journal-title":"Growth Factors"},{"key":"2249_CR510","doi-asserted-by":"publisher","DOI":"10.1038\/srep26059","volume":"6","author":"D Huang","year":"2016","unstructured":"Huang, D. et al. VEGF-B inhibits hyperglycemia- and Macugen-induced retinal apoptosis. Sci. Rep. 6, 26059 (2016).","journal-title":"Sci. Rep."},{"key":"2249_CR511","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202300987RR","volume":"38","author":"Y Xu","year":"2024","unstructured":"Xu, Y. et al. VEGF-B prevents chronic hyperglycemia-induced retinal vascular leakage by regulating the CDC42-ZO1\/VE-cadherin pathway. FASEB J. 38, e70019 (2024).","journal-title":"FASEB J."},{"key":"2249_CR512","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.2337\/diacare.25.12.2352","volume":"25","author":"Y Mitamura","year":"2002","unstructured":"Mitamura, Y. et al. Vitreous levels of placenta growth factor and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. Diab. Care 25, 2352 (2002).","journal-title":"Diab. Care"},{"key":"2249_CR513","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1111\/aos.13325","volume":"96","author":"QD Nguyen","year":"2018","unstructured":"Nguyen, Q. D. et al. Placental growth factor and its potential role in diabetic retinopathy and other ocular neovascular diseases. Acta Ophthalmol. 96, e1\u2013e9 (2018).","journal-title":"Acta Ophthalmol."},{"key":"2249_CR514","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.preteyeres.2018.10.006","volume":"69","author":"T Van Bergen","year":"2019","unstructured":"Van Bergen, T. et al. The role of placental growth factor (PlGF) and its receptor system in retinal vascular diseases. Prog. Retin. Eye Res. 69, 116\u2013136 (2019).","journal-title":"Prog. Retin. Eye Res."},{"key":"2249_CR515","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s00125-006-0539-2","volume":"50","author":"N Miyamoto","year":"2007","unstructured":"Miyamoto, N. et al. Placental growth factor-1 and epithelial haemato-retinal barrier breakdown: potential implication in the pathogenesis of diabetic retinopathy. Diabetologia 50, 461\u2013470 (2007).","journal-title":"Diabetologia"},{"key":"2249_CR516","doi-asserted-by":"publisher","first-page":"200","DOI":"10.2337\/db14-0016","volume":"64","author":"H Huang","year":"2015","unstructured":"Huang, H. et al. Deletion of placental growth factor prevents diabetic retinopathy and is associated with Akt activation and HIF1alpha-VEGF pathway inhibition. Diabetes 64, 200\u2013212 (2015).","journal-title":"Diabetes"},{"key":"2249_CR517","doi-asserted-by":"publisher","first-page":"e17462","DOI":"10.1371\/journal.pone.0017462","volume":"6","author":"L Kowalczuk","year":"2011","unstructured":"Kowalczuk, L. et al. Placental growth factor contributes to micro-vascular abnormalization and blood-retinal barrier breakdown in diabetic retinopathy. PLoS ONE 6, e17462 (2011).","journal-title":"PLoS ONE"},{"key":"2249_CR518","doi-asserted-by":"publisher","first-page":"779413","DOI":"10.3389\/fmed.2021.779413","volume":"8","author":"X Zhang","year":"2021","unstructured":"Zhang, X. et al. Dysregulated serum lipid metabolism promotes the occurrence and development of diabetic retinopathy associated with upregulated circulating levels of VEGF-A, VEGF-D, and PlGF. Front. Med. 8, 779413 (2021).","journal-title":"Front. Med."},{"key":"2249_CR519","first-page":"849","volume":"43","author":"AN Witmer","year":"2002","unstructured":"Witmer, A. N. et al. Altered expression patterns of VEGF receptors in human diabetic retina and in experimental VEGF-induced retinopathy in monkey. Invest. Ophthalmol. Vis. Sci. 43, 849\u2013857 (2002).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"2249_CR520","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41572-021-00265-2","volume":"7","author":"M Fleckenstein","year":"2021","unstructured":"Fleckenstein, M. et al. Age-related macular degeneration. Nat. Rev. Dis. Prim. 7, 31 (2021).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"2249_CR521","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1056\/NEJMcibr0804551","volume":"359","author":"LP Aiello","year":"2008","unstructured":"Aiello, L. P. Targeting intraocular neovascularization and edema\u2013one drop at a time. New Engl. J. Med. 359, 967\u2013969 (2008).","journal-title":"New Engl. J. Med."},{"key":"2249_CR522","doi-asserted-by":"publisher","first-page":"6152","DOI":"10.1073\/pnas.0813061106","volume":"106","author":"F Zhang","year":"2009","unstructured":"Zhang, F. et al. VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis. Proc. Natl. Acad. Sci. USA 106, 6152\u20136157 (2009).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2249_CR523","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s40123-022-00618-4","volume":"12","author":"H Zhou","year":"2023","unstructured":"Zhou, H., Zhao, X., Wang, S. & Chen, Y. Determination of vascular endothelial growth factor-B concentrations in aqueous humor and plasma of neovascular age-related macular degeneration and polypoidal choroidal vasculopathy patients before and after anti-VEGF therapy. Ophthalmol. Ther. 12, 827\u2013837 (2023).","journal-title":"Ophthalmol. Ther."},{"key":"2249_CR524","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.exer.2006.05.007","volume":"83","author":"Y Ikeda","year":"2006","unstructured":"Ikeda, Y. et al. The regulation of vascular endothelial growth factors (VEGF-A, -C, and -D) expression in the retinal pigment epithelium. Exp. Eye Res. 83, 1031\u20131040 (2006).","journal-title":"Exp. Eye Res."},{"key":"2249_CR525","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1007\/s40123-024-00973-4","volume":"13","author":"IM Leitch","year":"2024","unstructured":"Leitch, I. M. et al. Vascular endothelial growth factor C and D signaling pathways as potential targets for the treatment of neovascular age-related macular degeneration: a narrative review. Ophthalmol. Ther. 13, 1857\u20131875 (2024).","journal-title":"Ophthalmol. Ther."},{"key":"2249_CR526","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.oret.2017.04.004","volume":"2","author":"T Cabral","year":"2018","unstructured":"Cabral, T. et al. Bevacizumab injection in patients with neovascular age-related macular degeneration increases angiogenic biomarkers. Ophthalmol. Retin. 2, 31\u201337 (2018).","journal-title":"Ophthalmol. Retin."},{"key":"2249_CR527","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/jcp.22708","volume":"227","author":"CN Nagineni","year":"2012","unstructured":"Nagineni, C. N., Kommineni, V. K., William, A., Detrick, B. & Hooks, J. J. Regulation of VEGF expression in human retinal cells by cytokines: implications for the role of inflammation in age-related macular degeneration. J. Cell. Physiol. 227, 116\u2013126 (2012).","journal-title":"J. Cell. Physiol."},{"key":"2249_CR528","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-019-1278-8","volume":"20","author":"H Zhou","year":"2020","unstructured":"Zhou, H., Zhao, X., Yuan, M. & Chen, Y. Comparison of cytokine levels in the aqueous humor of polypoidal choroidal vasculopathy and neovascular age-related macular degeneration patients. BMC Ophthalmol. 20, 15 (2020).","journal-title":"BMC Ophthalmol."},{"key":"2249_CR529","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.ophtha.2023.02.001","volume":"130","author":"TL Jackson","year":"2023","unstructured":"Jackson, T. L. et al. A randomized controlled trial of OPT-302, a VEGF-C\/D inhibitor for neovascular age-related macular degeneration. Ophthalmology 130, 588\u2013597 (2023).","journal-title":"Ophthalmology"},{"key":"2249_CR530","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1182\/blood.V97.3.785","volume":"97","author":"A Sawano","year":"2001","unstructured":"Sawano, A. et al. Flt-1, vascular endothelial growth factor receptor 1, is a novel cell surface marker for the lineage of monocyte-macrophages in humans. Blood 97, 785\u2013791 (2001).","journal-title":"Blood"},{"key":"2249_CR531","doi-asserted-by":"publisher","first-page":"4997","DOI":"10.1167\/iovs.16-21283","volume":"58","author":"S Crespo-Garcia","year":"2017","unstructured":"Crespo-Garcia, S. et al. Inhibition of placenta growth factor reduces subretinal mononuclear phagocyte accumulation in choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 58, 4997\u20135006 (2017).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"2249_CR532","doi-asserted-by":"publisher","first-page":"e71808","DOI":"10.1371\/journal.pone.0071808","volume":"8","author":"H Huang","year":"2013","unstructured":"Huang, H., Parlier, R., Shen, J. K., Lutty, G. A. & Vinores, S. A. VEGF receptor blockade markedly reduces retinal microglia\/macrophage infiltration into laser-induced CNV. PLoS ONE 8, e71808 (2013).","journal-title":"PLoS ONE"},{"key":"2249_CR533","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.celrep.2013.08.002","volume":"4","author":"AG Marneros","year":"2013","unstructured":"Marneros, A. G. NLRP3 inflammasome blockade inhibits VEGF-A-induced age-related macular degeneration. Cell Rep. 4, 945\u2013958 (2013).","journal-title":"Cell Rep."},{"key":"2249_CR534","doi-asserted-by":"publisher","first-page":"18751","DOI":"10.1073\/pnas.0905010106","volume":"106","author":"M Saint-Geniez","year":"2009","unstructured":"Saint-Geniez, M., Kurihara, T., Sekiyama, E., Maldonado, A. E. & D\u2019Amore, P. A. An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris. Proc. Natl. Acad. Sci. USA 106, 18751\u201318756 (2009).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2249_CR535","doi-asserted-by":"publisher","first-page":"4213","DOI":"10.1172\/JCI65157","volume":"122","author":"T Kurihara","year":"2012","unstructured":"Kurihara, T., Westenskow, P. D., Bravo, S., Aguilar, E. & Friedlander, M. Targeted deletion of Vegfa in adult mice induces vision loss. J. Clin. Invest. 122, 4213\u20134217 (2012).","journal-title":"J. Clin. Invest."},{"key":"2249_CR536","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1161\/ATVBAHA.114.303090","volume":"34","author":"KY Howangyin","year":"2014","unstructured":"Howangyin, K. Y. & Silvestre, J. S. Diabetes mellitus and ischemic diseases: molecular mechanisms of vascular repair dysfunction. Arterioscler. Thromb. Vasc. Biol. 34, 1126\u20131135 (2014).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2249_CR537","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.2337\/db06-0690","volume":"55","author":"M Brissova","year":"2006","unstructured":"Brissova, M. et al. Pancreatic islet production of vascular endothelial growth factor-A is essential for islet vascularization, revascularization, and function. Diabetes 55, 2974\u20132985 (2006).","journal-title":"Diabetes"},{"key":"2249_CR538","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1507\/endocrj.K09E-035","volume":"57","author":"H Watada","year":"2010","unstructured":"Watada, H. Role of VEGF-A in pancreatic beta cells. Endocr. J. 57, 185\u2013191 (2010).","journal-title":"Endocr. J."},{"key":"2249_CR539","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1007\/s00125-006-0512-0","volume":"50","author":"N Iwashita","year":"2007","unstructured":"Iwashita, N. et al. Impaired insulin secretion in vivo but enhanced insulin secretion from isolated islets in pancreatic beta cell-specific vascular endothelial growth factor-A knock-out mice. Diabetologia 50, 380\u2013389 (2007).","journal-title":"Diabetologia"},{"key":"2249_CR540","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1111\/j.1748-1716.2006.01666.x","volume":"189","author":"L Jansson","year":"2007","unstructured":"Jansson, L., Andersson, A., Bodin, B. & Kallskog, O. Pancreatic islet blood flow during euglycaemic, hyperinsulinaemic clamp in anaesthetized rats. Acta Physiol. 189, 319\u2013324 (2007).","journal-title":"Acta Physiol."},{"key":"2249_CR541","doi-asserted-by":"publisher","first-page":"8636","DOI":"10.1074\/jbc.M112.422949","volume":"288","author":"X Xiao","year":"2013","unstructured":"Xiao, X. et al. Hypoglycemia reduces vascular endothelial growth factor A production by pancreatic beta cells as a regulator of beta cell mass. J. Biol. Chem. 288, 8636\u20138646 (2013).","journal-title":"J. Biol. Chem."},{"key":"2249_CR542","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.2337\/db12-0134","volume":"61","author":"J Agudo","year":"2012","unstructured":"Agudo, J. et al. Vascular endothelial growth factor-mediated islet hypervascularization and inflammation contribute to progressive reduction of beta-cell mass. Diabetes 61, 2851\u20132861 (2012).","journal-title":"Diabetes"},{"key":"2249_CR543","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.ijcard.2014.04.117","volume":"174","author":"IV Kizub","year":"2014","unstructured":"Kizub, I. V., Klymenko, K. I. & Soloviev, A. I. Protein kinase C in enhanced vascular tone in diabetes mellitus. Int. J. Cardiol. 174, 230\u2013242 (2014).","journal-title":"Int. J. Cardiol."},{"key":"2249_CR544","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1161\/01.CIR.102.2.185","volume":"102","author":"J Waltenberger","year":"2000","unstructured":"Waltenberger, J., Lange, J. & Kranz, A. Vascular endothelial growth factor-A-induced chemotaxis of monocytes is attenuated in patients with diabetes mellitus: a potential predictor for the individual capacity to develop collaterals. Circulation 102, 185\u2013190 (2000).","journal-title":"Circulation"},{"key":"2249_CR545","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.cmet.2014.02.001","volume":"19","author":"M Brissova","year":"2014","unstructured":"Brissova, M. et al. Islet microenvironment, modulated by vascular endothelial growth factor-A signaling, promotes beta cell regeneration. Cell Metab. 19, 498\u2013511 (2014).","journal-title":"Cell Metab."},{"key":"2249_CR546","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1007\/s00125-013-3076-9","volume":"57","author":"N De Leu","year":"2014","unstructured":"De Leu, N. et al. Short-term overexpression of VEGF-A in mouse beta cells indirectly stimulates their proliferation and protects against diabetes. Diabetologia 57, 140\u2013147 (2014).","journal-title":"Diabetologia"},{"key":"2249_CR547","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1007\/s00125-019-4969-z","volume":"62","author":"W Staels","year":"2019","unstructured":"Staels, W., Heremans, Y., Heimberg, H. & De Leu, N. VEGF-A and blood vessels: a beta cell perspective. Diabetologia 62, 1961\u20131968 (2019).","journal-title":"Diabetologia"},{"key":"2249_CR548","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/nature11464","volume":"490","author":"CE Hagberg","year":"2012","unstructured":"Hagberg, C. E. et al. Targeting VEGF-B as a novel treatment for insulin resistance and type 2 diabetes. Nature 490, 426\u2013430 (2012).","journal-title":"Nature"},{"key":"2249_CR549","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3390\/cells12030472","volume":"12","author":"LM Brunner","year":"2023","unstructured":"Brunner, L. M. et al. Promotion of lymphangiogenesis by targeted delivery of VEGF-C improves diabetic wound healing. Cells 12, 472 (2023).","journal-title":"Cells"},{"key":"2249_CR550","doi-asserted-by":"publisher","first-page":"365","DOI":"10.4062\/biomolther.2020.204","volume":"29","author":"V Natesan","year":"2021","unstructured":"Natesan, V. & Kim, S. J. Diabetic nephropathy\u2014a review of risk factors, progression, mechanism, and dietary management. Biomol. Ther. 29, 365\u2013372 (2021).","journal-title":"Biomol. Ther."},{"key":"2249_CR551","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41392-023-01400-z","volume":"8","author":"Y Li","year":"2023","unstructured":"Li, Y. et al. Diabetic vascular diseases: molecular mechanisms and therapeutic strategies. Signal Transduct. Target. Ther. 8, 152 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2249_CR552","first-page":"F240","volume":"268","author":"M Simon","year":"1995","unstructured":"Simon, M. et al. Expression of vascular endothelial growth factor and its receptors in human renal ontogenesis and in adult kidney. Am. J. Physiol. 268, F240\u2013F250 (1995).","journal-title":"Am. J. Physiol."},{"key":"2249_CR553","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1038\/ki.1992.441","volume":"42","author":"LF Brown","year":"1992","unstructured":"Brown, L. F. et al. Vascular permeability factor mRNA and protein expression in human kidney. Kidney Int. 42, 1457\u20131461 (1992).","journal-title":"Kidney Int."},{"key":"2249_CR554","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1242\/dev.114.2.521","volume":"114","author":"G Breier","year":"1992","unstructured":"Breier, G., Albrecht, U., Sterrer, S. & Risau, W. Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation. Development 114, 521\u2013532 (1992).","journal-title":"Development"},{"key":"2249_CR555","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1681\/ASN.V1171236","volume":"11","author":"S Thomas","year":"2000","unstructured":"Thomas, S. et al. Vascular endothelial growth factor receptors in human mesangium in vitro and in glomerular disease. J. Am. Soc. Nephrol. 11, 1236\u20131243 (2000).","journal-title":"J. Am. Soc. Nephrol."},{"key":"2249_CR556","doi-asserted-by":"publisher","first-page":"F905","DOI":"10.1152\/ajprenal.2000.278.6.F905","volume":"278","author":"J Kanellis","year":"2000","unstructured":"Kanellis, J., Fraser, S., Katerelos, M. & Power, D. A. Vascular endothelial growth factor is a survival factor for renal tubular epithelial cells. Am. J. Physiol. Ren. Physiol. 278, F905\u2013F915 (2000).","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"2249_CR557","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/j.1523-1755.2005.00067.x","volume":"67","author":"NH Kim","year":"2005","unstructured":"Kim, N. H. et al. Vascular endothelial growth factor (VEGF) and soluble VEGF receptor FLT-1 in diabetic nephropathy. Kidney Int. 67, 167\u2013177 (2005).","journal-title":"Kidney Int."},{"key":"2249_CR558","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1053\/j.ajkd.2004.09.020","volume":"45","author":"Y Kanesaki","year":"2005","unstructured":"Kanesaki, Y. et al. Vascular endothelial growth factor gene expression is correlated with glomerular neovascularization in human diabetic nephropathy. Am. J. Kidney Dis. 45, 288\u2013294 (2005).","journal-title":"Am. J. Kidney Dis."},{"key":"2249_CR559","first-page":"11470","volume":"8","author":"H Huang","year":"2015","unstructured":"Huang, H. et al. Effect of fosinopril on chemerin and VEGF expression in diabetic nephropathy rats. Int. J. Clin. Exp. Pathol. 8, 11470\u201311474 (2015).","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"2249_CR560","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1677\/joe.1.05647","volume":"183","author":"DR Cha","year":"2004","unstructured":"Cha, D. R. et al. Vascular endothelial growth factor is increased during early stage of diabetic nephropathy in type II diabetic rats. J. Endocrinol. 183, 183\u2013194 (2004).","journal-title":"J. Endocrinol."},{"key":"2249_CR561","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1681\/ASN.2006050459","volume":"18","author":"T Nakagawa","year":"2007","unstructured":"Nakagawa, T. et al. Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy. J. Am. Soc. Nephrol. 18, 539\u2013550 (2007).","journal-title":"J. Am. Soc. Nephrol."},{"key":"2249_CR562","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1681\/ASN.V125993","volume":"12","author":"AS Vriese","year":"2001","unstructured":"Vriese, A. S. et al. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J. Am. Soc. Nephrol. 12, 993\u20131000 (2001).","journal-title":"J. Am. Soc. Nephrol."},{"key":"2249_CR563","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1681\/ASN.2006010064","volume":"17","author":"SH Sung","year":"2006","unstructured":"Sung, S. H. et al. Blockade of vascular endothelial growth factor signaling ameliorates diabetic albuminuria in mice. J. Am. Soc. Nephrol. 17, 3093\u20133104 (2006).","journal-title":"J. Am. Soc. Nephrol."},{"key":"2249_CR564","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/nature03987","volume":"437","author":"SM Weis","year":"2005","unstructured":"Weis, S. M. & Cheresh, D. A. Pathophysiological consequences of VEGF-induced vascular permeability. Nature 437, 497\u2013504 (2005).","journal-title":"Nature"},{"key":"2249_CR565","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.cmet.2017.01.004","volume":"25","author":"A Falkevall","year":"2017","unstructured":"Falkevall, A. et al. Reducing VEGF-B signaling ameliorates renal lipotoxicity and protects against diabetic kidney disease. Cell Metab. 25, 713\u2013726 (2017).","journal-title":"Cell Metab."},{"key":"2249_CR566","doi-asserted-by":"publisher","first-page":"862545","DOI":"10.3389\/fendo.2022.862545","volume":"13","author":"Y Wei","year":"2022","unstructured":"Wei, Y. et al. Increased serum VEGF-B level is associated with renal function impairment in patients with type 2 diabetes. Front. Endocrinol. 13, 862545 (2022).","journal-title":"Front. Endocrinol."},{"key":"2249_CR567","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.apsb.2020.07.002","volume":"11","author":"Y Shen","year":"2021","unstructured":"Shen, Y. et al. VEGF-B antibody and interleukin-22 fusion protein ameliorates diabetic nephropathy through inhibiting lipid accumulation and inflammatory responses. Acta Pharmacol. Sin. 11, 127\u2013142 (2021).","journal-title":"Acta Pharmacol. Sin."},{"key":"2249_CR568","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1038\/s41374-019-0259-0","volume":"99","author":"A Zarjou","year":"2019","unstructured":"Zarjou, A. et al. Dynamic signature of lymphangiogenesis during acute kidney injury and chronic kidney disease. Lab. Investig. 99, 1376\u20131388 (2019).","journal-title":"Lab. Investig."},{"key":"2249_CR569","doi-asserted-by":"publisher","first-page":"F196","DOI":"10.1152\/ajprenal.00431.2005","volume":"291","author":"RR Foster","year":"2006","unstructured":"Foster, R. R. et al. VEGF-C promotes survival in podocytes. Am. J. Physiol. Ren. Physiol. 291, F196\u2013F207 (2006).","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"2249_CR570","doi-asserted-by":"publisher","first-page":"938","DOI":"10.2353\/ajpath.2008.070416","volume":"173","author":"RR Foster","year":"2008","unstructured":"Foster, R. R. et al. Vascular endothelial growth factor-C, a potential paracrine regulator of glomerular permeability, increases glomerular endothelial cell monolayer integrity and intracellular calcium. Am. J. Pathol. 173, 938\u2013948 (2008).","journal-title":"Am. J. Pathol."},{"key":"2249_CR571","doi-asserted-by":"publisher","first-page":"172","DOI":"10.2337\/db18-0045","volume":"68","author":"KL Onions","year":"2019","unstructured":"Onions, K. L. et al. VEGFC reduces glomerular albumin permeability and protects against alterations in VEGF receptor expression in diabetic nephropathy. Diabetes 68, 172\u2013187 (2019).","journal-title":"Diabetes"},{"key":"2249_CR572","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41581-020-0260-2","volume":"16","author":"K Tanabe","year":"2020","unstructured":"Tanabe, K., Wada, J. & Sato, Y. Targeting angiogenesis and lymphangiogenesis in kidney disease. Nat. Rev. Nephrol. 16, 289\u2013303 (2020).","journal-title":"Nat. Rev. Nephrol."},{"key":"2249_CR573","doi-asserted-by":"publisher","first-page":"e28804","DOI":"10.1097\/MD.0000000000028804","volume":"101","author":"TTU Nguyen","year":"2022","unstructured":"Nguyen, T. T. U., Kim, H., Chae, Y. J., Jung, J. H. & Kim, W. Serum VEGF-D level is correlated with renal dysfunction and proteinuria in patients with diabetic chronic kidney disease. Medicine 101, e28804 (2022).","journal-title":"Medicine"},{"key":"2249_CR574","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1172\/JCI86418","volume":"127","author":"LS Keir","year":"2017","unstructured":"Keir, L. S. et al. VEGF regulates local inhibitory complement proteins in the eye and kidney. J. Clin. Invest. 127, 199\u2013214 (2017).","journal-title":"J. Clin. Invest."},{"key":"2249_CR575","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1038\/s41379-018-0186-4","volume":"32","author":"F Person","year":"2019","unstructured":"Person, F. et al. Bevacizumab-associated glomerular microangiopathy. Mod. Pathol. 32, 684\u2013700 (2019).","journal-title":"Mod. Pathol."},{"key":"2249_CR576","first-page":"1715","volume":"147","author":"L Iruela-Arispe","year":"1995","unstructured":"Iruela-Arispe, L. et al. Participation of glomerular endothelial cells in the capillary repair of glomerulonephritis. Am. J. Pathol. 147, 1715\u20131727 (1995).","journal-title":"Am. J. Pathol."},{"key":"2249_CR577","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/S0002-9440(10)61731-2","volume":"159","author":"Y Masuda","year":"2001","unstructured":"Masuda, Y. et al. Vascular endothelial growth factor enhances glomerular capillary repair and accelerates resolution of experimentally induced glomerulonephritis. Am. J. Pathol. 159, 599\u2013608 (2001).","journal-title":"Am. J. Pathol."},{"key":"2249_CR578","doi-asserted-by":"publisher","first-page":"F422","DOI":"10.1152\/ajprenal.00448.2005","volume":"291","author":"F Guan","year":"2006","unstructured":"Guan, F., Villegas, G., Teichman, J., Mundel, P. & Tufro, A. Autocrine VEGF-A system in podocytes regulates podocin and its interaction with CD2AP. Am. J. Physiol. Ren. Physiol. 291, F422\u2013F428 (2006).","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"2249_CR579","doi-asserted-by":"publisher","first-page":"245","DOI":"10.7861\/clinmedicine.18-3-245","volume":"18","author":"J Maurice","year":"2018","unstructured":"Maurice, J. & Manousou, P. Non-alcoholic fatty liver disease. Clin. Med. 18, 245\u2013250 (2018).","journal-title":"Clin. Med."},{"key":"2249_CR580","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani, N. et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 67, 328\u2013357 (2018).","journal-title":"Hepatology"},{"key":"2249_CR581","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1136\/gut.52.9.1347","volume":"52","author":"H Yoshiji","year":"2003","unstructured":"Yoshiji, H. et al. Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis. Gut 52, 1347\u20131354 (2003).","journal-title":"Gut"},{"key":"2249_CR582","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.3390\/jcm10071338","volume":"10","author":"L Lei","year":"2021","unstructured":"Lei, L., Ei Mourabit, H., Housset, C., Cadoret, A. & Lemoinne, S. Role of angiogenesis in the pathogenesis of NAFLD. J. Clin. Med. 10, 1338 (2021).","journal-title":"J. Clin. Med."},{"key":"2249_CR583","doi-asserted-by":"publisher","first-page":"786","DOI":"10.4254\/wjh.v15.i6.786","volume":"15","author":"YQ Li","year":"2023","unstructured":"Li, Y. Q., Xin, L., Zhao, Y. C., Li, S. Q. & Li, Y. N. Role of vascular endothelial growth factor B in nonalcoholic fatty liver disease and its potential value. World J. Hepatol. 15, 786\u2013796 (2023).","journal-title":"World J. Hepatol."},{"key":"2249_CR584","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.cyto.2012.05.001","volume":"59","author":"S Coulon","year":"2012","unstructured":"Coulon, S. et al. Evaluation of inflammatory and angiogenic factors in patients with non-alcoholic fatty liver disease. Cytokine 59, 442\u2013449 (2012).","journal-title":"Cytokine"},{"key":"2249_CR585","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.arcmed.2010.12.001","volume":"42","author":"Y Yilmaz","year":"2011","unstructured":"Yilmaz, Y. et al. Circulating levels of vascular endothelial growth factor A and its soluble receptor in patients with biopsy-proven nonalcoholic fatty liver disease. Arch. Med. Res. 42, 38\u201343 (2011).","journal-title":"Arch. Med. Res."},{"key":"2249_CR586","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.1038\/s41401-022-00907-5","volume":"43","author":"H Shen","year":"2022","unstructured":"Shen, H. et al. Hepatocyte-derived VEGFA accelerates the progression of non-alcoholic fatty liver disease to hepatocellular carcinoma via activating hepatic stellate cells. Acta Pharmacol. Sin. 43, 2917\u20132928 (2022).","journal-title":"Acta Pharmacol. Sin."},{"key":"2249_CR587","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1002\/hep.26219","volume":"57","author":"S Coulon","year":"2013","unstructured":"Coulon, S. et al. Role of vascular endothelial growth factor in the pathophysiology of nonalcoholic steatohepatitis in two rodent models. Hepatology 57, 1793\u20131805 (2013).","journal-title":"Hepatology"},{"key":"2249_CR588","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/j.jhep.2023.01.014","volume":"78","author":"A Falkevall","year":"2023","unstructured":"Falkevall, A. et al. Inhibition of VEGF-B signaling prevents non-alcoholic fatty liver disease development by targeting lipolysis in the white adipose tissue. J. Hepatol. 78, 901\u2013913 (2023).","journal-title":"J. Hepatol."},{"key":"2249_CR589","doi-asserted-by":"publisher","first-page":"10541","DOI":"10.3390\/ijms221910541","volume":"22","author":"O Osorio-Conles","year":"2021","unstructured":"Osorio-Conles, O. et al. A distinctive NAFLD signature in adipose tissue from women with severe obesity. Int. J. Mol. Sci. 22, 10541 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"2249_CR590","doi-asserted-by":"publisher","first-page":"582","DOI":"10.3389\/fphar.2019.00582","volume":"10","author":"W Hong","year":"2019","unstructured":"Hong, W. et al. Prediction of VEGF-C as a key target of pure total flavonoids from citrus against NAFLD in mice via network pharmacology. Front. Pharmacol. 10, 582 (2019).","journal-title":"Front. Pharmacol."},{"key":"2249_CR591","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJM199005033221805","volume":"322","author":"ED Harris Jr","year":"1990","unstructured":"Harris, E. D. Jr Rheumatoid arthritis. Pathophysiology and implications for therapy. New Engl. J. Med. 322, 1277\u20131289 (1990).","journal-title":"New Engl. J. Med."},{"key":"2249_CR592","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.autrev.2011.04.020","volume":"10","author":"A Marrelli","year":"2011","unstructured":"Marrelli, A. et al. Angiogenesis in rheumatoid arthritis: a disease specific process or a common response to chronic inflammation?. Autoimmun. Rev. 10, 595\u2013598 (2011).","journal-title":"Autoimmun. Rev."},{"key":"2249_CR593","doi-asserted-by":"publisher","first-page":"R193","DOI":"10.1186\/ar756","volume":"5","author":"A Giatromanolaki","year":"2003","unstructured":"Giatromanolaki, A. et al. Upregulated hypoxia inducible factor-1alpha and -2alpha pathway in rheumatoid arthritis and osteoarthritis. Arthritis Res. Ther. 5, R193\u2013R201 (2003).","journal-title":"Arthritis Res. Ther."},{"key":"2249_CR594","doi-asserted-by":"publisher","first-page":"129873","DOI":"10.1155\/2008\/129873","volume":"2008","author":"SA Yoo","year":"2008","unstructured":"Yoo, S. A., Kwok, S. K. & Kim, W. U. Proinflammatory role of vascular endothelial growth factor in the pathogenesis of rheumatoid arthritis: prospects for therapeutic intervention. Mediators Inflamm. 2008, 129873 (2008).","journal-title":"Mediators Inflamm."},{"key":"2249_CR595","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1046\/j.1365-2249.2000.01272.x","volume":"121","author":"T Kasama","year":"2000","unstructured":"Kasama, T. et al. Expression of vascular endothelial growth factor by synovial fluid neutrophils in rheumatoid arthritis (RA). Clin. Exp. Immunol. 121, 533\u2013538 (2000).","journal-title":"Clin. Exp. Immunol."},{"key":"2249_CR596","first-page":"321","volume":"19","author":"SS Lee","year":"2001","unstructured":"Lee, S. S. et al. Vascular endothelial growth factor levels in the serum and synovial fluid of patients with rheumatoid arthritis. Clin. Exp. Rheumatol. 19, 321\u2013324 (2001).","journal-title":"Clin. Exp. Rheumatol."},{"key":"2249_CR597","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1080\/03009749850154429","volume":"27","author":"M Harada","year":"1998","unstructured":"Harada, M. et al. Vascular endothelial growth factor in patients with rheumatoid arthritis. Scand. J. Rheumatol. 27, 377\u2013380 (1998).","journal-title":"Scand. J. Rheumatol."},{"key":"2249_CR598","first-page":"92","volume":"22","author":"WX Cheng","year":"2020","unstructured":"Cheng, W. X. et al. Genistein inhibits angiogenesis developed during rheumatoid arthritis through the IL-6\/JAK2\/STAT3\/VEGF signalling pathway. J. Orthop. Transl. 22, 92\u2013100 (2020).","journal-title":"J. Orthop. Transl."},{"key":"2249_CR599","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.1002\/art.11232","volume":"48","author":"AW Mould","year":"2003","unstructured":"Mould, A. W. et al. Vegfb gene knockout mice display reduced pathology and synovial angiogenesis in both antigen-induced and collagen-induced models of arthritis. Arthritis Rheum. 48, 2660\u20132669 (2003).","journal-title":"Arthritis Rheum."},{"key":"2249_CR600","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1002\/art.30421","volume":"63","author":"Q Zhou","year":"2011","unstructured":"Zhou, Q. et al. Vascular endothelial growth factor C attenuates joint damage in chronic inflammatory arthritis by accelerating local lymphatic drainage in mice. Arthritis Rheum. 63, 2318\u20132328 (2011).","journal-title":"Arthritis Rheum."},{"key":"2249_CR601","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1038\/labinvest.3780127","volume":"80","author":"J Miotla","year":"2000","unstructured":"Miotla, J., Maciewicz, R., Kendrew, J., Feldmann, M. & Paleolog, E. Treatment with soluble VEGF receptor reduces disease severity in murine collagen-induced arthritis. Lab. Investig. 80, 1195\u20131205 (2000).","journal-title":"Lab. Investig."},{"key":"2249_CR602","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1006\/bbrc.2001.4395","volume":"281","author":"H Sone","year":"2001","unstructured":"Sone, H. et al. Neutralization of vascular endothelial growth factor prevents collagen-induced arthritis and ameliorates established disease in mice. Biochem. Biophys. Res. Commun. 281, 562\u2013568 (2001).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2249_CR603","doi-asserted-by":"publisher","first-page":"114702","DOI":"10.1016\/j.taap.2019.114702","volume":"380","author":"AE Abdel-Maged","year":"2019","unstructured":"Abdel-Maged, A. E., Gad, A. M., Wahdan, S. A. & Azab, S. S. Efficacy and safety of Ramucirumab and methotrexate co-therapy in rheumatoid arthritis experimental model: involvement of angiogenic and immunomodulatory signaling. Toxicol. Appl. Pharmacol. 380, 114702 (2019).","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"2249_CR604","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","volume":"323","author":"AW Armstrong","year":"2020","unstructured":"Armstrong, A. W. & Read, C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA 323, 1945\u20131960 (2020).","journal-title":"JAMA"},{"key":"2249_CR605","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1111\/j.1365-2613.2009.00669.x","volume":"90","author":"R Heidenreich","year":"2009","unstructured":"Heidenreich, R., Rocken, M. & Ghoreschi, K. Angiogenesis drives psoriasis pathogenesis. Int. J. Exp. Pathol. 90, 232\u2013248 (2009).","journal-title":"Int. J. Exp. Pathol."},{"key":"2249_CR606","first-page":"461","volume":"32","author":"D Vybohova","year":"2017","unstructured":"Vybohova, D., Adamicova, K., Mellova, Y. & Heskova, G. Microvascular changes in relation to inflammation and epidermal hyperplasia in chronic cutaneous lesions of psoriasis vulgaris. Histol. Histopathol. 32, 461\u2013470 (2017).","journal-title":"Histol. Histopathol."},{"key":"2249_CR607","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/1346-8138.16588","volume":"50","author":"A Watanabe","year":"2023","unstructured":"Watanabe, A. et al. Serum levels of angiogenesis-related factors in patients with psoriasis. J. Dermatol. 50, 222\u2013228 (2023).","journal-title":"J. Dermatol."},{"key":"2249_CR608","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/S0002-9440(10)61213-8","volume":"167","author":"TA Wilgus","year":"2005","unstructured":"Wilgus, T. A. et al. Novel function for vascular endothelial growth factor receptor-1 on epidermal keratinocytes. Am. J. Pathol. 167, 1257\u20131266 (2005).","journal-title":"Am. J. Pathol."},{"key":"2249_CR609","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2119\/2006-00024.Man","volume":"12","author":"XY Man","year":"2006","unstructured":"Man, X. Y., Yang, X. H., Cai, S. Q., Yao, Y. G. & Zheng, M. Immunolocalization and expression of vascular endothelial growth factor receptors (VEGFRs) and neuropilins (NRPs) on keratinocytes in human epidermis. Mol. Med. 12, 127\u2013136 (2006).","journal-title":"Mol. Med."},{"issue":"Suppl 1","key":"2249_CR610","doi-asserted-by":"publisher","first-page":"S78","DOI":"10.1016\/S0923-1811(00)00145-6","volume":"24","author":"M Detmar","year":"2000","unstructured":"Detmar, M. The role of VEGF and thrombospondins in skin angiogenesis. J. Dermatol. Sci. 24(Suppl 1), S78\u2013S84 (2000).","journal-title":"J. Dermatol. Sci."},{"key":"2249_CR611","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/j.1365-2133.2008.08889.x","volume":"160","author":"A Henno","year":"2009","unstructured":"Henno, A. et al. Altered expression of angiogenesis and lymphangiogenesis markers in the uninvolved skin of plaque-type psoriasis. Br. J. Dermatol. 160, 581\u2013590 (2009).","journal-title":"Br. J. Dermatol."},{"key":"2249_CR612","doi-asserted-by":"publisher","DOI":"10.1186\/1756-0500-5-201","volume":"5","author":"SC Liew","year":"2012","unstructured":"Liew, S. C. et al. Differential expression of the angiogenesis growth factors in psoriasis vulgaris. BMC Res. Notes 5, 201 (2012).","journal-title":"BMC Res. Notes"},{"key":"2249_CR613","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1182\/blood-2002-12-3793","volume":"102","author":"YP Xia","year":"2003","unstructured":"Xia, Y. P. et al. Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood 102, 161\u2013168 (2003).","journal-title":"Blood"},{"key":"2249_CR614","doi-asserted-by":"publisher","first-page":"21264","DOI":"10.1073\/pnas.0907550106","volume":"106","author":"HB Schonthaler","year":"2009","unstructured":"Schonthaler, H. B., Huggenberger, R., Wculek, S. K., Detmar, M. & Wagner, E. F. Systemic anti-VEGF treatment strongly reduces skin inflammation in a mouse model of psoriasis. Proc. Natl. Acad. Sci. USA 106, 21264\u201321269 (2009).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2249_CR615","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41572-023-00417-6","volume":"9","author":"E Dimitriadis","year":"2023","unstructured":"Dimitriadis, E. et al. Pre-eclampsia. Nat. Rev. Dis. Prim. 9, 8 (2023).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"2249_CR616","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3892\/ijmm.2023.5292","volume":"52","author":"A Velegrakis","year":"2023","unstructured":"Velegrakis, A., Kouvidi, E., Fragkiadaki, P. & Sifakis, S. Predictive value of the sFlt\u20111\/PlGF ratio in women with suspected preeclampsia: an update (Review). Int. J. Mol. Med. 52, 89 (2023).","journal-title":"Int. J. Mol. Med."},{"key":"2249_CR617","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.immuni.2018.03.030","volume":"48","author":"M Gamliel","year":"2018","unstructured":"Gamliel, M. et al. Trained memory of human uterine NK cells enhances their function in subsequent pregnancies. Immunity 48, 951\u2013962 (2018).","journal-title":"Immunity"},{"key":"2249_CR618","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/j.ajog.2004.03.043","volume":"190","author":"T Chaiworapongsa","year":"2004","unstructured":"Chaiworapongsa, T. et al. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. Am. J. Obstet. Gynecol. 190, 1541\u20131547 (2004).","journal-title":"Am. J. Obstet. Gynecol."},{"key":"2249_CR619","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/14767050400028816","volume":"17","author":"T Chaiworapongsa","year":"2005","unstructured":"Chaiworapongsa, T. et al. Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J. Matern. Fetal Neonatal Med. 17, 3\u201318 (2005).","journal-title":"J. Matern. Fetal Neonatal Med."},{"key":"2249_CR620","doi-asserted-by":"publisher","first-page":"4838","DOI":"10.1210\/en.2004-0533","volume":"145","author":"T Nagamatsu","year":"2004","unstructured":"Nagamatsu, T. et al. Cytotrophoblasts up-regulate soluble fms-like tyrosine kinase-1 expression under reduced oxygen: an implication for the placental vascular development and the pathophysiology of preeclampsia. Endocrinology 145, 4838\u20134845 (2004).","journal-title":"Endocrinology"},{"key":"2249_CR621","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/ajh.2009.24","volume":"22","author":"JP Bridges","year":"2009","unstructured":"Bridges, J. P. et al. Oxidative stress contributes to soluble fms-like tyrosine kinase-1 induced vascular dysfunction in pregnant rats. Am. J. Hypertens. 22, 564\u2013568 (2009).","journal-title":"Am. J. Hypertens."},{"key":"2249_CR622","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1172\/JCI17189","volume":"111","author":"SE Maynard","year":"2003","unstructured":"Maynard, S. E. et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J. Clin. Invest. 111, 649\u2013658 (2003).","journal-title":"J. Clin. Invest."},{"key":"2249_CR623","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1414838","volume":"374","author":"H Zeisler","year":"2016","unstructured":"Zeisler, H. et al. Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia. New Engl. J. Med. 374, 13\u201322 (2016).","journal-title":"New Engl. J. Med."},{"key":"2249_CR624","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1056\/NEJMoa031884","volume":"350","author":"RJ Levine","year":"2004","unstructured":"Levine, R. J. et al. Circulating angiogenic factors and the risk of preeclampsia. New Engl. J. Med. 350, 672\u2013683 (2004).","journal-title":"New Engl. J. Med."},{"key":"2249_CR625","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1161\/HYPERTENSIONAHA.115.05883","volume":"66","author":"KR Palmer","year":"2015","unstructured":"Palmer, K. R. et al. Placental-specific sFLT-1 e15a protein is increased in preeclampsia, antagonizes vascular endothelial growth factor signaling, and has antiangiogenic activity. Hypertension 66, 1251\u20131259 (2015).","journal-title":"Hypertension"},{"key":"2249_CR626","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1161\/HYPERTENSIONAHA.107.092098","volume":"50","author":"Z Li","year":"2007","unstructured":"Li, Z. et al. Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia. Hypertension 50, 686\u2013692 (2007).","journal-title":"Hypertension"},{"key":"2249_CR627","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1161\/HYPERTENSIONAHA.107.096594","volume":"50","author":"JS Gilbert","year":"2007","unstructured":"Gilbert, J. S., Babcock, S. A. & Granger, J. P. Hypertension produced by reduced uterine perfusion in pregnant rats is associated with increased soluble fms-like tyrosine kinase-1 expression. Hypertension 50, 1142\u20131147 (2007).","journal-title":"Hypertension"},{"key":"2249_CR628","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1161\/HYPERTENSIONAHA.109.141937","volume":"55","author":"JS Gilbert","year":"2010","unstructured":"Gilbert, J. S. et al. Recombinant vascular endothelial growth factor 121 infusion lowers blood pressure and improves renal function in rats with placentalischemia-induced hypertension. Hypertension 55, 380\u2013385 (2010).","journal-title":"Hypertension"},{"key":"2249_CR629","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1161\/HYPERTENSIONAHA.115.06783","volume":"67","author":"FT Spradley","year":"2016","unstructured":"Spradley, F. T. et al. Placental growth factor administration abolishes placental ischemia-induced hypertension. Hypertension 67, 740\u2013747 (2016).","journal-title":"Hypertension"},{"key":"2249_CR630","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1161\/hy02t2.102904","volume":"39","author":"RL Davisson","year":"2002","unstructured":"Davisson, R. L. et al. Discovery of a spontaneous genetic mouse model of preeclampsia. Hypertension 39, 337\u2013342 (2002).","journal-title":"Hypertension"},{"key":"2249_CR631","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1161\/HYPERTENSIONAHA.110.160242","volume":"57","author":"AK Woods","year":"2011","unstructured":"Woods, A. K. et al. Adenoviral delivery of VEGF121 early in pregnancy prevents spontaneous development of preeclampsia in BPH\/5 mice. Hypertension 57, 94\u2013102 (2011).","journal-title":"Hypertension"},{"key":"2249_CR632","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1161\/HYPERTENSIONAHA.121.17713","volume":"78","author":"JP Waller","year":"2021","unstructured":"Waller, J. P. et al. Elastin-like polypeptide: VEGF-B fusion protein for treatment of preeclampsia. Hypertension 78, 1888\u20131901 (2021).","journal-title":"Hypertension"},{"key":"2249_CR633","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1161\/HYPERTENSIONAHA.118.12300","volume":"73","author":"R Hastie","year":"2019","unstructured":"Hastie, R. et al. EGFR (Epidermal growth factor receptor) signaling and the mitochondria regulate sFlt-1 (soluble FMS-like tyrosine kinase-1) secretion. Hypertension 73, 659\u2013670 (2019).","journal-title":"Hypertension"},{"key":"2249_CR634","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000358919","volume":"78","author":"G Benagiano","year":"2014","unstructured":"Benagiano, G., Brosens, I. & Lippi, D. The history of endometriosis. Gynecol. Obstet. Invest. 78, 1\u20139 (2014).","journal-title":"Gynecol. Obstet. Invest."},{"key":"2249_CR635","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1056\/NEJMra1810764","volume":"382","author":"KT Zondervan","year":"2020","unstructured":"Zondervan, K. T., Becker, C. M. & Missmer, S. A. Endometriosis. New Engl. J. Med. 382, 1244\u20131256 (2020).","journal-title":"New Engl. J. Med."},{"key":"2249_CR636","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/j.1749-6632.2002.tb02769.x","volume":"955","author":"RN Taylor","year":"2002","unstructured":"Taylor, R. N., Lebovic, D. I. & Mueller, M. D. Angiogenic factors in endometriosis. Ann. NY Acad. Sci. 955, 89\u2013100 (2002).","journal-title":"Ann. NY Acad. Sci."},{"issue":"Suppl 3","key":"2249_CR637","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/humrep\/15.suppl_3.67","volume":"15","author":"DI Lebovic","year":"2000","unstructured":"Lebovic, D. I. et al. Ovarian steroid and cytokine modulation of human endometrial angiogenesis. Hum. Reprod. 15(Suppl 3), 67\u201377 (2000).","journal-title":"Hum. Reprod."},{"key":"2249_CR638","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1080\/713773947","volume":"6","author":"ML Iruela-Arispe","year":"1999","unstructured":"Iruela-Arispe, M. L., Rodriguez-Manzaneque, J. C. & Abu-Jawdeh, G. Endometrial endothelial cells express estrogen and progesterone receptors and exhibit a tissue specific response to angiogenic growth factors. Microcirculation 6, 127\u2013140 (1999).","journal-title":"Microcirculation"},{"key":"2249_CR639","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1093\/humrep\/13.6.1686","volume":"13","author":"J Donnez","year":"1998","unstructured":"Donnez, J., Smoes, P., Gillerot, S., Casanas-Roux, F. & Nisolle, M. Vascular endothelial growth factor (VEGF) in endometriosis. Hum. Reprod. 13, 1686\u20131690 (1998).","journal-title":"Hum. Reprod."},{"key":"2249_CR640","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1530\/rep.1.01110","volume":"132","author":"V Bourlev","year":"2006","unstructured":"Bourlev, V. et al. The relationship between microvessel density, proliferative activity and expression of vascular endothelial growth factor-A and its receptors in eutopic endometrium and endometriotic lesions. Reproduction 132, 501\u2013509 (2006).","journal-title":"Reproduction"},{"key":"2249_CR641","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.jphs.2020.05.003","volume":"143","author":"K Hattori","year":"2020","unstructured":"Hattori, K. et al. Lymphangiogenesis induced by vascular endothelial growth factor receptor 1 signaling contributes to the progression of endometriosis in mice. J. Pharmacol. Sci. 143, 255\u2013263 (2020).","journal-title":"J. Pharmacol. Sci."},{"key":"2249_CR642","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-43185-8","volume":"9","author":"K Sekiguchi","year":"2019","unstructured":"Sekiguchi, K. et al. VEGF Receptor 1-expressing macrophages recruited from bone marrow enhances angiogenesis in endometrial tissues. Sci. Rep. 9, 7037 (2019).","journal-title":"Sci. Rep."},{"key":"2249_CR643","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1177\/1933719115607978","volume":"23","author":"I Filippi","year":"2016","unstructured":"Filippi, I. et al. Different expression of hypoxic and angiogenic factors in human endometriotic lesions. Reprod. Sci. 23, 492\u2013497 (2016).","journal-title":"Reprod. Sci."},{"key":"2249_CR644","doi-asserted-by":"publisher","first-page":"103205","DOI":"10.1016\/j.redox.2024.103205","volume":"73","author":"W Dai","year":"2024","unstructured":"Dai, W. et al. Hypoxia and the endometrium: an indispensable role for HIF-1alpha as therapeutic strategies. Redox Biol. 73, 103205 (2024).","journal-title":"Redox Biol."},{"key":"2249_CR645","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.prp.2018.12.022","volume":"215","author":"J Li","year":"2019","unstructured":"Li, J. et al. HIF1A and VEGF regulate each other by competing endogenous RNA mechanism and involve in the pathogenesis of peritoneal fibrosis. Pathol. Res. Pract. 215, 644\u2013652 (2019).","journal-title":"Pathol. Res. Pract."},{"key":"2249_CR646","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1093\/humrep\/der230","volume":"26","author":"S Keichel","year":"2011","unstructured":"Keichel, S. et al. Lymphangiogenesis in deep infiltrating endometriosis. Hum. Reprod. 26, 2713\u20132720 (2011).","journal-title":"Hum. Reprod."},{"key":"2249_CR647","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1016\/j.humpath.2004.07.020","volume":"35","author":"M Takehara","year":"2004","unstructured":"Takehara, M. et al. Vascular endothelial growth factor A and C gene expression in endometriosis. Hum. Pathol. 35, 1369\u20131375 (2004).","journal-title":"Hum. Pathol."},{"key":"2249_CR648","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s10456-013-9333-1","volume":"16","author":"H Xu","year":"2013","unstructured":"Xu, H. et al. Vascular endothelial growth factor C is increased in endometrium and promotes endothelial functions, vascular permeability and angiogenesis and growth of endometriosis. Angiogenesis 16, 541\u2013551 (2013).","journal-title":"Angiogenesis"},{"key":"2249_CR649","doi-asserted-by":"publisher","first-page":"25859","DOI":"10.1073\/pnas.1920037117","volume":"117","author":"WN Li","year":"2020","unstructured":"Li, W. N. et al. Extracellular vesicle-associated VEGF-C promotes lymphangiogenesis and immune cells infiltration in endometriosis. Proc. Natl. Acad. Sci. USA 117, 25859\u201325868 (2020).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2249_CR650","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1756-9966-29-4","volume":"29","author":"DE Machado","year":"2010","unstructured":"Machado, D. E., Berardo, P. T., Palmero, C. Y. & Nasciutti, L. E. Higher expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 (Flk-1) and metalloproteinase-9 (MMP-9) in a rat model of peritoneal endometriosis is similar to cancer diseases. J. Exp. Clin. Cancer Res. 29, 4 (2010).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2249_CR651","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1177\/1933719115584448","volume":"22","author":"C Yildiz","year":"2015","unstructured":"Yildiz, C. et al. Effects of pazopanib, sunitinib, and sorafenib, anti-VEGF agents, on the growth of experimental endometriosis in rats. Reprod. Sci. 22, 1445\u20131451 (2015).","journal-title":"Reprod. Sci."},{"key":"2249_CR652","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz, H. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New Engl. J. Med. 350, 2335\u20132342 (2004).","journal-title":"New Engl. J. Med."},{"key":"2249_CR653","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/nrc2403","volume":"8","author":"LM Ellis","year":"2008","unstructured":"Ellis, L. M. & Hicklin, D. J. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat. Rev. Cancer 8, 579\u2013591 (2008).","journal-title":"Nat. Rev. Cancer"},{"key":"2249_CR654","doi-asserted-by":"publisher","first-page":"11393","DOI":"10.1073\/pnas.172398299","volume":"99","author":"J Holash","year":"2002","unstructured":"Holash, J. et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc. Natl. Acad. Sci. USA 99, 11393\u201311398 (2002).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2249_CR655","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1200\/JCO.2012.42.8201","volume":"30","author":"E Van Cutsem","year":"2012","unstructured":"Van Cutsem, E. et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J. Clin. Oncol. 30, 3499\u20133506 (2012).","journal-title":"J. Clin. Oncol."},{"key":"2249_CR656","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","volume":"381","author":"I Ray-Coquard","year":"2019","unstructured":"Ray-Coquard, I. et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. New Engl. J. Med. 381, 2416\u20132428 (2019).","journal-title":"New Engl. J. Med."},{"key":"2249_CR657","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","volume":"381","author":"S Kopetz","year":"2019","unstructured":"Kopetz, S. et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer. New Engl. J. Med. 381, 1632\u20131643 (2019).","journal-title":"New Engl. J. Med."},{"key":"2249_CR658","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101580","volume":"8","author":"EB Garon","year":"2023","unstructured":"Garon, E. B. et al. Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results. ESMO Open 8, 101580 (2023).","journal-title":"ESMO Open"},{"key":"2249_CR659","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","volume":"20","author":"AX Zhu","year":"2019","unstructured":"Zhu, A. X. et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased \u03b1-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 20, 282\u2013296 (2019).","journal-title":"Lancet Oncol."},{"key":"2249_CR660","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1038\/s41591-024-02813-1","volume":"30","author":"F Wang","year":"2024","unstructured":"Wang, F. et al. Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS\/pMMR colorectal cancer: a randomized phase 2 trial. Nat. Med. 30, 1035\u20131043 (2024).","journal-title":"Nat. Med."},{"key":"2249_CR661","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1097\/01.iae.0000242842.14624.e7","volume":"26","author":"N Ferrara","year":"2006","unstructured":"Ferrara, N., Damico, L., Shams, N., Lowman, H. & Kim, R. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 26, 859\u2013870 (2006).","journal-title":"Retina"},{"key":"2249_CR662","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","volume":"127","author":"PU Dugel","year":"2020","unstructured":"Dugel, P. U. et al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology 127, 72\u201384 (2020).","journal-title":"Ophthalmology"},{"key":"2249_CR663","unstructured":"Therapeutics, O. Outlook Therapeutics\u00ae Announces Preliminary Topline Results of NORSE EIGHT Clinical Trial (New Jersey, 2024)."},{"key":"2249_CR664","unstructured":"Therapeutics, O. Outlook Therapeutics\u00ae Announces NICE Recommendation of LYTENAVA\u2122 (bevacizumabgamma) for the Treatment of Wet AMD (New Jersey, 2024)."},{"key":"2249_CR665","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.canlet.2006.06.011","volume":"248","author":"GJ Caine","year":"2007","unstructured":"Caine, G. J., Stonelake, P. S., Lip, G. Y. & Blann, A. D. Changes in plasma vascular endothelial growth factor, angiopoietins, and their receptors following surgery for breast cancer. Cancer Lett. 248, 131\u2013136 (2007).","journal-title":"Cancer Lett."},{"key":"2249_CR666","doi-asserted-by":"publisher","first-page":"107602962412380","DOI":"10.1177\/10760296241238010","volume":"30","author":"Y Chi","year":"2024","unstructured":"Chi, Y. et al. Role of Angiopoietin\/Tie2 system in sepsis: a potential therapeutic target. Clin. Appl. Thromb. Hemost. 30, 10760296241238010 (2024).","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"2249_CR667","doi-asserted-by":"publisher","first-page":"135","DOI":"10.4110\/in.2011.11.3.135","volume":"11","author":"TY Ha","year":"2011","unstructured":"Ha, T. Y. MicroRNAs in human diseases: from cancer to cardiovascular disease. Immune Netw. 11, 135\u2013154 (2011).","journal-title":"Immune Netw."},{"key":"2249_CR668","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-020-00874-w","volume":"12","author":"V Gorenjak","year":"2020","unstructured":"Gorenjak, V. et al. Epigenome-wide association study in healthy individuals identifies significant associations with DNA methylation and PBMC extract VEGF-A concentration. Clin. Epigenetics 12, 79 (2020).","journal-title":"Clin. Epigenetics"},{"key":"2249_CR669","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/sj.bjc.6605483","volume":"102","author":"N Murukesh","year":"2010","unstructured":"Murukesh, N., Dive, C. & Jayson, G. C. Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. Br. J. Cancer 102, 8\u201318 (2010).","journal-title":"Br. J. Cancer"},{"key":"2249_CR670","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1038\/sj.bjc.6603678","volume":"96","author":"RA Mohammed","year":"2007","unstructured":"Mohammed, R. A. et al. Prognostic significance of vascular endothelial cell growth factors -A, -C and -D in breast cancer and their relationship with angio- and lymphangiogenesis. Br. J. Cancer 96, 1092\u20131100 (2007).","journal-title":"Br. J. Cancer"},{"key":"2249_CR671","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1038\/sj.bjc.6603176","volume":"94","author":"G Des Guetz","year":"2006","unstructured":"Des Guetz, G. et al. Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br. J. Cancer 94, 1823\u20131832 (2006).","journal-title":"Br. J. Cancer"},{"key":"2249_CR672","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1056\/NEJMoa043814","volume":"353","author":"N Werner","year":"2005","unstructured":"Werner, N. et al. Circulating endothelial progenitor cells and cardiovascular outcomes. New Engl. J. Med. 353, 999\u20131007 (2005).","journal-title":"New Engl. J. Med."},{"key":"2249_CR673","doi-asserted-by":"publisher","first-page":"355","DOI":"10.4252\/wjsc.v6.i3.355","volume":"6","author":"PS Lee","year":"2014","unstructured":"Lee, P. S. & Poh, K. K. Endothelial progenitor cells in cardiovascular diseases. World J. Stem Cells 6, 355\u2013366 (2014).","journal-title":"World J. Stem Cells"},{"key":"2249_CR674","doi-asserted-by":"publisher","first-page":"504","DOI":"10.2353\/ajpath.2010.081152","volume":"176","author":"X Liu","year":"2010","unstructured":"Liu, X. et al. Endothelial progenitor cells (EPCs) mobilized and activated by neurotrophic factors may contribute to pathologic neovascularization in diabetic retinopathy. Am. J. Pathol. 176, 504\u2013515 (2010).","journal-title":"Am. J. Pathol."},{"key":"2249_CR675","doi-asserted-by":"publisher","first-page":"R15","DOI":"10.1172\/JCI8829","volume":"105","author":"G Klement","year":"2000","unstructured":"Klement, G. et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. 105, R15\u2013R24 (2000).","journal-title":"J. Clin. Invest."},{"key":"2249_CR676","first-page":"5736","volume":"61","author":"RE Bachelder","year":"2001","unstructured":"Bachelder, R. E. et al. Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells. Cancer Res. 61, 5736\u20135740 (2001).","journal-title":"Cancer Res."},{"key":"2249_CR677","doi-asserted-by":"publisher","first-page":"18513","DOI":"10.1073\/pnas.0807967105","volume":"105","author":"Y Xue","year":"2008","unstructured":"Xue, Y. et al. Anti-VEGF agents confer survival advantages to tumor-bearing mice by improving cancer-associated systemic syndrome. Proc. Natl. Acad. Sci. USA 105, 18513\u201318518 (2008).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2249_CR678","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/nrclinonc.2010.118","volume":"7","author":"Y Cao","year":"2010","unstructured":"Cao, Y. Off-tumor target\u2013beneficial site for antiangiogenic cancer therapy?. Nat. Rev. Clin. Oncol. 7, 604\u2013608 (2010).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2249_CR679","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1038\/nm1096-1096","volume":"2","author":"DI Gabrilovich","year":"1996","unstructured":"Gabrilovich, D. I. et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 2, 1096\u20131103 (1996).","journal-title":"Nat. Med."},{"key":"2249_CR680","doi-asserted-by":"publisher","first-page":"4878","DOI":"10.1182\/blood-2002-07-1956","volume":"101","author":"JE Ohm","year":"2003","unstructured":"Ohm, J. E. et al. VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood 101, 4878\u20134886 (2003).","journal-title":"Blood"},{"key":"2249_CR681","doi-asserted-by":"publisher","first-page":"4117","DOI":"10.1073\/pnas.1016220108","volume":"108","author":"D Zhang","year":"2011","unstructured":"Zhang, D. et al. Antiangiogenic agents significantly improve survival in tumor-bearing mice by increasing tolerance to chemotherapy-induced toxicity. Proc. Natl. Acad. Sci. USA 108, 4117\u20134122 (2011).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2249_CR682","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.3390\/ijms17091489","volume":"17","author":"MP Pinto","year":"2016","unstructured":"Pinto, M. P., Sotomayor, P., Carrasco-Avino, G., Corvalan, A. H. & Owen, G. I. Escaping antiangiogenic therapy: strategies employed by cancer cells. Int. J. Mol. Sci. 17, 1489 (2016).","journal-title":"Int. J. Mol. Sci."},{"key":"2249_CR683","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.3390\/cancers13081912","volume":"13","author":"D Belotti","year":"2021","unstructured":"Belotti, D., Pinessi, D. & Taraboletti, G. Alternative vascularization mechanisms in tumor resistance to therapy. Cancers 13, 1912 (2021).","journal-title":"Cancers"},{"key":"2249_CR684","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1016\/j.ijbiomac.2022.09.129","volume":"221","author":"S Vimalraj","year":"2022","unstructured":"Vimalraj, S. A concise review of VEGF, PDGF, FGF, Notch, angiopoietin, and HGF signalling in tumor angiogenesis with a focus on alternative approaches and future directions. Int. J. Biol. Macromol. 221, 1428\u20131438 (2022).","journal-title":"Int. J. Biol. Macromol."},{"key":"2249_CR685","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn, R. S. et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. New Engl. J. Med. 382, 1894\u20131905 (2020).","journal-title":"New Engl. J. Med."},{"key":"2249_CR686","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","volume":"380","author":"BI Rini","year":"2019","unstructured":"Rini, B. I. et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. New Engl. J. Med. 380, 1116\u20131127 (2019).","journal-title":"New Engl. J. Med."},{"key":"2249_CR687","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S2213-2600(19)30084-0","volume":"7","author":"M Reck","year":"2019","unstructured":"Reck, M. et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir. Med. 7, 387\u2013401 (2019).","journal-title":"Lancet Respir. Med."},{"key":"2249_CR688","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S0140-6736(23)00922-4","volume":"402","author":"SK Pal","year":"2023","unstructured":"Pal, S. K. et al. Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial. Lancet 402, 185\u2013195 (2023).","journal-title":"Lancet"},{"key":"2249_CR689","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1038\/s41571-024-00886-y","volume":"21","author":"HY Kuo","year":"2024","unstructured":"Kuo, H. Y., Khan, K. A. & Kerbel, R. S. Antiangiogenic-immune-checkpoint inhibitor combinations: lessons from phase III clinical trials. Nat. Rev. Clin. Oncol. 21, 468\u2013482 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2249_CR690","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/nrclinonc.2018.9","volume":"15","author":"KA Khan","year":"2018","unstructured":"Khan, K. A. & Kerbel, R. S. Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa. Nat. Rev. Clin. Oncol. 15, 310\u2013324 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2249_CR691","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","volume":"9","author":"B Wu","year":"2024","unstructured":"Wu, B., Zhang, B., Li, B., Wu, H. & Jiang, M. Cold and hot tumors: from molecular mechanisms to targeted therapy. Signal Transduct. Target. Ther. 9, 274 (2024).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2249_CR692","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","volume":"15","author":"D Fukumura","year":"2018","unstructured":"Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G. & Jain, R. K. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat. Rev. Clin. Oncol. 15, 325\u2013340 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2249_CR693","doi-asserted-by":"publisher","first-page":"1157461","DOI":"10.3389\/fonc.2023.1157461","volume":"13","author":"EE Paulsen","year":"2023","unstructured":"Paulsen, E. E. et al. Impact of microvessel patterns and immune status in NSCLC: a non-angiogenic vasculature is an independent negative prognostic factor in lung adenocarcinoma. Front. Oncol. 13, 1157461 (2023).","journal-title":"Front. Oncol."},{"key":"2249_CR694","doi-asserted-by":"publisher","first-page":"106575","DOI":"10.1016\/j.bioorg.2023.106575","volume":"137","author":"Y Li","year":"2023","unstructured":"Li, Y. et al. Discovery of novel antibody-drug conjugates bearing tissue protease specific linker with both anti-angiogenic and strong cytotoxic effects. Bioorg. Chem. 137, 106575 (2023).","journal-title":"Bioorg. Chem."},{"key":"2249_CR695","first-page":"4263795","volume":"2017","author":"B Caballero","year":"2017","unstructured":"Caballero, B., Sherman, S. J. & Falk, T. Insights into the mechanisms involved in protective effects of VEGF-B in dopaminergic neurons. Parkinsons Dis. 2017, 4263795 (2017).","journal-title":"Parkinsons Dis."},{"key":"2249_CR696","doi-asserted-by":"publisher","first-page":"107101","DOI":"10.1016\/j.phrs.2024.107101","volume":"201","author":"C Ceci","year":"2024","unstructured":"Ceci, C. et al. The VEGFs\/VEGFRs system in Alzheimer\u2019s and Parkinson\u2019s diseases: pathophysiological roles and therapeutic implications. Pharmacol. Res. 201, 107101 (2024).","journal-title":"Pharmacol. Res."},{"key":"2249_CR697","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-06192-0","volume":"23","author":"Y Liu","year":"2025","unstructured":"Liu, Y., Dong, G., Yu, J. & Liang, P. Integration of single-cell and spatial transcriptomics reveals fibroblast subtypes in hepatocellular carcinoma: spatial distribution, differentiation trajectories, and therapeutic potential. J. Transl. Med. 23, 198 (2025).","journal-title":"J. Transl. Med."},{"key":"2249_CR698","doi-asserted-by":"publisher","first-page":"368","DOI":"10.15252\/emmm.201404271","volume":"7","author":"A McIntyre","year":"2015","unstructured":"McIntyre, A. & Harris, A. L. Metabolic and hypoxic adaptation to anti-angiogenic therapy: a target for induced essentiality. EMBO Mol. Med. 7, 368\u2013379 (2015).","journal-title":"EMBO Mol. Med."},{"key":"2249_CR699","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17525-6","volume":"11","author":"K Hosaka","year":"2020","unstructured":"Hosaka, K. et al. Therapeutic paradigm of dual targeting VEGF and PDGF for effectively treating FGF-2 off-target tumors. Nat. Commun. 11, 3704 (2020).","journal-title":"Nat. Commun."},{"key":"2249_CR700","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1172\/JCI0214362","volume":"109","author":"I Stalmans","year":"2002","unstructured":"Stalmans, I. et al. Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms. J. Clin. Invest. 109, 327\u2013336 (2002).","journal-title":"J. Clin. Invest."},{"key":"2249_CR701","doi-asserted-by":"crossref","unstructured":"Nilsson, I. et al. Thrombolysis exacerbates cerebrovascular injury after ischemic stroke via a VEGF-B dependent effect on adipose lipolysis. Preprint at http:\/\/www.biorxiv.org\/content\/10.1101\/2024.10.11.617532v1.full.pdf (2024).","DOI":"10.1101\/2024.10.11.617532"},{"key":"2249_CR702","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-57599-2","volume":"10","author":"FC Ning","year":"2020","unstructured":"Ning, F. C. et al. VEGF-B ablation in pancreatic \u03b2-cells upregulates insulin expression without affecting glucose homeostasis or islet lipid uptake. Sci. Rep. 10, 923 (2020).","journal-title":"Sci. Rep."},{"key":"2249_CR703","doi-asserted-by":"publisher","DOI":"10.1172\/JCI176586","volume":"134","author":"J He","year":"2024","unstructured":"He, J. et al. Autocrine VEGF-B signaling maintains lipid synthesis and mitochondrial fitness to support T cell immune responses. J. Clin. Invest. 134, e176586 (2024).","journal-title":"J. Clin. Invest."},{"key":"2249_CR704","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1182\/blood.2019001736","volume":"134","author":"L Lim","year":"2019","unstructured":"Lim, L. et al. Hemostasis stimulates lymphangiogenesis through release and activation of VEGFC. Blood 134, 1764\u20131775 (2019).","journal-title":"Blood"},{"key":"2249_CR705","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1161\/CIRCULATIONAHA.112.091603","volume":"126","author":"VC Ho","year":"2012","unstructured":"Ho, V. C., Duan, L. J., Cronin, C., Liang, B. T. & Fong, G. H. Elevated vascular endothelial growth factor receptor-2 abundance contributes to increased angiogenesis in vascular endothelial growth factor receptor-1-deficient mice. Circulation 126, 741\u2013752 (2012).","journal-title":"Circulation"},{"key":"2249_CR706","doi-asserted-by":"publisher","first-page":"9349","DOI":"10.1073\/pnas.95.16.9349","volume":"95","author":"S Hiratsuka","year":"1998","unstructured":"Hiratsuka, S., Minowa, O., Kuno, J., Noda, T. & Shibuya, M. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc. Natl. Acad. Sci. USA 95, 9349\u20139354 (1998).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2249_CR707","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.cell.2014.09.025","volume":"159","author":"K Okabe","year":"2014","unstructured":"Okabe, K. et al. Neurons limit angiogenesis by titrating VEGF in retina. Cell 159, 584\u2013596 (2014).","journal-title":"Cell"},{"key":"2249_CR708","doi-asserted-by":"publisher","first-page":"e74686","DOI":"10.1371\/journal.pone.0074686","volume":"8","author":"MT Dellinger","year":"2013","unstructured":"Dellinger, M. T., Meadows, S. M., Wynne, K., Cleaver, O. & Brekken, R. A. Vascular endothelial growth factor receptor-2 promotes the development of the lymphatic vasculature. PLoS ONE 8, e74686 (2013).","journal-title":"PLoS ONE"},{"key":"2249_CR709","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/nrd1381","volume":"3","author":"N Ferrara","year":"2004","unstructured":"Ferrara, N., Hillan, K. J., Gerber, H. P. & Novotny, W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 3, 391\u2013400 (2004).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2249_CR710","doi-asserted-by":"publisher","first-page":"4709","DOI":"10.18632\/oncotarget.1671","volume":"5","author":"P M\u00e9sange","year":"2014","unstructured":"M\u00e9sange, P. et al. Intrinsic bevacizumab resistance is associated with prolonged activation of autocrine VEGF signaling and hypoxia tolerance in colorectal cancer cells and can be overcome by nintedanib, a small molecule angiokinase inhibitor. Oncotarget 5, 4709\u20134721 (2014).","journal-title":"Oncotarget"},{"key":"2249_CR711","doi-asserted-by":"publisher","first-page":"4365","DOI":"10.1158\/1078-0432.CCR-18-0566","volume":"24","author":"SJ Casak","year":"2018","unstructured":"Casak, S. J. et al. FDA\u2019s approval of the first biosimilar to bevacizumab. Clin. Cancer Res. 24, 4365\u20134370 (2018).","journal-title":"Clin. Cancer Res."},{"key":"2249_CR712","doi-asserted-by":"publisher","first-page":"5875","DOI":"10.1158\/1078-0432.CCR-14-1071","volume":"20","author":"M Javle","year":"2014","unstructured":"Javle, M., Smyth, E. C. & Chau, I. Ramucirumab: successfully targeting angiogenesis in gastric cancer. Clin. Cancer Res. 20, 5875\u20135881 (2014).","journal-title":"Clin. Cancer Res."},{"key":"2249_CR713","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1038\/bjc.2016.293","volume":"115","author":"CS Fuchs","year":"2016","unstructured":"Fuchs, C. S. et al. Biomarker analyses in REGARD gastric\/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab. Br. J. Cancer 115, 974\u2013982 (2016).","journal-title":"Br. J. Cancer"},{"key":"2249_CR714","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jnci.2016.03.001","volume":"28","author":"P Tiwari","year":"2016","unstructured":"Tiwari, P. Ramucirumab: boon or bane. J. Egypt. Natl. Cancer Inst. 28, 133\u2013140 (2016).","journal-title":"J. Egypt. Natl. Cancer Inst."},{"key":"2249_CR715","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.2165\/00003495-200767080-00007","volume":"67","author":"SK Blick","year":"2007","unstructured":"Blick, S. K., Keating, G. M. & Wagstaff, A. J. Ranibizumab. Drugs 67, 1199\u20131206 (2007).","journal-title":"Drugs"},{"key":"2249_CR716","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s40265-022-01713-3","volume":"82","author":"M Shirley","year":"2022","unstructured":"Shirley, M. Faricimab: first approval. Drugs 82, 825\u2013830 (2022).","journal-title":"Drugs"},{"key":"2249_CR717","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nrd3700","volume":"11","author":"MW Stewart","year":"2012","unstructured":"Stewart, M. W., Grippon, S. & Kirkpatrick, P. Aflibercept. Nat. Rev. Drug Discov. 11, 269\u2013270 (2012).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2249_CR718","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.2146\/ajhp130143","volume":"70","author":"C Chung","year":"2013","unstructured":"Chung, C. & Pherwani, N. Ziv-aflibercept: a novel angiogenesis inhibitor for the treatment of metastatic colorectal cancer. Am. J. Health Syst. Pharm. 70, 1887\u20131896 (2013).","journal-title":"Am. J. Health Syst. Pharm."},{"key":"2249_CR719","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/nrd1955","volume":"5","author":"EW Ng","year":"2006","unstructured":"Ng, E. W. et al. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat. Rev. Drug Discov. 5, 123\u2013132 (2006).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2249_CR720","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/nrd3073","volume":"9","author":"RM Bukowski","year":"2010","unstructured":"Bukowski, R. M., Yasothan, U. & Kirkpatrick, P. Pazopanib. Nat. Rev. Drug Discov. 9, 17\u201318 (2010).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2249_CR721","doi-asserted-by":"publisher","DOI":"10.1038\/srep45332","volume":"7","author":"N Yokoyama","year":"2017","unstructured":"Yokoyama, N. et al. Activation of ERK1\/2 causes pazopanib resistance via downregulation of DUSP6 in synovial sarcoma cells. Sci. Rep. 7, 45332 (2017).","journal-title":"Sci. Rep."},{"key":"2249_CR722","doi-asserted-by":"publisher","first-page":"7271","DOI":"10.1158\/1078-0432.CCR-06-1249","volume":"12","author":"RC Kane","year":"2006","unstructured":"Kane, R. C. et al. Sorafenib for the treatment of advanced renal cell carcinoma. Clin. Cancer Res. 12, 7271\u20137278 (2006).","journal-title":"Clin. Cancer Res."},{"key":"2249_CR723","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1158\/1078-0432.CCR-06-2328","volume":"13","author":"VL Goodman","year":"2007","unstructured":"Goodman, V. L. et al. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin. Cancer Res. 13, 1367\u20131373 (2007).","journal-title":"Clin. Cancer Res."},{"key":"2249_CR724","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15586\/jkcvhl.2014.7","volume":"1","author":"C Morais","year":"2014","unstructured":"Morais, C. Sunitinib resistance in renal cell carcinoma. J. Kidney Cancer VHL 1, 1\u201311 (2014).","journal-title":"J. Kidney Cancer VHL"},{"key":"2249_CR725","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1158\/1535-7163.MCT-17-1299","volume":"17","author":"P Makhov","year":"2018","unstructured":"Makhov, P. et al. Resistance to systemic therapies in clear cell renal cell carcinoma: mechanisms and management strategies. Mol. Cancer Ther. 17, 1355\u20131364 (2018).","journal-title":"Mol. Cancer Ther."},{"key":"2249_CR726","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1158\/1535-7163.MCT-11-0907","volume":"11","author":"PB Makhov","year":"2012","unstructured":"Makhov, P. B. et al. Modulation of Akt\/mTOR signaling overcomes sunitinib resistance in renal and prostate cancer cells. Mol. Cancer Ther. 11, 1510\u20131517 (2012).","journal-title":"Mol. Cancer Ther."},{"key":"2249_CR727","doi-asserted-by":"publisher","first-page":"269","DOI":"10.4137\/CMO.S10594","volume":"7","author":"M Gross-Goupil","year":"2013","unstructured":"Gross-Goupil, M., Fran\u00e7ois, L., Quivy, A. & Ravaud, A. Axitinib: a review of its safety and efficacy in the treatment of adults with advanced renal cell carcinoma. Clin. Med. Insights Oncol. 7, 269\u2013277 (2013).","journal-title":"Clin. Med. Insights Oncol."},{"key":"2249_CR728","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1038\/s41434-020-0137-9","volume":"28","author":"W Li","year":"2021","unstructured":"Li, W. et al. Knockdown of LINC00467 contributed to Axitinib sensitivity in hepatocellular carcinoma through miR-509-3p\/PDGFRA axis. Gene Ther. 28, 634\u2013645 (2021).","journal-title":"Gene Ther."},{"key":"2249_CR729","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1158\/1078-0432.CCR-16-1073","volume":"23","author":"H Singh","year":"2017","unstructured":"Singh, H. et al. U.S. Food and Drug Administration Approval: cabozantinib for the treatment of advanced renal cell carcinoma. Clin. Cancer Res. 23, 330\u2013335 (2017).","journal-title":"Clin. Cancer Res."},{"key":"2249_CR730","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1007\/s40265-014-0265-x","volume":"74","author":"SM Hoy","year":"2014","unstructured":"Hoy, S. M. Cabozantinib: a review of its use in patients with medullary thyroid cancer. Drugs 74, 1435\u20131444 (2014).","journal-title":"Drugs"},{"key":"2249_CR731","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/intbio\/zyab018","volume":"13","author":"KY Park","year":"2021","unstructured":"Park, K. Y. et al. Immune cell mediated cabozantinib resistance for patients with renal cell carcinoma. Integr. Biol. 13, 259\u2013268 (2021).","journal-title":"Integr. Biol."},{"key":"2249_CR732","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s40265-015-0383-0","volume":"75","author":"LJ Scott","year":"2015","unstructured":"Scott, L. J. Lenvatinib: first global approval. Drugs 75, 553\u2013560 (2015).","journal-title":"Drugs"},{"key":"2249_CR733","doi-asserted-by":"publisher","first-page":"1153991","DOI":"10.3389\/fphar.2023.1153991","volume":"14","author":"W Bo","year":"2023","unstructured":"Bo, W. & Chen, Y. Lenvatinib resistance mechanism and potential ways to conquer. Front. Pharmacol. 14, 1153991 (2023).","journal-title":"Front. Pharmacol."},{"key":"2249_CR734","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s40265-018-0932-4","volume":"78","author":"YA Heo","year":"2018","unstructured":"Heo, Y. A. & Syed, Y. Y. Regorafenib: a review in hepatocellular carcinoma. Drugs 78, 951\u2013958 (2018).","journal-title":"Drugs"},{"key":"2249_CR735","doi-asserted-by":"publisher","first-page":"3663","DOI":"10.3390\/cells11223663","volume":"11","author":"P Kehagias","year":"2022","unstructured":"Kehagias, P. et al. Regorafenib induces senescence and epithelial-mesenchymal transition in colorectal cancer to promote drug resistance. Cells 11, 3663 (2022).","journal-title":"Cells"},{"key":"2249_CR736","doi-asserted-by":"publisher","first-page":"4745","DOI":"10.18632\/oncotarget.2938","volume":"6","author":"N Wei","year":"2015","unstructured":"Wei, N., Chu, E., Wu, S. Y., Wipf, P. & Schmitz, J. C. The cytotoxic effects of regorafenib in combination with protein kinase D inhibition in human colorectal cancer cells. Oncotarget 6, 4745\u20134756 (2015).","journal-title":"Oncotarget"},{"key":"2249_CR737","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.2165\/11209300-000000000-00000","volume":"72","author":"JE Frampton","year":"2012","unstructured":"Frampton, J. E. Vandetanib: in medullary thyroid cancer. Drugs 72, 1423\u20131436 (2012).","journal-title":"Drugs"},{"key":"2249_CR738","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-02994-7","volume":"9","author":"T Nakaoku","year":"2018","unstructured":"Nakaoku, T. et al. A secondary RET mutation in the activation loop conferring resistance to vandetanib. Nat. Commun. 9, 625 (2018).","journal-title":"Nat. Commun."},{"key":"2249_CR739","doi-asserted-by":"publisher","first-page":"5091","DOI":"10.1158\/0008-5472.CAN-08-4204","volume":"69","author":"E Ichihara","year":"2009","unstructured":"Ichihara, E. et al. Effects of vandetanib on lung adenocarcinoma cells harboring epidermal growth factor receptor T790M mutation in vivo. Cancer Res. 69, 5091\u20135098 (2009).","journal-title":"Cancer Res."},{"key":"2249_CR740","doi-asserted-by":"publisher","first-page":"635","DOI":"10.2147\/OTT.S189391","volume":"12","author":"FH Tan","year":"2019","unstructured":"Tan, F. H., Putoczki, T. L., Stylli, S. S. & Luwor, R. B. Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies. OncoTargets Ther. 12, 635\u2013645 (2019).","journal-title":"OncoTargets Ther."},{"key":"2249_CR741","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.ccell.2019.08.004","volume":"36","author":"CA Eide","year":"2019","unstructured":"Eide, C. A. et al. Combining the allosteric inhibitor asciminib with ponatinib suppresses emergence of and restores efficacy against highly resistant BCR-ABL1 mutants. Cancer Cell 36, 431\u2013443.e435 (2019).","journal-title":"Cancer Cell"},{"key":"2249_CR742","doi-asserted-by":"publisher","first-page":"937307","DOI":"10.3389\/fimmu.2022.937307","volume":"13","author":"H Li","year":"2022","unstructured":"Li, H. et al. Apatinib: a novel antiangiogenic drug in monotherapy or combination immunotherapy for digestive system malignancies. Front. Immunol. 13, 937307 (2022).","journal-title":"Front. Immunol."},{"key":"2249_CR743","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05079-y","volume":"13","author":"X Zhou","year":"2022","unstructured":"Zhou, X. et al. Activated amino acid response pathway generates apatinib resistance by reprograming glutamine metabolism in non-small-cell lung cancer. Cell Death Dis. 13, 636 (2022).","journal-title":"Cell Death Dis."},{"key":"2249_CR744","first-page":"1203","volume":"40","author":"F Teng","year":"2018","unstructured":"Teng, F. et al. DUSP1 induces apatinib resistance by activating the MAPK pathway in gastric cancer. Oncol. Rep. 40, 1203\u20131222 (2018).","journal-title":"Oncol. Rep."},{"key":"2249_CR745","first-page":"101","volume":"8","author":"L Fala","year":"2015","unstructured":"Fala, L. Ofev (nintedanib): first tyrosine kinase inhibitor approved for the treatment of patients with idiopathic pulmonary fibrosis. Am. Health Drug Benefits 8, 101\u2013104 (2015).","journal-title":"Am. Health Drug Benefits"},{"key":"2249_CR746","doi-asserted-by":"publisher","first-page":"50161","DOI":"10.18632\/oncotarget.10324","volume":"7","author":"B Englinger","year":"2016","unstructured":"Englinger, B. et al. Acquired nintedanib resistance in FGFR1-driven small cell lung cancer: role of endothelin-A receptor-activated ABCB1 expression. Oncotarget 7, 50161\u201350179 (2016).","journal-title":"Oncotarget"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02249-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02249-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02249-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,18]],"date-time":"2025-05-18T19:02:54Z","timestamp":1747594974000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02249-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,19]]},"references-count":746,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2249"],"URL":"https:\/\/doi.org\/10.1038\/s41392-025-02249-0","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,19]]},"assertion":[{"value":"22 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"170"}}